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Background: Pain affects over 70% of individuals with inflammatory bowel disease 
(IBD), with abdominal and musculoskeletal (MSK) pain representing the most 
common complaints identified by patients. To date most studies in IBD have 
concentrated on inflammatory arthropathies. However, recent guidelines and 
investigations suggest that the majority of MSK pain in IBD is likely to be non-
inflammatory in nature, although the scope and nature of MSK pain in IBD remains 
unclear with limited understanding of underlying mechanisms and factors moderating 
pain experiences. Consequently, further investigation and expanded theoretical 
frameworks are required in order to develop effective assessment and treatment 
pathways to improve patient outcomes in this population.  
Aim: The aim of the present thesis was to explore persistent MSK pain in individuals 
with IBD, in order to identify shared mechanisms and factors which influence MSK 
pain experiences in this population.  
Methods: Two narrative reviews of current literature were conducted to identify 
fundamental concepts and models in IBD and pain pathways, in order to develop a new 
framework for persistent MSK pain, primary thesis domains, and thesis methodologies. 
Two primary thesis studies were used to investigate MSK pain within this framework, 
including 1) a population-based survey characterizing MSK pain in New Zealand 
adults through subgrouping and mediation analyses, and 2) a clinic-based investigation 
investigating measures of central sensitization in American adults with IBD.  
Results: Subgrouping analysis of Study 1 demonstrated three distinct profiles of MSK 
pain in individuals with IBD. These profiles indicated that individuals with worse pain 
experiences presented with greater symptoms related to central sensitization, increased 
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probability of presenting with multiple pain qualities, and active IBD. Sub-analysis of 
Study 1 further indicated that IBD activity was a significant predictor of worse MSK 
pain experiences, where symptoms of central sensitization demonstrated significant 
mediation of this relationship. 
Study 2 of the present thesis indicated that assessments of somatosensory functioning 
did not differ between three study groups (i.e. IBD patients with MSK pain, IBD 
patients without MSK pain, and healthy controls). However, the burden of symptoms 
related to central sensitization was found to be significantly different between all study 
groups. Furthermore, Study 2 demonstrated association of measures of central 
sensitization and a range of participant features (i.e. IBD, psychological, and lifestyle 
factors). 
Conclusion: The current thesis presents a new framework to consider and explore 
persistent MSK pain in IBD patients. Findings from the two primary thesis studies 
indicated that a sub-population of IBD patients with and without MSK pain presented 
with features suggesting the presence central sensitization. Individuals with MSK pain 
and symptoms of central sensitization presented with worse IBD, HRQOL, and pain 
experiences. MSK pain in IBD presented as distinct profiles, suggesting influences 
from worse IBD severity to pain presentations and the presence of central sensitization. 
Measures of central sensitization in IBD were associated with a range of patient 
features (i.e. IBD, pain, psychological, lifestyle, and comorbidity), highlighting 
potential risk factors for the development of central sensitization leading to worse pain 
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Inflammatory bowel disease (IBD) comprises a group of conditions, the most 
prevalent of which are Crohn’s disease and ulcerative colitis. These chronic 
inflammatory diseases are characterized by relapsing-remitting courses of 
gastrointestinal tract inflammation, as a result of dysregulated immune responses 
(Böhmig, 2019; Burisch & Munkholm, 2015; M'Koma, 2013). Although the 
epidemiology of IBD varies considerably both within and between geographic regions, 
global trends show an increasing prevalence worldwide, especially in regions where the 
incidence was once low (Burisch & Munkholm, 2015; Molodecky et al., 2012). The 
prevalence of IBD is reported to be highest in the Western world, affecting up to 0.5% 
of the general population, with an incidence ranging from 10 to 30 per 100,000 
(Molodecky et al., 2012). A recent systematic review indicated that Southern Australia 
and New Zealand represent some of the highest global incidence rates for IBD 
(Molodecky et al., 2012).  
The variation in incidence rates of IBD around the world has led to theories for 
the evolution of this disease coinciding with industrialization of societies, north-south 
geographic gradients, and patient demographics (e.g. ethnicity, age, and gender) 
(Karlinger, Györke, Makö, Mester, & Tarján, 2000; Molodecky et al., 2012). However, 
influences of westernization (e.g. diets, food additives, and medications) alongside 
and/or independently to that of industrialization have more recently received 
consideration (Kaplan, 2015; Molodecky et al., 2012). As a whole, current literature 
clearly indicates a global rise in the presence of IBD with disease onset occurring at a 
significantly younger ages than previously noted (Burisch & Munkholm, 2015; 
2 
Molodecky et al., 2012). As a result, the direct and indirect health-care burden of 
managing IBD in the western world has become substantial (Kaplan, 2015). 
In addition to characteristic gut symptoms, pain is a commonly reported 
symptom which affects over 70% of IBD patients, with abdominal and musculoskeletal 
(MSK) pain representing the most common pain complaints (Brakenhoff, van der 
Heijde, & Hommes, 2011; Palm, Bernklev, Moum, & Gran, 2005; van der Have et al., 
2015; S. J. van Erp et al., 2016; Zeitz et al., 2016). MSK pain in IBD is typically 
considered within the framework of extra-intestinal manifestations (EIMs), a group of 
comorbidities with known associations to IBD. Although EIMs encompass a broad 
range of conditions affecting nearly every organ system, MSK manifestations are 
reported to be the most common EIM in IBD (Marcus Harbord et al., 2016; Levine & 
Burakoff, 2011; Trikudanathan, Venkatesh, & Navaneethan, 2012).  
While reports from the literature describe several MSK-related EIMs, such as 
arthropathies (inflammatory and non-inflammatory), osteoporosis, and tendinopathies 
(M. Harbord et al., 2016; Levine & Burakoff, 2011; Trikudanathan et al., 2012), to date 
inflammatory arthropathies are by far the most studied MSK-related EIM in IBD. 
Interest in investigating inflammatory arthropathies may reflect ongoing efforts to 
understand underlying inflammatory pathways which are common to joint conditions 
and IBD (Levine & Burakoff, 2011). As a result, the clinical assessment and treatment 
of inflammatory arthritis in the context of active IBD shares a common approach 
(Fornaciari et al., 2001; Levine & Burakoff, 2011; Zeitz et al., 2016).  
Although inflammatory arthropathies are predominantly considered in IBD 
literature, an investigation of back/joint pain in IBD demonstrated that 87.7% of study 
participants did not satisfy inflammatory diagnostic criteria, suggesting that the 
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majority of joint pain in IBD is potentially non-inflammatory in nature (S. J. van Erp et 
al., 2016). Furthermore, numerous reports and guidelines regarding MSK-related EIMs 
state that non-inflammatory joint pain, or arthralgia, is more common in IBD than 
primary inflammatory arthritis (M. Harbord et al., 2016; T. Sheth, Pitchumoni, & Das, 
2015; S. J. van Erp et al., 2016). Unfortunately, studies investigating joint pain in IBD 
typically exclude non-inflammatory pain or mention it without further investigation 
(Brakenhoff et al., 2011). Consequently, the scope and nature of MSK pain in IBD 
remains unclear with a limited understanding of underlying mechanisms and 
influencing factors (Brakenhoff et al., 2011). This narrow focus when considering MSK 
pain has led to potentially incomplete management pathways, leaving many patients 
without treatment strategies for their pain. As a result, further investigation and an 
expanded theoretical framework for the presence of MSK pain are required in this 
population and proposed in the present thesis. 
 
1.2 Framework for Persistent Musculoskeletal Pain in IBD 
The present thesis proposes a new framework to consider and explore persistent 
MSK pain in IBD (Figure 1.1). This framework integrates current IBD, chronic 
inflammatory, and chronic MSK pain literature to describe the potential for shared 





Figure 1.1.  Framework for MSK-related pain in IBD. Inflammatory processes sensitize 
visceral afferent neurons, leading to increased central input and neural sensitization. 
Affective responses and coexisting emotional problems (stress model) influence arousal 
and cognitive processing in higher brain centres, thereby potentially further enhancing 
sensory input. Resultant neuroplastic changes in the CNS potentially contribute to 
multiple chronic pain states and central sensitivity syndromes. 
 
 
1.2.1 Chronic MSK pain models 
The literature presents complex pain models involving dynamic relationships 
between the nervous system, primary disease features, and concomitant pain states. The 
mechanisms involved in the generation and maintenance of chronic pain are postulated 
to include altered peripheral and central nervous system (CNS) activity. Peripheral 
injuries and/or inflammatory processes are believed to trigger changes in the nervous 
systems which may lead to the neuroplastic changes within the CNS seen in persistent 
pain states, including central sensitization, altered pain modulation, and structural brain 
changes (Curatolo & Arendt-Nielsen, 2015; Vardeh, Mannion, & Woolf, 2016).  
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In addition to altered nervous system activity, psychological factors, such as 
mood disorders and psychological distress, have been identified as important 
determinants of pain experiences in both acute and chronic conditions (Boersma & 
Linton, 2005; Roth, Tripp, Harrison, Sullivan, & Carson, 2007; Michael JL Sullivan et 
al., 2001; Villemure & Bushnell, 2002). As a result, evaluation of cognitive and 
affective features are commonly used to explore the modulation of pain perceptions 
(Villemure & Bushnell, 2002). Mechanisms by which psychological factors modulate 
pain experiences are complex. However, psychological factors have demonstrated an 
independent association with pain severity, disability, as well as neural hypersensitivity 
in multiple chronic pain (Finan, Quartana, & Smith, 2013; Sterling, Hodkinson, 
Pettiford, Souvlis, & Curatolo, 2008; Villemure & Bushnell, 2002) and healthy 
populations (Hven, Frost, & Bonde, 2017; Villemure & Bushnell, 2002).  
1.2.1.1 Central sensitivity syndromes 
The term ‘central sensitivity syndromes’ (CSSs) has been proposed to describe a 
group of interrelated disorders where the common aetiology is thought to be central 
sensitization, such as irritable bowel syndrome (IBS), temporomandibular joint 
disorder, and fibromyalgia (Arendt‐ Nielsen et al., 2018; Yunus, 2008). CSSs typically 
present with overlapping features, such as: psychological distress, sleep disturbances, 
fatigue, pain, allodynia, and hyperalgesia (Arendt‐ Nielsen et al., 2018; Verne, 
Robinson, & Price, 2001; Yunus, 2008). Although IBS is well-understood to be distinct 
from IBD, with separate aetiology and pathophsyiology (Schoepfer, Trummler, 
Seeholzer, Seibold-Schmid, & Seibold, 2008), reports of patients in long-standing 
remission have indicated that IBD patients are two to three times more likely to have 
comorbid IBS than the general population (Simrén et al., 2002). Similarly, although 
reports for the prevalence of fibromyalgia in IBD have been conflicting (Buskila, Odes, 
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Neumann, & Odes, 1999; Palm, Moum, Jahnsen, & Gran, 2001), a recent longitudinal 
investigation of 3,465 newly diagnosed IBD patients indicated a 2-fold increased risk of 
being diagnosed with fibromyalgia compared to patients without IBD (Larrosa Pardo, 
Bondesson, Schelin, & Jöud, 2019).  
Although these findings highlight potential contributions of central sensitization 
to comorbid clinical presentations in some IBD patients, current literature has not 
investigated the presence of central sensitization related to features of IBD, including 
persistent MSK pain experiences. A large (N = 6309) epidemiology study in IBD 
indicated that only 20% of patients reported a coexisting IBS diagnosis (Abdalla et al., 
2017). With pain reports in over 70% of IBD patients (Brakenhoff et al., 2011; Palm et 
al., 2005; van der Have et al., 2015; S. J. van Erp et al., 2016; Zeitz et al., 2016), these 
results suggest that mechanisms of central sensitization related to comorbid IBS are 
insufficient to explain ongoing pain presentations across the whole of IBD patients. As 
such, there is a need to explore potential pain mechanisms, including the presence of 
central sensitization, in the broader population of IBD patients in order to better 
understand the potential for shared mechanisms in persistent MSK pain experiences.  
1.2.2 IBD Pain models 
Although theoretical models regarding persistent MSK pain in IBD are lacking, 
over the past decade models for chronic abdominal pain in IBD have been described. 
Abdominal pain in IBD is well-understood to be a consequence of active inflammatory 
processes. However, current literature also reports abdominal pain experienced in 
periods beyond active inflammation (Bielefeldt, Davis, & Binion, 2009; Kristen E 
Farrell, Keely, Graham, Callister, & Callister, 2014). Consequently, abdominal pain in 
IBD is understood to often trigger pain in other body regions, such as the back and legs 
(Bielefeldt et al., 2009; Kristen E Farrell et al., 2014). This referred pain is thought to 
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be the result of central sensitization causing an overlap in activity between visceral and 
somatosensory neurons within the spinal cord (Bielefeldt et al., 2009; Kristen E Farrell 
et al., 2014). Additionally, contributions from altered affective and cognitive processing 
have been proposed in IBD abdominal pain models (Bielefeldt et al., 2009) and have 
demonstrated an independent association with IBD activity (Alessandro Agostini et al., 
2014; Charles N Bernstein et al., 2010; Targownik et al., 2015). It is therefore 
unsurprising that models for chronic abdominal pain in IBD propose influences from 
central mechanisms, such as central sensitization, as well as changes to higher brain 
centres as a consequence of multiple pathways in IBD patients (Bielefeldt et al., 2009; 
Kristen E Farrell et al., 2014). 
Similarly, investigations of chronic postsurgical pain indicate that IBD patients 
are two to three times more likely to develop chronic pain following gastrointestinal 
surgery than non-IBD populations (Bruce & Krukowski, 2006; Joris et al., 2015). 
Central sensitization has been found to play a major role in the pathophysiology of 
chronic postsurgical pain, with potentiation from prior disease inflammation thought to 
explain the increased prevalence of chronic pain in IBD patients (Bruce & Krukowski, 
2006; Joris et al., 2015). It has been suggested that central sensitization in conditions 
such as IBD, reflect nervous systems primed with the potential to generate amplified 
and/or persistent pain states from subsequent injury and/or systemic inflammation 
(Hains et al., 2010).  
1.2.3 Shared pain mechanisms 
Previous studies of chronic inflammatory and MSK pain conditions in non-IBD 
populations have described influences from psychological and disease features (Arendt-
Nielsen, Skou, Nielsen, & Petersen, 2015; Atzeni et al., 2015; Catalano et al., 2017; 
Kiltz, Baraliakos, Regel, Bühring, & Braun, 2017). These investigations highlight the 
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potential for multiple pain mechanisms which overlap in their presentation (Arendt-
Nielsen et al., 2015; Atzeni et al., 2015; Catalano et al., 2017; Kiltz et al., 2017). For 
instance, in conditions such as ankylosing spondylitis and rheumatoid arthritis, it is not 
uncommon for patients to demonstrate both neuropathic and chronic widespread pain 
states, as a consequence of active inflammation and central mechanisms (Coutaux, 
Adam, Willer, & Le Bars, 2005; Koop, Peter, Vonkeman, Steunebrink, & van de Laar, 
2015; Y. C. Lee, 2013; Wu, Inman, & Davis, 2013). Persistent MSK pain conditions, 
such as osteoporosis and chronic joint pain, have similarly demonstrated multiple pain 
mechanisms with concurrent nociceptive and central mechanisms in observed patients 
(Catalano et al., 2017).  
Results from these investigations suggest that traditional frameworks for 
considering MSK pain in IBD, which tend to focused on isolated inflammatory 
mechanisms, may represent an over-simplification of the pathophysiology leading to 
persistent MSK pain in IBD. As such, there is a pressing need to reconsider how MSK 
pain is contextualized in IBD, in order to develop appropriate and effective assessment 
and treatment strategies in the future. The present thesis endeavoured to address this 
notable gap in current research and clinical practice through a series of investigations 
exploring a broader framework of self-reported MSK pain in IBD. 
Although there are numerous approaches which could be employed to explore 
persistent MSK pain experiences in IBD, including both qualitative and quantitative 
methodologies, reports from current literature suggest quantitative designs may 
represent the best approach for objectively identifying the presence of shared 
mechanisms in this population (Arendt-Nielsen, Graven-Nielsen, & Petrini, 2012; 
Arendt‐ Nielsen et al., 2018; Catalano et al., 2017; Koop et al., 2015; S. M. Smith et 
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al., 2017; Wu et al., 2013). Therefore, the present thesis utilizes quantitative 
methodologies to explore the following research question and aims. 
1.3 Research Question 
Do persistent MSK pain experiences in patients with IBD represent shared 
mechanisms? 
1.4 Research aims 
 To review and synthesize IBD and chronic pain literature in order to develop a 
theoretical framework and identify primary thesis domains for exploring 
persistent MSK pain in IBD patients. 
 To explore whether self-reported MSK pain presents in clinically meaningful 
patterns describing contribution from primary pain mechanisms and potential 
relationships between IBD, pain, and psychological features. 
 To investigate potential predictive and causal relationships between IBD, central 
sensitization, and pain experiences.  
 To investigate the presence of central sensitization, through symptomatic and 
bedside assessments, in patients with IBD and whether these measures of central 
sensitization differ in IBD patients with MSK pain.  
 To investigate whether individual patient features are associated with measures of 
central sensitization in patients with IBD. 
  
1.5 Research Pathway 
The research pathway of this thesis is illustrated in Figure 1.2. As previously 
stated, consideration of central sensitization in patients with IBD has primarily been 
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reported in theoretical models of chronic abominal pain, without ojective investigation 
of related mechanisms and/or contributing factors in IBD patients. Furthermore, 
frameworks for considering persistent MSK pain in IBD, to include mechanisms of 
central sensitization, are lacking in current literature. Therefore, although a systematic 
review of constructs related to central sensitization in other populations may have 
highlighted general domains of interest to persistent pain exerpeiences across a 
spectrum of conditions, it is uncertain whether these findings would have been 
generalizable to IBD patients. Alternatively, a narrative review of the broader research 
themes identified in IBD and pain literature used to highlight shared constructs was 
considered useful for describing a new theoretical framework for exploring MSK pain 
experiences in IBD (Chapter 2). Constructs identified in this initial narrative literature 
review were further explored as the primary thesis domains in a second review of the 
literature, including a review of study methodologies relevant to the present thesis 
(Chapter 3). Results from the second literature review contributed to the 
methodological framework for two primary thesis studies, including Study 1: Profiles 
of self-reported MSK pain in IBD patients (Chapter 4) and Study 2: Assessment of 
central sensitization in IBD patients with and without MSK pain and healthy controls 
(Chapter 7). Study 1 examined self-reported pain and disease features in New Zealand 
adults with IBD. These self-report measures were used to identify profiles of MSK pain 
through subgroup-based analysis (Chapter 5). Predominant pain and IBD features 
identified during subgrouping were further explored in a sub-analysis examining the 
predictive relationship between these features (Chapter 6). Study 2 investigated 
differences in assessments of central sensitization across three study groups: 1) IBD 
patients with MSK pain, 2) IBD patients without MSK pain, and 3) health controls 
(Chapter 8). Additionally, Study 2 explored associations of psychological, IBD, 
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demographic, comorbidity, and lifestyle features to measures of central sensitization in 
IBD patients (Chapter 9). Finally, the present thesis concludes with a general discussion 
of overall thesis findings, strengths, limitations, and recommendations for future 
research (Chapter 10). 
 
1.6 Significance of the Research 
This research contributes to a broader understanding of the mechanisms 
involved in MSK pain experiences in patients with IBD. The proposed theoretical 
framework for considering MSK pain experiences (Figure 1.1) provides a new context 
to guide current and future research efforts and clinical practice. Specifically, this 
research explores the presence of central sensitization and the relationships between 
measures of central sensitization, psychological factors, IBD features, and painful MSK 
experiences. Results provide not only a deeper understanding of mechanisms of 
persistent MSK pain in IBD but also highlights the need for new targeted management 














2 Inflammatory Bowel Disease, Fundamental Pain Pathways, and the 
Gut-Brain-Axis: Review of the Literature 
 
2.1 Chapter overview 
The current chapter first presents an overview of the literature regarding IBD 
processes and management frameworks, as well as fundamental pathways leading to 
chronic MSK pain experiences. These pathways are contextualised within the ‘gut-
brain-axis’ (GBA) paradigm in order to illustrate constructs common to both 
gastrointestinal and pain literature (Figure 2.1).  
 
2.2 Inflammatory Bowel Disease  
The gastrointestinal tract is primarily protected by a mechanical barrier and the 
intestinal immune system (Figure 2.1) (Tortora & Derrickson, 2008). The inner mucus 
layer of the tract allows small molecules to pass through while preventing large 
particles from contacting the epithelial layer (Böhmig, 2019; Tortora & Derrickson, 
2008). The structure of the epithelial layer includes a single layer of tightly joined cell 
junctions which selectively allows particles to pass from the intestinal lumen (Böhmig, 
2019; Tortora & Derrickson, 2008). The epithelial layer also provides additional 
protection by secreting chemical mediators which further prevent microorganisms from 




Figure 2.1. Intestinal barrier and local immune system, adapted from: (Böhmig, 2019). 
 
The gastrointestinal tract, particularly the terminal ileum and the colon, are 
colonised by over 1014 commensal bacteria (Böhmig, 2019; Tortora & Derrickson, 
2008). In fact, there are more bacteria living in the human gut than cells in the body. 
This complex ecosystem is collectively termed the human gut microbiome and is 
essential to nutrition, metabolism, and development of the immune system (Böhmig, 
2019; Tortora & Derrickson, 2008). Homeostasis between an adequate tolerance to 
“healthy” bacteria and appropriate responsiveness to pathogenic bacteria is carried out 
by balanced immune responses (Böhmig, 2019). Evidence is emerging that disruption 
of this balance, termed dysbiosis, may trigger and maintain active IBD; furthermore, 
IBD in itself may promote microbiome dysbiosis (Gevers et al., 2014; Halfvarson et al., 
2017).  
IBD is associated with increased permeability of the intestinal epithelial layer, 
which causes continuous stimulation of the immune system (Hanauer, 2006). IBD is 
understood to be a consequence of inappropriate activation of immune cells as a result 
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of both genetic and environmental factors (Bernstein, 2017; Hanauer, 2006). 
Characterized by relapsing and remitting episodes of inflammation, IBD presents with 
periods of active inflammation (i.e. “flares”), followed by periods of no activity (i.e. 
“remission”). Crohn’s disease and ulcerative colitis both have distinct as well as 
overlapping pathologic and clinical characteristics. For instance, inflammation in 
ulcerative colitis is limited to the mucosal layer and is confined to the colon, whereas 
Crohn’s disease can present with transmural inflammation which may affect any part of 
the gastrointestinal tract from mouth to anus (Böhmig, 2019). The most important 
prognostic factor for ulcerative colitis is reported to be the extent of bowel involvement 
(Conrad, Roggenbuck, & Laass, 2014). In Crohn’s disease an unfavourable prognosis is 
commonly associated with young age at initial diagnosis, location of disease in both the 
small bowel and colon, perianal disease, and/or the necessity of steroids on first flare 
(Peyrin-Biroulet et al., 2016).  
2.2.1 Management framework 
Management paradigms for both Crohn’s disease and ulcerative colitis aim at 
inducing and maintaining clinical remission (M. D. Regueiro, Greer, & Hanauer, 2016). 
Algorithms for treating the different IBD subtypes reflect the differences between these 
conditions, and in recent years have changed from an emphasis on symptom 
management towards control of inflammation and normalization of biologic processes 
(M. D. Regueiro et al., 2016). The foundation for management of both IBD subtypes is 
based on evaluating disease extent and severity, through endoscopic, histologic, 
radiographic, and biomarker investigations (Neurath & Travis, 2012; Walsh, Bryant, & 
Travis, 2016). However, additional factors are reported to significantly influence 
clinical decision making, including response or loss of response to medications, number 
of hospitalizations, risk of surgery, risk of developing colorectal cancer, impact on 
18 
health-related quality of life (HRQOL), as well as the presence of extra-intestinal 
manifestations (EIMs) (M. D. Regueiro et al., 2016). As noted earlier, EIMs are defined 
as a group of comorbidities with known associations to IBD, which may be diagnosed 
before, concurrently, or after IBD diagnosis (M. Harbord et al., 2016; Levine & 
Burakoff, 2011; Trikudanathan et al., 2012).  
2.2.1.1 Musculoskeletal manifestations 
Although EIMs are understood to encompass a broad range of conditions 
affecting nearly every organ system (Table 2.1), MSK manifestations are the most 
commonly reported EIMs in IBD (M. Harbord et al., 2016; Levine & Burakoff, 2011; 
Trikudanathan et al., 2012). Of the MSK EIMs reported in current literature, previous 
studies have primarily focused on inflammatory arthropathies with little consideration 
of other painful conditions (Trikudanathan et al., 2012; Vavricka et al., 2015). The 
aetiopathogenesis of inflammatory arthropathies in IBD patients is not well understood. 
Inflammatory arthropathies in IBD include peripheral arthritis (Type 1 & 2), as well as 
axial arthropathies including the spine and sacroiliac joints (Brakenhoff et al., 2011; 
Levine & Burakoff, 2011; Tejas Sheth, Pitchumoni, & Das, 2014; Zeitz et al., 2016). 
Unlike other types of inflammatory arthropathies, such as psoriatic arthritis, 
peripheral arthropathies associated with IBD are generally non-erosive (M. Harbord et 
al., 2016). The clinical classification of peripheral arthropathies in IBD is based on a 
large study of IBD patients, where two empirical types of arthritis were identified 
(Table 2.2) (Orchard, Wordsworth, & Jewell, 1998). Type 1 arthritis is defined as joint 
pain with evidence of swelling or effusion affecting fewer than five joints, typically the 
large weight-bearing joints of the lower limb (M. Harbord et al., 2016). The symptoms 
related to Type 1 arthritis correlate with IBD flares and are usually acute (less than 10 
weeks) without permanent damage to the affected joints. Type 2 arthritis affects more 
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than five joints with symmetrical distribution and predominantly affects the upper 
limbs. Symptoms associated with Type 2 arthritis are independent of IBD activity and 
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Inflammatory Arthritis in Inflammatory Bowel Disease  
Type 1 arthritis Type 2 arthritis 
Less than five joints affected Five or more joints affected 
Asymmetric involvement Symmetric or asymmetric 
Lower limb more affected Affects both large and small joints 
Self-limited episodes that last < 10 weeks Persistent inflammation for months/years 
Usually concomitant IBD flares Independent of IBD activity 
High frequency of other EIMs May be erosive 
Note. Inflammatory bowel disease (IBD), and extra-intestinal manifestations (EIMs) 
(M. Harbord et al., 2016). 
 
Despite acknowledgement that non-inflammatory MSK pain is more common in 
IBD (M. Harbord et al., 2016; T. Sheth et al., 2015; S. J. van Erp et al., 2016), previous 
MSK-related studies typically exclude non-inflammatory pain or mention it without 
further investigation (Brakenhoff et al., 2011). Consequently, while inflammatory 
arthropathies continue to remain the most investigated MSK condition in IBD, the 
scope and nature of other MSK conditions are still widely unknown. Furthermore, this 
bias in current research suggests the potential for a significant underestimation of the 
overall prevalence and burden of MSK pain in IBD. 
2.3 Pain 
The following section provides an overview of the literature regarding the 
pathway leading to MSK pain experiences, followed by an overview of the GBA 




Figure 2.2. Shared peripheral and central pathways of inflammatory bowel disease and musculoskeletal pain experiences within the context of the gut-brain 
axis. 
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2.3.1 Pain pathway
An overview of the fundamental nociceptive pathways integral to pain 
experiences, including processes of transduction, transmission, modulation, and 
perception are described below and organised by peripheral versus central components 
to this framework. 
2.3.1.1 Peripheral components  
Nociceptive transduction is the process by which noxious thermal, mechanical, 
or chemical stimuli are detected and transformed into a perceivable signal by a group of 
peripheral sensory neurons, termed nociceptors (Basbaum, Bautista, Scherrer, & Julius, 
2009; McEntire et al., 2016; C. J. Woolf, 2004). There are two major classes of 
nociceptors (Aδ and C fibres) that spread between epidermal cells and somatosensory 
organs in the periphery (Basbaum et al., 2009; DeLeo, 2006; McEntire et al., 2016). 
Both classes of nociceptors are functionally and molecularly heterogeneous, with 
subpopulations that respond to different types of stimuli (e.g. thermal vs mechanical). 
In general, medium-diameter myelinated (Aδ) afferents transmit acute, well-localized 
“first” or fast pain responses, whereas small-diameter unmyelinated “C” fibres convey 
poorly localized, “second” or slow pain responses (DeLeo, 2006; Meyer, 2008; C. J. 
Woolf, 2004). The peripheral terminal of the nociceptor will respond to environmental 
stimuli (e.g. thermal and mechanical), while both the peripheral and central terminals of 
the nociceptor will respond to a host of endogenous molecules (i.e. lipids and 
neurotransmitters) that regulate its sensitivity (Basbaum et al., 2009; DeLeo, 2006; 
McEntire et al., 2016).  
With the exception of the face, all cell bodies of nociceptors are located in the 
dorsal root ganglia, with a peripheral axon that innervates their peripheral target organ 
and a central axon that terminates in the dorsal horn of the spinal cord (Basbaum et al., 
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2009; Meyer, 2008). Consequently, once the noxious signal is transduced by the 
peripheral organ, a variety of voltage-gated ion channels are activated along the axon, 
transmitting signals to the dorsal horn of the spinal cord (DeLeo, 2006). These voltage-
gated ion channels are critical for the generation of action potentials that deliver 
nociceptive signals (Cummins, Sheets, & Waxman, 2007; DeLeo, 2006).  
2.3.1.1.1 Peripheral sensitization 
One of the most important characteristics of both nociceptor subtypes is their 
ability to sensitize, thereby lowering their threshold for activation (Basbaum et al., 
2009; DeLeo, 2006; McEntire et al., 2016). Similarly, axon voltage-gated ion channels 
also have this ability to sensitize and modify nociceptive signals en route to the dorsal 
horn (Cummins et al., 2007). These adaptive changes in sensitivity allow stimuli that 
would not normally cause pain to now do so (C. J. Woolf, 2004). Although important 
during acute pain states, maladaptive changes in peripheral nociceptors may lead to 
spontaneous firing, as well as changes in conduction and/or neurotransmitter properties. 
This process has been implicated in persistent pain associated with injury or diseases 
(i.e. diabetes, arthritis, or cancer) (Basbaum et al., 2009; DeLeo, 2006). 
Hyperexcitability of the peripheral nervous system (i.e. peripheral sensitization) 
is thought to be associated with inflammatory changes in the chemical environment 
surrounding neurons (Basbaum et al., 2009; DeLeo, 2006). For instance, injury and 
subsequent tissue damage is often accompanied by the accumulation of endogenous 
factors released from activated nociceptors and/or immune cells that either reside 
within or infiltrate into the injured area, such as: mast cells, platelets, macrophages, 
neutrophils, endothelial cells, and fibroblasts (Basbaum et al., 2009). These endogenous 
factors increase the excitability of nociceptors, thereby increasing its sensitivity to, for 
instance, thermal and touch stimuli (Basbaum et al., 2009). Consequently, an increase 
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in nociceptor excitability results in greater nociceptive input into the spinal cord 
(Basbaum et al., 2009; DeLeo, 2006). 
2.3.1.2 Central components 
Primary afferent neurons terminate in the dorsal horn of the spinal cord in a 
highly organized fashion, innervating both dorsal horn interneurons and second-order 
projection neurons (Costigan & Woolf, 2000). Within the dorsal horn, afferent impulses 
are subjected to considerable local and descending pathway modulation, a process 
fundamental to the generation of pain and pain hypersensitivity (Costigan & Woolf, 
2000). This complex network of synaptic transmission is mediated by neurotransmitters 
released within the dorsal horn (DeLeo, 2006). For instance, in the case of persistent 
injury, C fiber nociceptors fire repetitively thereby increasing the response of dorsal 
horn neurons. This phenomenon, referred to as ‘wind-up’, is dependent on the release 
of neurotransmitters (e.g. glutamate) as a consequence of repeated nociceptive input 
(Costigan & Woolf, 2000; DeLeo, 2006). Conversely, other neurotransmitters, such as 
serotonin, are released into the dorsal horn by descending inhibitory neurons from the 
brainstem, for instance during ‘fight-or-flight’ responses (Tracey & Mantyh, 2007).  
The net sum of synaptic transmission between primary afferent and dorsal horn 
neurons results in the facilitation or inhibition of secondary afferent projection neurons 
(Basbaum et al., 2009; DeLeo, 2006). Secondary afferents then cross the midline of the 
spinal cord and transmit through ascending pathways (e.g. spinothalamic and 
spinoreticular tracts) to the thalamus and brainstem (Basbaum et al., 2009; Costigan & 
Woolf, 2000; DeLeo, 2006). Spinal projections to the brainstem are particularly 
important for integrating nociceptive activity with arousal and autonomic processes, as 
well as indirectly conveying nociceptive information to the forebrain after brainstem 
processing (Tracey & Mantyh, 2007). Secondary afferents projected to the brainstem 
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can directly influence both spinal (i.e. descending inhibitory projections) and forebrain 
activity, suggesting that these pathways mediate changes in pain perception (Tracey & 
Mantyh, 2007).  
The thalamus is thought to have a prominent role in nociceptive processing and 
is the main relay for nociceptive signals to supra-spinal regions of the brain (Tracey & 
Mantyh, 2007). Literature suggests that no single region of the brain is essential nor 
solely responsible for painful experiences (Apkarian, Bushnell, Treede, & Zubieta, 
2005). Rather, pain results from parallel activation of multiple supra-spinal structures, 
including the somatosensory, prefrontal, cingulate, and insular cortices (Apkarian et al., 
2005). These regions have been implicated in the modulation of pain experiences 
through components related to sensory-discriminative features (somatosensory cortex 
and insula), as well as cognitive and affective features (prefrontal, cingulate, and insular 
cortices) of pain perception (Basbaum et al., 2009). It is important to note that these 
supra-spinal regions are not exclusively activated by nociception nor restricted solely to 
pain perception. These regions serve many neurological processes involved in 
cognition, emotion, motivation, and sensation (Apkarian et al., 2005; Basbaum et al., 
2009). However, interaction among these sites provides a pathway whereby emotional 
and cognitive triggers can alter pain experiences and perceptions through interactions 
with descending modulatory systems. 
2.3.1.2.1 Central sensitization 
Peripherally sensitized neurons exhibit an increased discharge rate with each 
peripheral stimulus. This barrage of activity within the dorsal horn can have a number 
of consequences, including changes in ionic currents, altered receptor properties, 
modified gene expression, and loss of inhibition neurons (Costigan & Woolf, 2000). 
These alterations are believed to underlie the mechanisms leading to increased 
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responsiveness of nociceptive neurons within the CNS, termed central sensitization. In 
the present thesis central sensitization is defined according to the International 
Association for the Study of Pain (2017) definition: “increased responsiveness of 
nociceptive neurons in the central nervous system to their normal or subthreshold 
afferent input”. 
Central sensitization is a broad concept that includes multiple complex 
pathophysiological mechanisms, including changes to nociceptive facilitation, 
inhibition, and sensory processing (Clifford J Woolf, 2011, 2014). Common 
mechanisms are described as (Clifford J Woolf, 2011):  
 Windup from individual neurons (temporal summation) 
 Persistent increase in neural synaptic strength (long-term potentiation) 
 Changes in the strength of synaptic connections (heterosynaptic potentiation) 
 Dysfunctional descending inhibition and facilitatory pathways 
 Neural receptive field expansion 
These mechanisms are commonly reported to result in hyperalgesia (i.e. 
increased sensitivity to painful stimulus), allodynia (i.e. painful perception of non-
painful stimuli), and increased temporal summation (i.e. increased pain perception in 
response to repetitive noxious stimuli over time) (den Boer et al., 2019; Clifford J 
Woolf, 2011). 
2.3.1.2.2 Descending modulation 
Modulation, including facilitation and inhibition, of nociceptive inputs by 
brainstem regions at the level of the spinal cord is a well-documented phenomenon 
(Basbaum et al., 2009; Porreca, Ossipov, & Gebhart, 2002). Descending modulation in 
this manner utilizes neurons of the rostral ventromedial medulla and periaqueductal 
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grey of the brainstem in order to influence the excitation of primary afferent terminals 
and/or dorsal horn interneuron excitability (Behbehani & Fields, 1979; Fields & 
Basbaum, 1978; Porreca et al., 2002). 
Descending modulation of pain experiences is likely to be the result of multiple 
cognitive, attentional, and affective processes (Basbaum et al., 2009; Porreca et al., 
2002). For example, acute stress and anticipation of pain relief (i.e. placebo effect) have 
shown to produce analgesic effects (i.e. inhibition) (Butler & Finn, 2009; Wager & 
Atlas, 2015), whereas chronic stress and anxiety have demonstrated facilitation of 
nociceptive pathways (Jennings, Okine, Roche, & Finn, 2014; Quartana, Campbell, & 
Edwards, 2009). Although classically, descending inhibitory processes have received 
significant attention in pain research, it has been suggested that descending facilitation 
may contribute to the development and maintenance of hyperalgesia seen in chronic 
pain states (Fields, 1992; Porreca et al., 2002).  
2.3.1.2.3 Cortical grey matter 
Changes to cortical grey matter have been described in multiple clinical pain 
populations, such as fibromyalgia (Kuchinad et al., 2007), low back pain (Apkarian et 
al., 2004), and ankylosing spondylitis (Wu et al., 2013). Investigations utilizing voxel-
based morphometry have demonstrated changes in regions associated, for instance, 
with pain processing (e.g. cingulate, insulate, and prefrontal cortices) which have been 
linked to functional abnormalities in descending modulation of pain, as well as 
cognitive and emotional functioning (A Agostini et al., 2017; Kuchinad et al., 2007; 
Wu et al., 2013). Proposed mechanisms underlying grey matter changes in these 
populations include possible reduction in cell size, atrophy, and apoptosis from 
excitotoxicity and/or inflammatory mediators (A Agostini et al., 2013; Apkarian et al., 
2004; Kuchinad et al., 2007; May, 2008). In chronic pain populations, for instance, the 
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often excessive and ongoing nociceptive inputs, as a consequence of nervous system 
sensitization, are thought to cause excitotoxicity resulting in neural loss (A Agostini et 
al., 2013; Apkarian et al., 2004; Kuchinad et al., 2007; May, 2008). 
A study investigating Crohn’s disease demonstrated a strong overlap in grey 
matter abnormalities compared with those seen in chronic pain conditions, suggesting a 
common basis (A Agostini et al., 2013). These authors suggest that the structural brain 
changes observed in Crohn’s disease may account for persistent abdominal pain in 
patients demonstrating clinical disease remission. Similar to studies investigating 
chronic pain, Agostini et al. (2013) postulated that grey matter loss in IBD patients may 
also be related to excitotoxicity from excessive nociceptive afferents. However, these 
authors suggested that neuronal loss in IBD may be the consequences of recurrent 
intestinal inflammation, as well as the overproduction of inflammatory mediators. 
Circulating inflammatory cytokines are thought to directly induce neural apoptosis and 
decreased neurogenesis through signals which may be projected to several cortical and 
subcortical regions of the brain (A Agostini et al., 2013; Miller, Maletic, & Raison, 
2009). 
 
2.4 Gut-brain axis 
Current literature describes multiple direct and indirect pathways that maintain 
an extensive bidirectional communication network between the gastrointestinal tract 
and the CNS, involving neuroendocrine and neuroimmune pathways (Carabotti, 
Scirocco, Maselli, & Severi, 2015; Grenham, Clarke, Cryan, & Dinan, 2011; Tillisch & 
Labus, 2014). Exploration of this communication network has led to the term GBA to 
describe the complex interactions of these systems. The GBA is thought to monitor and 
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integrate gut function with systemic processes, by linking higher brain centres with the 
gut through mechanisms such as immune activation, intestinal permeability, enteric 
reflexes, and neuroendocrine signalling (Carabotti et al., 2015).  
2.4.1 Gut-brain-axis interactions 
The GBA is comprised of multiple feedback loops with downstream effects 
aimed at maintaining homeostasis, involving the CNS, enteric nervous system (ENS), 
autonomic nervous system (ANS), and the hypothalamic-pituitary-adrenal (HPA) axis 
(Carabotti et al., 2015).  The most consistent supra-spinal regions involved in GBA 
interactions include the limbic system (e.g. hypothalamus, amygdala, anterior cingulate 
cortex, prefrontal cortex, and hippocampus), and sensorimotor and integration centres 
(e.g. somatosensory cortices, insula, and thalamus) (Jones, Dilley, Drossman, & 
Crowell, 2006). The limbic system mediates emotional responses and is likely to be the 
primary driver for CNS interactions in the GBA (Jones et al., 2006). 
Residing as two plexuses within the intestinal walls, the ENS is responsible for 
the intrinsic innervation of the gastrointestinal tract, primarily controlling motility, 
absorption, secretion, and visceral sensitivity (Mukhtar, Nawaz, & Abid, 2019). The 
ENS contains multiple terminals from efferent and afferent spinal pathways, as well as 
ANS pathways (e.g. vagal and sympathetic transmission). Within the brain, the ANS is 
primarily controlled by the hypothalamus, which acts to influence gut motility and 
secretion by modulating ENS activity (Taché & Bonaz, 2007). Factors such as stress, 
emotion, and cognition, modulated by supra-spinal regions, can independently trigger 
and/or influence ANS interactions with the gut (Mukhtar et al., 2019; Taché & Bonaz, 
2007).  
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It has been understood for several decades that stress, whether inflammatory, 
traumatic, or psychological, triggers activation of the HPA axis (Tsigos & Chrousos, 
2002). As the primary neuroendocrine driver of the body’s stress response, HPA 
activation results in multiple protective processes, regulating immune activity to protect 
the individual from excessive inflammation (Toljan & Vrooman, 2017; Tsigos & 
Chrousos, 2002). During acute stress events, glucocorticoids (e.g. cortisol) are released 
from the adrenal glands as a consequence of HPA activation and act as the primary 
mediators of the stress response. In terms of the GBA, glucocorticoids are understood 
to affect local (gut) and systemic immune cell activity, thereby affecting gut 
permeability and gut microbiome composition (Toljan & Vrooman, 2017). In addition 
to immune regulating effects, glucocorticoids also act to downregulate the HPA axis 
itself through a negative feedback loop. 
The GBA paradigm has previously been considered largely in the context of 
functional gastrointestinal disorders (e.g. irritable bowel syndrome (IBS) and 
gastroesophageal reflux disease) (Mukhtar et al., 2019). However, the role of the GBA 
in IBD has more recently received attention, primarily focusing on models exploring 
psychological features in patients with IBD, such as depression, anxiety, and stress 
(Bonaz & Bernstein, 2013; Borren, van der Woude, & Ananthakrishnan, 2018; Taché 
& Bonaz, 2007). Interestingly, it is well-understood that IBS is commonly reported in 
IBD, with patients in long-standing remission reported to be two to three times more 
likely to have IBS than the general population (Halpin & Ford, 2012; Simrén et al., 
2002).  
IBS is characterized by abdominal pain and altered bowel habits, where the 
diagnosis is based solely on clinical features and exclusion of other organic conditions, 
such as IBD (Canavan, West, & Card, 2014). IBS belongs to a group of conditions 
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termed ‘central sensitivity syndromes’ (CSS), also including interstitial cystitis, 
temporomandibular joint disorder, and fibromyalgia (Yunus, 2008). The underlying 
pathophysiology of CSSs is thought to be related to changes in higher brain centres, 
resulting in common symptomologies, such as psychological distress, sleep 
disturbances, fatigue, pain, allodynia, and hyperalgesia (Verne et al., 2001; Yunus, 
2008). Specifically, systematic reviews reporting investigation of mechanisms related 
to central sensitization have been reported in individuals with IBS (Albusoda et al., 
2018; Chakiath et al., 2015; Marcuzzi et al., 2019). Therefore, in addition to the notable 
overlap in neural pathways described in chronic pain and GBA literature, the high 
prevalence of IBS in IBD patients further suggests the potential for shared mechanisms 
mediating disease and pain processes in IBD.  
 
2.5 Chapter Summary 
Review of current IBD and chronic pain literature suggests an overlap in 
constructs seen in patient populations. Consideration of these constructs within the 
paradigm of the GBA illustrates shared mechanisms and the potential for common 
pathways in the maintenance of persistent MSK pain in IBD populations. In 
consideration of these shared constructs, the multifactorial nature of persistent MSK 
pain in patients with IBD is not well characterized nor fully captured through previous 
investigations. Therefore, Chapter 3 further explores these constructs as the primary 





3 Primary Thesis Domains and Study Methodologies: Review of the 
Literature 
 
3.1 Chapter overview 
The previous chapter highlighted the potential for shared mechanisms and 
constructs between pain responses and features of IBD, including nervous system 
pathways (peripheral, autonomic, enteric, and central) and psychological features. The 
following chapter presents a review of the literature exploring these shared constructs, 
including IBD, pain, central sensitization, and psychological features. This chapter also 
presents a review of the methodologies used to test study hypotheses in the current 
thesis.  
 
3.2 Primary Domains  
3.2.1 IBD features 
Current literature describes ongoing challenges of characterizing features of 
IBD within broader clinical and research constructs, such as IBD activity and severity 
of the disease. Disease activity and severity are distinct yet overlapping concepts in 
IBD, both of which are used to evaluate the effectiveness of treatment (Peyrin-Biroulet 
et al., 2016; Siegel et al., 2016; Walsh et al., 2016). IBD activity is conceptualized as a 
cross-sectional assessment of inflammatory activity, whereas disease severity includes 
additional longitudinal and historical factors which are thought to provide a more 
complete clinical picture (Peyrin-Biroulet et al., 2016; Siegel et al., 2016; Walsh et al., 
2016). Current literature suggests that some or all of the following factors may indicate 
the progression to severe IBD, including persisting disabling symptoms, impaired 
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health-related quality of life (HRQOL), repeated flares, development of irreversible 
penetrating and/or stricturing lesions, need for repeated courses of steroids, and need 
for surgery (Gomollón et al., 2016; Peyrin-Biroulet et al., 2016; Satsangi, Silverberg, 
Vermeire, & Colombel, 2006). Therefore, features of IBD explored in the present thesis 
are presented below under the sub-headings: IBD activity, disease course, and impact of 
the disease.  
3.2.1.1 IBD activity 
Following IBD diagnosis, the construct monitored by gastroenterologists is IBD 
activity in efforts to classify and treat the relapsing/remitting nature of this disease. 
From a theoretical and methodological point of view, diagnostic criteria and 
classification of a disease are understood to be distinct (Vitali & Del Papa, 2017). The 
differential diagnosis of IBD was not identified as an aim of the current research, 
therefore this thesis included investigation of individuals with previously established 
IBD diagnoses. As such, criteria for the differential diagnosis of IBD is not presented in 
the thesis. Conversely, IBD activity as a classification of relapsing or remitting IBD 
status, reflects a cross-sectional assessment of biological inflammatory activity using 
standardised tools with the intended purpose of guiding ongoing IBD management (C. 
N. Bernstein et al., 2010; Best, 2006; Siegel et al., 2016). Therefore, IBD activity in the 
present thesis is explored as separate construct from differential IBD diagnosis, and is 
presented below. 
The current recommendation for assessing IBD activity include assessment of 
endoscopic, histologic, radiographic, biomarker, and symptomatic domains (Neurath & 
Travis, 2012; Walsh et al., 2016). Defining active IBD versus remission status 
generally involves a combination of these domains. However, characterizing IBD 
activity is challenging due to the heterogeneous nature of IBD, as well as the lack of 
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validated definitions of targets within some domains and consequently the disparity 
between findings in assessment domains (Walsh et al., 2016). For instance, mucosal 
healing (i.e. absence of ulcerations and erosions) is identified as a surrogate marker for 
effective disease control, and therefore the remission target of endoscopic assessments 
(Neurath & Travis, 2012; Walsh et al., 2016). The value in identifying endoscopic 
remission lies in its correlation with symptom relief, decreased surgical and hospital 
encounters, and overall improved HRQOL. However, current literature reflects a lack 
of defined and validated thresholds for mucosal healing (Khanna et al., 2016; Neurath 
& Travis, 2012; Sandborn et al., 2002; Vashist et al., 2018). Furthermore, poor 
correlation between measures within symptomatic and endoscopic domains are well-
described (Neurath & Travis, 2012; Walsh et al., 2016).  
Measures of symptomatic IBD activity, such as the Simple Clinical Colitis 
Activity Index, have previously demonstrated good to excellent psychometrics (Higgins 
et al., 2007) with sufficient validity to discriminate IBD activity (area under the 
receiver operating characteristic curve > 0.90) and strong test-retest reliability (ICC, 
0.94; 95% CI, 0.86 – 0.97) (Turner et al., 2009). However, they have often been 
criticised for their poor correlation with the objective clinical features, such as 
endoscopic and biomarker assessments (Gracie et al., 2016; Sipponen et al., 2008). 
Functional gastrointestinal disorders (e.g. IBS) present with similar symptoms as active 
IBD, but without intestinal inflammation (Burgmann et al., 2006). The presence of 
overlapping IBS has been proposed as an explanation for the inconsistent correlation of 
symptomatic IBD assessments with other measures of disease activity (Burgmann et al., 
2006). However, when considering the collective versus individual indications of IBD 
activity, symptomatic assessments have demonstrated adequate ability to discriminate 
between remission and active IBD status (Turner et al., 2009).  Assessing IBD activity 
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using more invasive endoscopic and radiologic investigations is costly, limiting the 
ability for regular and/or repeated testing in some patients. Thus, symptomatic 
assessments, such as the Harvey-Bradshaw Index and Simple Clinical Colitis Activity 
Index, have become popular as screening tools to indicate the need for further clinical 
assessment of IBD activity (Turner et al., 2009).  
3.2.1.2 Disease course 
Current opinion in IBD literature suggests that assessment of disease course in 
IBD should include consideration of IBD subtype, previous surgical interventions, 
medication use, presence of EIMs, age at diagnosis, and disease extent (Peyrin-Biroulet 
et al., 2016; Siegel et al., 2016). Disease extent in Crohn’s disease and ulcerative colitis 
is most frequently assessed using the Montreal classification system, which is currently 
considered the gold standard for describing phenotypes of IBD and takes into account 
the location and behaviour of active disease (Gomollón et al., 2016). Using this criteria 
Crohn’s disease is classified by age at diagnosis and disease extent (location and 
behaviour), and ulcerative colitis is classified by disease extent. Disease location in 
Crohn’s disease is classified as terminal ileum, colonic, and ileocolonic, as well as with 
or without upper gastrointestinal tract location (Satsangi et al., 2006). Disease extent in 
ulcerative colitis is described as: (1) disease limited to the rectum (i.e. distal to the 
rectosigmoid junction), termed ulcerative proctitis, (2) disease distal to the splenic 
flexure, termed left-sided or distal ulcerative colitis, and (3) disease extending proximal 
to the splenic flexure, termed extensive ulcerative colitis or pancolitis (Satsangi et al., 
2006). Although the classification of ulcerative colitis by disease behaviour has 
received significantly less attention, identification of stricturing and penetrating disease, 
as well as perianal involvement, are understood to be important indicators of disease 
severity in Crohn’s disease (Satsangi et al., 2006).  
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3.2.1.3 Impact of the disease 
Review of the current literature suggests widespread agreement that a primary 
outcome of IBD management is improved HRQOL (Gomollón et al., 2016; Peyrin-
Biroulet et al., 2016; Satsangi et al., 2006). A number of clinical, psychological, and 
demographic factors have been found to be predictors of HRQOL in IBD. Current 
literature demonstrates differences in predictors of  Gender, clinical symptoms, severity 
of disease, surgical interventions, flares per year, comorbidity, and perceived stress 
have consistently demonstrated association with HRQOL (Francesc Casellas, López-
Vivancos, Badia, Vilaseca, & Malagelada, 2000; F Casellas, Lopez-Vivancos, Vergara, 
& Malagelada, 1999; Hjortswang et al., 2003; Moradkhani, Beckman, & Tabibian, 
2013). However, factors such as age, type of IBD, socioeconomic status, and marital 
status have less consistently been found to influence HRQOL (E. J. Irvine, 1997; 
Moradkhani, Kerwin, Dudley-Brown, & Tabibian, 2011; Oxelmark, Magnusson, 
Löfberg, & Hillerås, 2006).  
Interestingly, although the different phenotypes of IBD have not been identified 
as a predictor of HRQOL, a recent study (Perera et al., 2018) suggests the IBD 
phenotypes may demonstrate a unique profile of predictors. For instance, factors such 
as current age, age at diagnosis, and disease duration have not shown to be predictors of 
with phenotype (Gurková & Soósová, 2018; Perera et al., 2018), psychological stress 
and disease extent were shown to have a negative impact on patients with CD only 
(Perera et al., 2018). These results suggest that although disease features, such as 
activity, have been identified as important determinants of HRQOL in IBD, the 
assumption that IBD phenotypes represent similar determinants and that achieving 
clinical remission results in improved HRQOL is less supported. Consequently, current 
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literature would signify the need to specifically evaluate HRQOL across the different 
types of IBD in order to indicate the presence of additional risk factors.   
 
3.2.2 Pain features 
The use of a mechanistic approach to evaluate features of chronic MSK pain has 
been actively promoted over the past few decades in reflection of the growing 
knowledge related to underlying pathophysiological processes (Smart, Blake, Staines, 
& Doody, 2011; Vardeh et al., 2016; C. J. Woolf, 2004; Clifford J Woolf et al., 1998). 
It has been suggested that exploration of pain features with mechanism-based 
considerations could improve management pathways by facilitating targeted treatment 
strategies, thereby optimizing patient outcomes (Nijs et al., 2014; Smart et al., 2011; 
Clifford J Woolf et al., 1998). As such, mechanism-based classification, whereby pain 
is classified according to the dominant pathophysiological mechanisms responsible for 
its generation and/or maintenance, has been proposed (Smart et al., 2011). Distinct 
categories within this classification system commonly include nociceptive, peripheral 
neuropathic, and central sensitization pain types (Smart, Blake, Staines, Thacker, & 
Doody, 2012a, 2012b, 2012c).  
The ongoing challenge of mechanism-based classification lies in the absence of 
gold standards for directly assessing pathophysiological pain mechanisms. However, it 
has been suggested that the different categories of pain mechanisms (i.e. nociceptive, 
peripheral neuropathic, and central sensitization pain) may be clinically identifiable and 
distinguishable, through clinical and self-reported measures, based on the pattern of 
signs and symptoms of each category (Cruz-Almeida & Fillingim, 2014; Nijs et al., 
2015; Smart et al., 2011). As such, exploration of MSK pain in the present thesis 
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includes evaluation of typical pain features, including severity, location, quality, and 
interference.  
3.2.2.1 Severity 
Pain severity is widely accepted as one of the most fundamental dimensions of 
pain experiences regardless of the disease. The level of pain severity at initial 
assessment was found to be a significant predictor of complex pain management in 
some patients (Hjermstad et al., 2011). Pain severity is thought to be a primary factor 
that determines the impact of pain on the patient and is the most common feature 
explored within the “sensory/discriminative” dimension of pain experiences (Melzack 
& Casey, 1968). Current literature describes a vast array of pain severity assessment 
tools, of which the self-report unidimensional scales (i.e. numeric rating scale (NRS), 
visual analogue scale, or verbal rating scale) are recommended by expert consensus 
(Hjermstad et al., 2011; Williamson & Hoggart, 2005) and by far the most widely 
employed measures. 
3.2.2.2 Location 
Assessment and interpretation of MSK pain distribution is a fundamental 
consideration in the identification of predominant neuropathic, nociceptive, or central 
sensitization pain mechanisms (Nijs et al., 2015; Smart et al., 2011). For instance, the 
strongest indicator of predominately nociceptive pain was found to be pain localized to 
the area of injury or dysfunction (with or without some somatic referral) (Smart et al., 
2011). In patients with low back pain, those presenting with localized pain were over 
69 times more likely to be classified with a dominance of nociceptive pain compared to 
other pain types (Smart et al., 2011). Conversely, patients with low back pain 
distributed in a dermatomal or cutaneous referral pattern were over 24 times more 
likely to be classified with a dominance of neuropathic pain (Smart et al., 2011). 
40 
Finally, patients presenting with an unpredictable pattern in addition to other features, 
such as disproportionate pain severity and multiple/nonspecific aggravating/easing 
factors, were over 30 times more likely to be classified with a dominance of central 
sensitization pain (Smart et al., 2011). Specifically, distribution patterns indicative of 
central sensitization pain are thought to include diffused pain, such as bilateral pain, 
pain varying in anatomical locations, non-segmental distribution, and generalized pain 
(Nijs et al., 2014). As such, current literature supports distinguishing MSK pain 
locations as regional versus generalized in an effort to suggest dominant pain types 
described above.  
3.2.2.3 Quality 
Evaluating descriptors of pain may be useful in identifying pain types (Edwards 
et al., 2016; Jensen, 2006; Nijs et al., 2014; Victor et al., 2008; Clifford J Woolf, 2011). 
It has been well-described, for instance, that pain arising from nociception has a clear 
and proportionate mechanical/anatomical nature(Smart et al., 2011). Nociceptive pain 
may be described as ‘sharp’, intermittent pain occurring with movement and a more 
constant dull ache or throb described at rest (Smart et al., 2011). Conversely, 
neuropathic pain is commonly described as burning, shooting, or electrical in nature, 
with pain commonly referred to in dermatomal or cutaneous distributions (Smart et al., 
2011).  
Individuals who present with chronic pain often describe characteristics 
common to multiple pain types (Finnerup et al., 2016; Hochman, Davis, Elkayam, 
Gagliese, & Hawker, 2013; Spahr et al., 2017). For example, studies of patients with 
chronic low back pain report description of both neuropathic and central components, 
without meeting the diagnostic criteria for neuropathic lesions (Spahr et al., 2017).  
Similarly, changes to supra-spinal regions have been reported in nociceptive as well as 
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non-nociceptive pain types (Apkarian et al., 2004). Therefore, current literature 
suggests that consideration of pain quality within broader clinical algorithms may be 
more useful in differentiating pain types than using quality descriptors alone (Nijs et al., 
2015; Smart et al., 2011). 
3.2.2.4 Interference 
Exploration of the extent to which pain hinders engagement with social, 
cognitive, and emotional activities, termed pain interference (Jensen et al., 2017), has 
been identified as an important construct of pain investigations. Previous pain models 
describe interference with daily activities resulting from ongoing painful experiences, 
with the assumption that relief from pain correlates with an improvement in function 
(Dworkin et al., 2005). However, exploration of interference constructs indicates that 
although severity, interference, and function are related, they are understood to be 
distinct domains, each requiring consideration (Amtmann et al., 2010; Karayannis, 
Sturgeon, Chih-Kao, Cooley, & Mackey, 2017).  
The complexity of interference constructs is further highlighted by 
investigations of age-related influences on pain interference, specifically directional 
influences. A large study investigating pain interference in IBD patients demonstrated 
slightly improved scores in older adults (> 60 years) compared to younger individuals 
(Kappelman et al., 2014). However, indication of worse interference in older adults has 
been reported within the general population (Thomas, Mottram, Peat, Wilkie, & Croft, 
2007). Here, poor social networks were found to be strongly linked with reports of 
worse pain interference (Thomas et al., 2007). Conversely, chronic pain populations 
have demonstrated greater interference in younger individuals, where results were 
strongly associated with greater social dissatisfaction (Blyth et al., 2001). As such, 
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current literature suggests influences to pain interference from common features of pain 
(i.e. severity and disability), as well as psychosocial factors. 
3.2.3 Central sensitization  
Risk factors associated with the development of central sensitization pain have 
been identified as greater pain severity, female gender, history of abuse, greater pain 
interference, sleep disturbances, stress, and multiple painful comorbidities (Kindler, 
Jones, Perrin, & Bennett, 2010; Nijs et al., 2017). However, in the absence of a gold 
standard to directly identify mechanisms related to central sensitization, a variety of 
diagnostic surrogate markers are commonly used to explore various clinical and 
experimental characteristics (Clifford J Woolf, 2011). Clinical algorithms have been 
proposed to identify central sensitization pain through symptom identification (Nijs et 
al., 2015). In addition exploration of somatosensory functioning through assessments, 
such as quantitative sensory testing (QST), have been proposed (Cruz-Almeida & 
Fillingim, 2014). Therefore, investigation of central sensitization in the present thesis is 
through assessment of symptoms related to central sensitization and assessment of 
somatosensory functioning. 
3.2.3.1 Central sensitization symptomology 
 Current literature suggests that central sensitization represents the 
pathophysiological mechanisms responsible for the overlapping clinical features of 
central sensitivity syndromes (CSSs), such as fibromyalgia, chronic fatigue, IBS, and 
temporomandibular joint disorder (Mayer et al., 2012; Yunus, 2008). It has been 
proposed that the symptoms of these conditions can be considered not as belonging to 
individual disorders, but as different manifestations of a common aetiology (i.e. central 
sensitization) (Mayer et al., 2012). This viewpoint led to the development of the central 
sensitization inventory (CSI) as a screening tool which broadly assesses overlapping 
43 
dimensions of CSSs and quantifies the degree of related symptomatology (Mayer et al., 
2012).  
CSI has been validated to investigate an array of symptoms and risk factors 
associated with the development of central sensitization and CSSs, within the domains 
of physical, emotional distress, headache/jaw, and urological features (Mayer et al., 
2012). The presence of these symptoms is understood to be related to sensitivity of the 
somatosensory system, where increased sensitivity implicates changes to sensory 
processing within the CNS (Mayer et al., 2012). A CSI score of ≥ 40 was originally 
validated as the benchmark to identify patients with positive symptomology correlating 
with the presence of CSSs (Neblett et al., 2013).  
Psychometric evaluations of the CSI across languages have demonstrated good 
test-retest reliability (intraclass correlation coefficients ranging from 0.88 to 0.97) and 
internal consistency (Cronbach’s a ranging from 0.88 to 0.91) (Cuesta-Vargas, Roldan-
Jimenez, Neblett, & Gatchel, 2016; Kregel et al., 2017; Mayer et al., 2012; Pitance et 
al., 2016). Evidence of convergent and discriminant validity has also been found in a 
number of studies. Total CSI scores have shown strong correlations with other 
validated self-report measures of pain severity, depressive and anxiety symptoms, as 
well as sleep disturbance, all of which have been associated with central 
sensitization/CSSs (Neblett et al., 2013; Neblett, Hartzell, Mayer, Cohen, & Gatchel, 
2017). When compared to healthy controls, higher CSI scores have demonstrated 
association with the presence of one or more CSSs in chronic pain patients (Neblett et 
al., 2013; Neblett, Hartzell, Mayer, et al., 2017). Total CSI scores have shown to 
discriminated between individuals with chronic musculoskeletal pain and pain-free 
controls (Kregel et al., 2017), individuals with fibromyalgia from both acute ankle 
sprain and pain-free controls (Pitance et al., 2016), and between individuals with 
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fibromyalgia/chronic widespread pain, regional chronic low back pain, and health 
controls. Higher CSI scores have demonstrated association with a wider body area 
distribution of self-reported pain in a group of osteoarthritis patients scheduled to 
undergo primary total knee arthroplasty (Lluch Girbés et al., 2016) and increased 
widespread pain sensitivity in shoulder patients undergoing QST testing (Coronado & 
George, 2018).  
Recently, the use of five CSI severity levels has been proposed to offer better 
clinical utility in assessing a patient’s symptom presentation, making initial treatment 
decisions, and identifying meaningful clinical changes in response to treatment 
(Neblett, Hartzell, Mayer, et al., 2017; Scerbo et al., 2018). The mean CSI scores in 
each different CSI severity categories have been shown to correlate with female gender, 
the number of CSS diagnoses, as well as the presence of psychological features. 
Although female gender is a known risk factor for CSS diagnoses (Arnold et al., 2006; 
Kurland, Coyle, Winkler, & Zable, 2006), the highest CSI severity group demonstrated 
the strongest association with female gender (Neblett, Hartzell, Mayer, et al., 2017). 
Higher CSI scores were also found to correlate with individuals presenting with more 
CSS diagnoses. Individuals presenting with one CSS diagnosis demonstrated mean CSI 
scores within the moderate severity range, while those with four or more diagnoses fell 
within the extreme severity range (Neblett, Hartzell, Mayer, et al., 2017). The lowest 
CSI severity group reported the least amount of depressive symptoms, pain intensity, 
and perceived disability, whereas the highest CSI severity group reported the greatest 
amount of these symptoms. Although the use of CSI severity levels described in this 
emerging literature has not been validated, it provides a useful way of interpreting this 
central sensitization screening tool in clinical practice (Scerbo et al., 2018). 
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3.2.3.2 Somatosensory 
Over the last two decades, assessments such as QST and conditioned pain 
modulation (CPM) have been developed as bedside assessments of somatosensory 
functioning (Arendt-Nielsen & Yarnitsky, 2009; Fillingim, Loeser, Baron, & Edwards, 
2016; Rolke et al., 2006). QST is a group of assessments (e.g. pressure pain threshold 
(PPT) and temporal summation (TS)) which evaluate the perceptual responses to 
systematically applied sensory stimuli, in an effort to characterize function or 
dysfunction within nociceptive pathways (Arendt-Nielsen & Yarnitsky, 2009; Fillingim 
et al., 2016; Rolke et al., 2006). Similarly, CPM is believed to reflect the perceptual 
manifestation of descending inhibition projection neurons from the brainstem to the 
dorsal horn (Arendt‐ Nielsen et al., 2018). 
Although somatosensory assessments, such as QST, are understood to assess the 
functionality of the entire neural circuit from peripheral receptor to higher brain centres, 
they cannot identify the exact source of somatosensory dysfunction (Arendt‐ Nielsen et 
al., 2018; Cruz-Almeida & Fillingim, 2014). However, QST and CPM assessments are 
useful, non-invasive methods for assessing the loss and gain of sensory function, which 
may contribute to our understanding of participating pathophysiological pain 
mechanisms (Arendt‐ Nielsen et al., 2018; Cruz-Almeida & Fillingim, 2014). 
Therefore, exploration of somatosensory functioning in the present thesis is presented 
below and include assessments of PPT, TS, and CPM. 
3.2.3.2.1 Pressure pain threshold 
PPT is a static QST assessment, defined as the minimum force applied which 
induces pain (Arendt‐ Nielsen et al., 2018). Decreased thresholds are related to 
facilitated gains within pain pathways, and are used clinically to identify localised or 
widespread hyperalgesia (Arendt‐ Nielsen et al., 2018; Fillingim et al., 2016). PPT 
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performed at painful regions, such as the low back, may detect local hypersensitivity 
related to processes of peripheral sensitization, or alternatively detect regional 
hypersensitivity related to processes of central sensitization (Neziri et al., 2012). As 
such, PPT in isolation is unable to determine whether assessments at the painful region 
reflect peripheral sensitization, central sensitization, or both. 
A recent systematic review indicated PPT to be both reliable and valid in the 
assessment of somatosensory functioning in low back pain patients (Alqarni, 2018). 
The reliability and discriminative validity of PPT were found to be a strong diagnostic 
predictor for ruling in/out chronic low back pain (Neziri et al., 2012; Vuilleumier et al., 
2015). Additionally, after adjusting for confounders, such as age, gender, and 
psychological factors, PPT was identified as the most sensitive QST assessment to 
discriminate chronic low back pain patients from healthy controls (Neziri et al., 2012; 
Neziril et al., 2011). Interestingly, adjustments for these confounders demonstrated 
little effect on associations with PPT, suggesting PPT was confounded only to a small 
extent by these covariates (Neziri et al., 2012).  
Results from an investigation exploring age and gender effects of PPT in 
healthy individuals, demonstrated a significant increase in PPT sensitivity in 
individuals aged 63 years and older at the distal phalanges; however no gender effects 
were found (Lautenbacher, Kunz, Strate, Nielsen, & Arendt-Nielsen, 2005). 
Conversely, PPT investigation of the face, hands, and feet in healthy controls identified 
gender effects in PPT, but only as a function of age (i.e. only patients ≤ 50 years old) 
(Magerl et al., 2010). As such, current literature suggests age effects on PPT may differ 
regionally, as well as mediate gender effects in a non-linear fashion. 
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3.2.3.2.2 Temporal summation 
TS describes the wind-up process leading to a progressive increase in neuronal 
output within the dorsal horn from a barrage of identical afferent nociceptive stimuli 
(Arendt‐ Nielsen et al., 2018; Staud, Vierck, Cannon, Mauderli, & Price, 2001). In the 
presence of central sensitization, this increase in neuronal output translates into an 
integration of signalling causing greater pain experiences which last after the end of the 
repeated stimuli (Arendt‐ Nielsen et al., 2018). In experimental TS, it has been 
demonstrated that a painful stimulus repeated up to 3 times per second for 5 to 10 
seconds will integrate, causing increased pain at the end of the stimulus series 
(Arendt‐ Nielsen et al., 2018). The increase in excitability of spinal cord neurons from 
TS is commonly quantified by a wind-up ratio and considered a measure of increased 
central gain of nociception or pain facilitation (Rolke et al., 2006).   
Similar to PPT, after adjusting for confounders, TS was found to discriminate 
between chronic low back pain patients and healthy controls, where confounders 
ultimately demonstrated a little effect on associations (Neziri et al., 2012). However, 
unlike PPT, TS was found to be a strong predictor for ruling in chronic low back pain, 
while demonstrating a poor ability for ruling out chronic low back pain (Neziri et al., 
2012). An investigation of TS performed at the volar forearm (Lautenbacher et al., 
2005), as well as the face, hands, and feet (Magerl et al., 2010), in healthy controls 
found no age or gender effects on TS assessments. 
3.2.3.2.3 Conditioned pain modulation 
CPM is a dynamic sensory test believed to assess the descending inhibitory 
pathways in pain modulation (Arendt‐ Nielsen et al., 2018). CPM explores the change 
in pain reported from one stimulus (the test stimulus) before and after the application of 
a second pain stimulus at a remote body site (the conditioning stimulus). The 
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magnitude of the CPM effect is defined as the absolute difference of the test stimulus 
after minus before the conditioning stimulus. A positive CPM effect indicates 
successful modulation and the individual is said to be a CPM responder. This “pain-
inhibits-pain” phenomenon is thought to trigger activation of a cortically regulated 
spinal-bulbo-spinal loop that involves the activation of descending inhibition processes 
(David Yarnitsky et al., 2010). 
A recent systematic review identified CPM as a valid and reliable assessment of 
somatosensory functioning in low back pain patients (Alqarni, 2018). Decreased CPM 
responses have also been reported in patients with a variety of pain disorders (Lewis, 
Rice, & McNair, 2012; van Wijk & Veldhuijzen, 2010) compared with healthy 
individuals. Additionally, CPM responses were found to predict outcomes suggesting 
the development of chronic pain (David Yarnitsky et al., 2008), as well as predict pain 
treatment outcomes (David Yarnitsky, Granot, Nahman-Averbuch, Khamaisi, & 
Granovsky, 2012). Interestingly, a recent meta-analysis indicated that IBS patients are 
almost 5 times more likely to demonstrate decreased CPM responses compared to 
healthy controls (Albusoda et al., 2018).  
A systematic review with meta-analysis indicated age to be the strongest 
moderator of CPM effects, with a decreased response in older adults (Lewis et al., 
2012). Similarly, gender effects have been reported, with men demonstrating greater 
CPM responses compared to women (Popescu, LeResche, Truelove, & Drangsholt, 
2010). Although psychological factors (i.e. depression, anxiety, and pain 
catastrophizing) have demonstrated association with CPM responses, influences of 
psychological features are reported to be specific to the CPM test modalities (i.e. 
electrical, heat, or pressure) (Nahman-Averbuch, Nir, Sprecher, & Yarnitsky, 2016). 
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3.2.4 Psychological features 
Psychological factors, such as mood disorders, stress, and coping, have been 
identified as important influences not only to IBD HRQOL and frequency of flares, but 
also to acute and chronic pain experiences (Boersma & Linton, 2005; Roth et al., 2007; 
Michael JL Sullivan et al., 2001; Sweeney et al., 2018; Villemure & Bushnell, 2002). 
Evaluation of cognitive and affective features are commonly used to explore the 
modulation of pain perceptions and nociceptive transmission (Villemure & Bushnell, 
2002). Mechanisms by which psychological factors modulate pain experiences are 
complex and include multiple supra-spinal regions. Psychological factors have 
demonstrated an independent association with pain severity, disability, as well as neural 
hypersensitivity in multiple chronic pain (Finan, Quartana, et al., 2013; Sterling et al., 
2008; Villemure & Bushnell, 2002) and healthy populations (Hven et al., 2017; 
Villemure & Bushnell, 2002). Interstingly, psychological variables were found to more 
frequently change in parallel with fluctuations in CSS, specifically temporomandibar 
disorders, when compared to QST measures (Fillingim et al., 2018). Psychological 
factors explored in the present thesis are introduced below, including mood disorders, 
perceived stress, affective style, and pain catastrophizing. 
3.2.4.1 Mood disorders 
The presence of mood disorders is well-recognised in patients with IBD 
(Andrews, Barczak, & Allan, 1987; Farrokhyar, Marshall, Easterbrook, & Irvine, 2006; 
Guthrie et al., 2002; Simrén et al., 2002; Sweeney et al., 2018). Mood disorders in IBD 
have been shown to be associated with decreased HRQOL, increased bowel symptoms, 
and led to speculations for an aetiological role in IBD (Farrokhyar et al., 2006; Guthrie 
et al., 2002; Simrén et al., 2002). Furthermore, a large US survey indicated individuals 
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with chronic pain were over four times more likely than individuals with non-chronic 
pain to experience anxiety, and over twice as likely to experience depressive disorders 
(McWilliams, Cox, & Enns, 2003). Similarly, a meta-analysis looking at studies of 
psychological functioning in chronic pain indicated that individuals with chronic pain 
were consistently more depressed than healthy individuals and were comparatively 
more anxious, both generally and in response to pain (Burke, Mathias, & Denson, 
2015). Much like in IBD, temporal effects of mood disorders in chronic pain patients 
are difficult to measure. In both conditions, it is unknown the degree to which the 
presence of mood disorders is a risk factor for the development of these chronic 
conditions, or whether mood disorders are a consequence of these troublesome 
conditions (Kurina, Goldacre, Yeates, & Gill, 2001).  
3.2.4.2 Perceived stress 
The psychological paradigm addressing how an individual appraises situations 
in their life as stressful is described as an individual’s ‘perceived stress’ (Cohen, 
Kamarck, & Mermelstein, 1983). An important distinction between perceived and 
objective stress lies in the argument that the development of stress is the cognitively 
mediated emotional response to the objective event, not the objective event itself 
(Cohen et al., 1983). This paradigm conceptualises the stress response not as an 
inherent quality of the event (e.g. intensity), but rather as dependent on personal and 
contextual factors (e.g. coping resources) (Cohen et al., 1983).  Therefore, the 
assessment of perceived stress is thought to evaluate an individual’s appraisal of events 
and may be useful in understanding the role of cognitive/affective features in an 
individual’s disease process and HRQOL.  
A significant association between perceived stress, high job strain, and altered 
PPT was reported in a large investigation of asymptomatic workers (N=3123) (Hven et 
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al., 2017). These results suggest that perceived stress may modulate somatosensory 
functioning in otherwise healthy individuals. Investigation of stress influences on MSK 
pain experiences includes a diversity of stress domains, such as recovery-stress (Heidari 
et al., 2018), work-stress (Joksimovic, Starke, vd Knesebeck, & Siegrist, 2002), early-
life stress (Kopec & Sayre, 2005), and perceived stress (Buscemi, Chang, Liston, 
McAuley, & Schabrun, 2019). A recent systematic review indicated that perceived 
stress and life stressors may have an etiologic role on the development of certain MSK 
pain types (i.e. arthritis and spinal pain) (Buscemi et al., 2019). Unfortunately, studies 
specifically investigating the influences from perceived stress to MSK pain experiences 
are limited and present with high levels of heterogeneity (Buscemi et al., 2019). Thus 
the difficulty in comparing known studies highlights the need for higher quality 
investigations to clarify and validate the roll of perceived stress in MSK pain 
experiences (Buscemi et al., 2019).  
Measures of perceived stress have demonstrated a significant association with 
an increase in IBD flares (Charles N Bernstein et al., 2010) and reduced HRQOL in 
IBD patients (Moradkhani et al., 2013). A multivariate logistic regression model 
exploring common IBD risk factors (i.e. medication, infection, smoking, negative 
affect, perceived stress, etc.), indicated that high perceived stress was the only variable 
found to be associated with symptomatic IBD flares in the final model (Charles N 
Bernstein et al., 2010). Within the gut-brain axis (GBA) paradigm, the physiological 
response to stress is understood to involve a cascade of reactions along the 
hypothalamus pituitary adrenal axis and the autonomic nervous system that affects both 
immune and inflammatory functions. The consequence of these events is thought to 
contribute to intestinal inflammation (S. M. Collins, 2001).  
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3.2.4.3 Affective style 
The two-dominant dimensions of emotional (i.e. affect) styles are referred to as 
positive and negative affect. Positive affect describes the extent to which a person feels 
enthusiastic, active, and alert (Watson, Clark, & Tellegen, 1988). A state of high 
positive affect reflects high energy, full concentration, and pleasurable engagement, 
whereas low positive affect is characterized by sadness and lethargy (Watson et al., 
1988). Conversely, negative affect is characterized by distress, anger, contempt, 
disgust, guilt, fear, and nervousness (Watson et al., 1988). States of low negative affect 
reflect calmness and serenity. Positive and negative affect styles have been shown to 
independently associated with immune function (Cohen, Alper, Doyle, Treanor, & 
Turner, 2006), somatosensory function in chronic pain (Finan, Quartana, et al., 2013), 
CSI scores and widespread pain distribution (Coronado & George, 2018), as well as 
symptomatic flares in IBD (Charles N Bernstein et al., 2010). 
Affective styles have demonstrated psychometric independence (Watson et al., 
1988), where the absence of one does not necessarily reflect the presence of the other. 
Furthermore, an investigation in patients with osteoarthritis showed distinct differences 
in dispositional affect (i.e. trait) compared to situational affect (i.e. state) in response to 
clinical and experimental pain (Finan, Quartana, et al., 2013). Additionally, 
investigations in chronic pain populations have challenged the common preoccupation 
in research and clinical practice for assessing and treating negative affect style over 
positive effect (Strand et al., 2007; Zautra, Johnson, & Davis, 2005). These 
investigations demonstrated a strong association between positive affect and pain 
resilience in pain populations (Strand et al., 2007; Zautra et al., 2005). Therefore, it 
would appear that not only are positive and negative affect styles distinct dimensions 
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within this construct, their temporal behaviour and effect outcomes are also understood 
to be distinct requiring independent consideration.  
3.2.4.4 Pain catastrophizing 
Catastrophizing has been described as negative cognitive and affective 
responses to pain that includes elements of magnification, helplessness, pessimism, and 
focused attention on pain (Michael JL Sullivan et al., 2001). The literature indicates 
that the tendency to “catastrophize” during painful experiences is related to worse pain 
perceptions and increased emotional distress (Michael JL Sullivan et al., 2001). 
Similarly, significantly greater pain catastrophizing, alongside increased sensitivity in 
QST testing, has been demonstrated in individuals with chronic low back pain 
compared to healthy controls (Meints et al., 2019). Interestingly, a high degree of pain 
catastrophizing in chronic pain individuals demonstrated an association to increased 
serum inflammatory markers in response to experimental pain, when compared to 
health controls (Lazaridou et al., 2018). This general effect suggests that inflammatory 
responses to acute pain in persistent pain patients may be selective to those with greater 
catastrophizing thoughts. 
The relationship between catastrophizing and pain experiences has shown 
remarkable consistency across a wide range of pain populations (Quartana et al., 2009; 
Michael JL Sullivan et al., 2001), including mixed chronic pain (Michael J Sullivan & 
D'Eon, 1990), low back pain (Flor, Behle, & Birbaumer, 1993), and rheumatoid 
arthritis (Keefe, Brown, Wallston, & Caldwell, 1989). Robust associations have been 
described between high level catastrophizing and worse pain-related measures, such as 
severity, interference, disability, and depression (Quartana et al., 2009). Longitudinal 
investigations found that higher baseline pain catastrophizing was associated with an 
increased risk of worse pain reports at 12 months in patients with osteoarthritis 
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(Edwards, Haythornthwaite, Smith, Klick, & Katz, 2009) and rheumatoid arthritis 
(Covic, Adamson, Spencer, & Howe, 2003). A prospective study in rheumatoid arthritis 
found that initial levels of catastrophizing predicted perceived disability scores in 
patients at 6 months, even after controlling for age, gender, illness duration, and initial 
perceived disability (Keefe et al., 1989). 
Research exploring catastrophizing and pain is largely based on the premise that 
catastrophizing is causally linked to worse pain experiences, or at least precedes painful 
experiences (Michael JL Sullivan et al., 2001). As such, less consideration has been 
given to the influences that pain experiences may have on the initial development of 
catastrophic thinking (Quartana et al., 2009; Michael JL Sullivan et al., 2001). 
Additionally, the literature describes ongoing controversy around whether 
catastrophizing is a dispositional (trait) or a situational (state) psychological feature 
(Quartana et al., 2009; Michael JL Sullivan et al., 2001). Earlier perceptions regarding 
catastrophizing viewed it as a highly modifiable and situationally-specific cognition, 
whereas more contemporary perspectives suggest this modifiability does not negate 
catastrophizing as a trait, but rather that it is moderated by additional factors and may 
demonstrate a treatment response (Quartana et al., 2009; Spanos, Stam, & Brazil, 1981; 
Michael JL Sullivan et al., 2001; Vallis, 1984). 
 
3.2.5 Study Methodologies 
As previously stated, there are numerous methodologies which could have been 
used to investigation the current research question and stated reseach aims, to included 
both qualitative and quantitative methodologies. However, current literature suggests 
that quantitative designs may represent the best approach for the objective assessment 
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of the research domains identified above (Arendt-Nielsen et al., 2012; Arendt‐ Nielsen 
et al., 2018; Catalano et al., 2017; Koop et al., 2015; S. M. Smith et al., 2017; Wu et al., 
2013). Therefore, exploration of persistent MSK pain in the current thesis includes two 
primary studies, which utilized quantitative methodologies, including: subgrouping-
based analysis (Study 1, Chapter 5), mediation analysis (Study 1, Chapter 6), and 
classic regression-based modelling (Study 2, Chapters 8 and 9) to perform hypothesis 
testing. Of these methodologies, subgrouping and mediation analyses present with 
greater complexity and controversy regarding their application and interpretation. As 
such, an overview of these two models with recommendations from statistical literature 
is presented below.  
3.2.5.1 Subgroup-based model 
Bergman and Magnusson (Bergman & Magnusson, 1997) have described an 
important distinction in statistical methods used to explore human processes and 
development. Authors describe two fundamental paradigms as variable-oriented 
approaches or person-oriented approaches. Variable-oriented approaches aim to 
identify relationships between observed variables, with the assumption that these 
relationships apply to all individuals in a population (Bergman & Magnusson, 1997). 
The difficulty of variable-oriented research lies in translating findings into statements 
about individuals, not simply the variables (Bergman & Magnusson, 1997). This has 
led to an interest in person-oriented approaches, where the focus is the individual as a 
whole. As Bergman and Magnusson (Bergman & Magnusson, 1997) noted: 
“Operationally, this focus often involves studying individuals on the basis of their 
patterns of observed characteristics that are relevant for the problem under 
consideration”. However, these authors acknowledge that the goal is not simply to 
study individuals but to evaluate variable presentation within individuals in order to 
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draw broad conclusions and identify important constructs within a population 
(Bergman & Magnusson, 1997). Person-oriented approaches that have gained in 
popularity are subgrouping-based statistical models, such as k-means cluster and latent 
class analyses (LCA) (Bergman & Magnusson, 1997; L. M. Collins & Lanza, 2013). 
A strength of subgroup-based models relates to the understanding that human 
processes, whether social, behavioural, or biological in nature, evolve over time (Nagin 
& NAGIN, 2005). Efforts to understand the developmental pathway of these processes 
have long been the focus of research efforts in the health sciences: for instance, to 
evaluate the impact of treatments on the progression of diseases (Nagin & NAGIN, 
2005). However, a common challenge is that human processes often have multiple yet 
distinct developmental pathways, which are not identifiable based on individual 
characteristics, such as age or gender (L. M. Collins & Lanza, 2013; Nagin & NAGIN, 
2005). Consequently, the aims of many research endeavours have focused on 
identifying distinct subgroups within a condition, by exploring what factors account for 
their distinctiveness (L. M. Collins & Lanza, 2013; Nagin & NAGIN, 2005).  
Common subgrouping approaches used in health research include finite mixture 
modelling (e.g. LCA and latent transition analysis) or cluster analyses (e.g. hierarchical 
and k-means). Although several unique complexities exist within and between these 
two categories of subgroup-based analyses, a few key differences are described here. 
One of the main differences between finite mixture modelling and other clustering 
algorithms relates to how subgroups are identified. In models, such as LCA, subgroups 
are derived using a probabilistic model that describes the distribution of the data (L. M. 
Collins & Lanza, 2013). This allows the researcher to assess the probability of a patient 
belonging to a particular subgroup (L. M. Collins & Lanza, 2013). A strength of 
probabilistic approaches, such as LCA, means that patients are not fully assigned to a 
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subgroup, but rather allow for the uncertainty of some individuals to present with 
overlapping traits characteristic of more than one subgroup.  
Conversely, cluster analyses involve algorithms which identify subgroups by 
partitioning variables that statistically exist in relatively close proximity to each other 
(Eshghi, Haughton, Legrand, Skaletsky, & Woolford, 2011). Unlike LCA, subgroups 
identified by cluster analyses are based on a predetermined, yet arbitrary, statistical 
distance between observed variables. This type of subgrouping often creates clear and 
compact subgroups by assigning individuals to one subgroup, regardless whether they 
demonstrate traits characteristic of differing subgroups. Additionally, clustering 
algorithms typically benefit from an assumed number of subgroups, whereas LCA can 
be used to explore data where a strong a priori hypothesis regarding the number or 
nature of subgroups does not exist (Hoijtink, 2001). In such cases, LCA allows several 
proposed models to be fit to the data, in order to later compare and determine which 
model best corresponds to the observed population (Finch & Bronk, 2011). 
The different subgroup-based approaches require assumptions to be made about 
the distribution of the observed variables in the population (Nagin & NAGIN, 2005). 
Cluster analyses assume that the observed variables are continuously distributed 
throughout a population, according to the multivariate normal distribution (Nagin & 
NAGIN, 2005). Conversely, LCA utilizes categorical variables, where strict normality 
distributional assumptions are unnecessary (L. M. Collins & Lanza, 2013). This is 
particularly useful when individuals in a population present with different scoring 
patterns of observed variables where, for instance, some individuals may score high on 
one variable and low on another, while others may have the opposite scoring patterns 
(Kongsted & Nielsen, 2017).  
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Since the 1960s the conceptual and mathematical composition of LCA has 
evolved, including the development of reliable methods for obtaining model parameters 
(L. M. Collins & Lanza, 2013). Conceptually, LCA identifies a construct, or latent 
variable, by which subgroups are derived (L. M. Collins & Lanza, 2013). Here the 
construct itself is not directly measured as an independent variable, but is 
conceptualized through the assessment of observed variables, commonly referred to as 
indicators of the construct (L. M. Collins & Lanza, 2013). It is important to note that in 
LCA, the causal flow is understood to be from the construct to the indicator variables, 
not the other way around (L. M. Collins & Lanza, 2013). As such, the observed 
indicator variables measure the construct, but the observed indicator variables do not 
cause the construct (L. M. Collins & Lanza, 2013).  
Within many pain conditions, such as fibromyalgia, osteoarthritis, chronic 
pelvic pain, and rheumatoid arthritis, multiple clinical features and patient 
characteristics are active to varying degrees in different individuals (Davis, Binik, 
Amsel, & Carrier, 2013; de Luca, Parkinson, Downie, Blyth, & Byles, 2016; Draper et 
al., 2012; Dworkin et al., 2005; Edwards et al., 2016; Rehm et al., 2010; Verra et al., 
2009). Efforts to contextualize pain in these chronic conditions has led to investigations 
utilizing subgrouping-based analyses to explore complex interactions of such features 
in order to identify distinct patient profiles (de Luca et al., 2016; Y. C. Lee et al., 2014; 
Loevinger, Shirtcliff, Muller, Alonso, & Coe, 2012; Rehm et al., 2010). The ability to 
describe unique subgroups in this manner not only allows for a deeper understanding 
and context of potential pain mechanisms in patient populations, it also subsequently 
aids in the identification of targeted treatment strategies (de Luca et al., 2016; Edwards 
et al., 2016). However, unlike other chronic conditions, to date, there have been no 
investigations utilizing subgroup-based modelling to explore the scope of MSK-related 
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pain experiences in IBD. Therefore, as current IBD literature is unable to suggest the 
number and/or nature of MSK pain subgroups, the use of cluster analyses may be less 
useful. As such, the exploratory nature of present thesis investigations is most suited for 
finite mixture modelling, such as LCA. 
3.2.5.2 Mediation analysis 
Investigation of the process or mechanism by which an independent variable 
affects another dependent variable is a common method of hypothesis testing reported 
in current literature (Baron & Kenny, 1986; Hayes, 2009; MacKinnon, Fairchild, & 
Fritz, 2007). Although there are multiple methods of performing such hypothesis 
testing, the cornerstone of this analysis typically includes exploration of how a third 
variable affects the relationship between two such variables (Baron & Kenny, 1986; 
Hayes, 2009; MacKinnon et al., 2007). The third variable in these analyses are typically 
identified as having a moderator or mediator effect on the dependent variable. A 
moderating variable is one that affects the direction and/or strength of the relation 
between the independent and dependent variable (Baron & Kenny, 1986). Conversely, 
mediators are identified as: “behavioral, biological, psychological, or social constructs 
that transmit the effect of one variable to another variable” (MacKinnon et al., 2007).  
Generally speaking, mediation analysis can be used to explore both 
experimental and observational data (Imai, King, & Stuart, 2008). Although somewhat 
overlapping in application, the purpose and interpretation in these two designs are 
distinct (Imai et al., 2008). Experimental studies typically aim to understand the 
treatment effects of the mediator as an intervention on the outcome (MacKinnon et al., 
2007). Conversely, observational studies aim to explore theories as to how an 
independent variable affects a dependent variable by providing empirical evidence of 
mediating causal pathways (Imai et al., 2008; MacKinnon et al., 2007).  
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Of the mediation models reported, the causal steps approach made popular by 
Baron and Kenny (Baron & Kenny, 1986) has traditionally been the most widely-used 
model in research (Hayes, 2009; MacKinnon & Fairchild, 2009). However, this method 
of performing mediation analysis has received significant criticism, namely for its 
notable underperformance in simulation studies to detect mediating effects 
(MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002). Further, unlike the Baron 
and Kenny model which relies on examining multiple model pathways to infer the 
possibility of a mediating effect (Baron & Kenny, 1986), other methods, such as the 
Sobel test and bootstrapping, directly examine mediating pathways (Hayes, 2009). Of 
these two methods, bootstrapping, which uses resampling processes to generate an 
empirical representation of the mediating effect, has grown in popularity (Hayes, 2009).  
Current literature indicates that the spectrum of mediation models continue to be 
utilized in causal hypothesis testing. The classic causal steps approach is still 
considered popular in current literature, including recent IBD investigations 
(Chouliaras et al., 2018). However, modernized statistical methods, such as the Sobel 
test (Freitas et al., 2015) and bootstrapping (Reed-Knight, Lee, Greenley, Lewis, & 
Blount, 2016; Sanne JH van Erp et al., 2017), have also been used to detect mediation 
in several cross-sectional IBD investigations. A systematic review with meta-analysis 
reporting on mediation studies in back and neck pain, indicated that the majority (7 out 
of 12) of included studies utilized a combination of Baron and Kenny’s causal steps 
approach and Sobel’s test of significance, with only 2 studies using bootstrapping 
analysis (H. Lee et al., 2015).  
Despite the broad application of mediation analysis throughout current 
literature, simulation studies have demonstrated that bootstrapping is one of the more 
valid and powerful methods for directly testing mediating effects (MacKinnon, 
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Lockwood, & Williams, 2004). Therefore, mediation analyses included in the current 
thesis utilize the Baron and Kenny (Baron & Kenny, 1986) causal steps approach to 
illustrate associations of individual pathways within the model, while using 
bootstrapping to determine overall significance of the model through direct 
examination of mediating pathways (Hayes, 2009).   
3.3 Chapter Summary 
The current chapter presented an overview of primary domains used to explore 
persistent MSK pain in the present thesis. Additionally, this chapter reviewed 
methodologies of interest with implications for use in Study 1 (Chapters 4-6). The 
following chapter presents the protocol for Study 1: Profiles of Self-reported MSK Pain 




4 Study One: A National Survey of Self-reported MSK Pain in 
Individuals with IBD – Study Protocol 
 
4.1 Chapter overview 
Review of the literature highlights the potential for multiple pain mechanisms, 
notably central sensitization, in the maintenance of persistent MSK pain in patients with 
IBD. However, previous investigations exploring MSK pain in IBD have not included 
an exploration of mechanisms beyond traditional inflammatory nociceptive models. As 
such, Study 1 of the present thesis aimed to investigate self-reported MSK pain in IBD 
in order to better characterize the nature, influences, and mechanisms contributing to 
persistent painful experiences. Study 1 of the present thesis includes a primary study 
aim to explore mechanism-based profiles of MSK pain in IBD (Chapter 5), and a sub-
analysis aimed to investigate predictive and causal relationships between predominate 
features identified during the primary study analysis (Chapter 6).  
The following chapter presents the full protocol for Study 1: A national survey 
assessing the multidimensional experience of self-reported MSK pain in adults with 
IBD living in New Zealand. Statistical analysis, results, and discussion of the primary 
and sub-analysis aims of Study 1 are presented in Chapters 5 and 6, respectively. 
 
4.2 Background 
Although potential for shared pathways have been proposed in the maintenance 
of MSK pain in IBD (Chapter 2), the multifactorial nature of these painful conditions is 
not well understood nor fully captured through standard investigations (Bielefeldt et al., 
2009; Conigliaro et al., 2016; Zeitz et al., 2016). Population-based surveys have 
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described significant diversity in MSK pain in IBD, with reports of fluctuating and 
varying patterns of presentation (van der Have et al., 2015; S. Van Erp et al., 2015; 
Zeitz et al., 2016). While MSK pain in IBD is reported to be influenced by multiple 
clinical features of pain and disease (S. Van Erp et al., 2015; Vavricka et al., 2015), the 
scope and contribution of these features to pain experiences has not been investigated in 
this population.  
The use of mechanism-based classification to explore the differing and 
potentially overlapping contributions of diverse pathophysiological mechanisms to 
MSK pain experiences has been presented (Chapter 3). However, studies investigating 
MSK pain in IBD rarely assess features, such as pain quality (de Luca et al., 2016; 
Schirbel et al., 2010), which has been previously been useful in identifying pain 
mechanism in clinical populations (Edwards et al., 2016; Jensen, 2006; Victor et al., 
2008). As such, the use of mechanism-based assessments of MSK pain in IBD is 
indicated, where pain is characterized according to the dominant pain mechanism, 
including nociceptive pain, peripheral neuropathic pain, and ‘central sensitization’ pain 
(Nijs et al., 2014; Smart, Blake, et al., 2012a; Clifford J Woolf, 2011). 
Current literature suggests that exploring profiles of MSK pain through 
subgroup-based analysis, such as latent class analysis (LCA) (Chapter 3), may provide 
a deeper understanding of pain experiences through consideration of identified pain 
mechanisms in relation to patient features (i.e. IBD, demographic, comorbidity, and 
pain) (de Luca et al., 2016; Edwards et al., 2016; Jensen, 2006; Clifford J Woolf, 2011). 
Additionally, the ability to describe unique patient profiles in this manner would not 
only provide empirical evidence for pain mechanisms active in this population, but also 
inform the development of targeted treatment strategies, leading to improved patient 
outcomes (de Luca et al., 2016; Edwards et al., 2016).  
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As previously described (Chapter 2), the predictive relationship between active 
IBD and the presence of certain MSK conditions is well documented in current 
literature (Brakenhoff et al., 2011; Vavricka et al., 2015). However, whether IBD 
activity influences MSK pain experiences (e.g. severity and interference) has received 
little attention. Similarly, although the presence of central sensitization has been 
proposed in theoretical models for chronic abdominal and post-surgical pain in IBD 
patients, the role of central sensitization leading to worse MSK pain experiences has 
not been considered. As presented in Chapter 3, exploration for how variables such as 
these are potentially linked, while assessing the significance of these links, is a common 
goal of mediation analysis.  
  
4.3 Study Aims 
4.3.1 Primary aims 
 To investigate profiles, or subgroups, of self-reported MSK pain in 
individuals with IBD through LCA, exploring features of pain (location, 
intensity, quality, and interference), IBD (abdominal pain, IBD activity, and 
health-related quality of life (HRQOL)), and central sensitization 
symptomology (i.e. central sensitization inventory (CSI)). 
 To investigate differences between subgroups with respect to patient 
characteristics, including demographics, comorbidity, and IBD (subtype 
and IBD course).  
4.3.2 Sub-analysis aims 
 To investigate the predictive relationship between IBD activity and MSK 
pain experiences (severity and interference). 
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 To investigate the mediating effects of CSI scores between IBD activity and 
MSK pain experiences.  
 
4.4 Study Hypotheses 
4.4.1 Primary hypothesis 
It was hypothesized that the exploration of multiple patient features through 
LCA will demonstrate distinct subgroups related to MSK pain, IBD, and central 
sensitization symptomology. It is further hypothesized that patient characteristics (i.e. 
demographics, comorbidity, and IBD features) will differ between subgroups. 
4.4.2 Sub-analysis hypothesis 
It was hypothesized that active IBD is predictive of worse MSK pain 




4.5.1 Research Design 
Alongside Māori consultation, the present cross-sectional survey was granted 
ethical approval by the University of Otago Human Ethics Committee (Health) 
(approval number - H17/095), in accordance with the Declaration of Helsinki 
(Appendix A and B).  
4.5.2 Participants 
Individuals with self-reported previous IBD diagnosis aged 18 years and older 
were invited to participate in an online survey. Investigation of self-reported medical 
history demonstrated that IBD patients are able to accurately report (κ = 0.96–0.97) 
67 
their medical history regarding type of disease through online investigations (Kelstrup, 
Juillerat, & Korzenik, 2014; Randell et al., 2014).  Invitation to participate in the 
current study was through the email database of Crohn's and Colitis New Zealand 
Charitable Trust, and additional social media outlets associated with: IBD research 
groups, New Zealand health forums, patient support groups, and practitioner resource 
groups (Appendix C). Crohn's and Colitis New Zealand is a national organisation that 
provides support, advice, and information to individuals suffering from IBD. 
All participants were provided with detailed information related to the study and 
signed an online consent form to participate (Appendix D and E). Participants were 
excluded if they reported any of the following: pregnancy, nerve injuries, neurological 
conditions (e.g. stroke, multiple sclerosis, peripheral neuropathy, and Parkinson’s 
disease), and surgery within the last 3 months. 
4.5.3 ‘New Zealand IBD Aches & Pains’ Survey 
4.5.3.1 Survey development 
The present online survey (Appendix F) included validated questionnaires 
identified in current literature used in the assessment of IBD, pain, and similar chronic 
inflammatory conditions. The survey included three sections: 1) demographics and 
comorbidity, 2) IBD status, and 3) pain status. To improve comprehension of the 
overall survey, the order of administration for included questionnaires was 
standardized; however, skip patterns were utilized within the survey to direct 
participants toward relevant questionnaires corresponding to individually reported IBD 
and pain features. Details regarding constructs assessed in each of the survey sections 
are presented in Chapter 3. Measures used to assess these constructs are listed in Table 
4.1 and described below.  
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Table 4.1  
Measures used to Evaluate Disease and Pain Features in the New Zealand IBD Aches 
& Pains Survey  
Domain Outcome/Measure 
Section 1: Demographics and comorbidity 
 Demographics Age 
Gender 
Ethnicity 
 Comorbidity Self-Administered Comorbidity Questionnaire  
Extra-intestinal manifestation checklist  
Central Sensitization Inventory  
Section 2: IBD status 
 IBD subtype Crohn’s disease 
Ulcerative colitis / indeterminate colitis 
 IBD activity Patient Harvey Bradshaw Index  
Patient Simple Clinical Colitis Activity Index 
 HRQOL Short Inflammatory Bowel Disease Questionnaire 
 IBD features Presence of abdominal pain  
Number of hospitalizations  
Number of surgeries 
Current medications 
Section 3: Pain status 
 Musculoskeletal  
       Location Body map 
       Severity Numeric rating scale 
       Interference PROMIS Pain Interference 4a 
       Quality PainDETECT 
PROMIS Nociceptive Pain Quality 5a 
 Abdominal     
       Severity  Numeric rating scale 
       Interference Numeric rating scale 
Notes. Inflammatory bowel disease (IBD), health-related quality of life (HRQOL), and 
Patient-Reported Outcomes Measurement Information System (PROMIS). 
 
 
4.5.3.2 Expert consensus  
Expert consensus for face and content validity of the present survey was 
conducted by four experienced clinicians/researchers in the fields of gastroenterology 
and chronic pain. Experts were asked to provide feedback on respective constructs used 
to evaluate stated IBD and pain domains. Experts (1, 2) in the field of gastroenterology 
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demonstrated 100% agreement for all consensus questions, with the exception of one 
recommendation (Expert 2) regarding the inclusion of an additional variable evaluating 
the severity of IBD course. Experts (3, 4) in the field of chronic pain similarly 
demonstrated 100% agreement for all consensus questions, with exception of one 
recommendation (Expert 3) regarding evaluation of an additional dimension of pain in 
the present survey. 
4.5.3.3 Pilot testing  
Pilot testing was performed on individuals with IBD, with a sample of 
convenience (n = 6). Pilot testing evaluated the feasibility of the present survey, 
including 1) time to complete, 2) overall clarity, and 3) ease of survey completion. 
Time to complete was calculated from 4 pilot testers, as 2 reported computer 
interruptions during testing. Average time to complete was 12:46 (min:sec), ranging 
from 8:23-15:13 (min:sec). Mean survey clarity was 8.40 (0 = unclear, 10 = very clear), 
and mean ease of completion was 9 (0 = difficult, 10 = very easy). 
Participants identified through social media outlets were directed to the present 
study’s primary webpage, with an associated information sheet, informed consent 
details, and hyperlink to the survey (Appendix E). Participants identified through 
Crohn's and Colitis New Zealand’s email database were sent reminder emails at three 
and seven weeks following the initial invitation email, with a total of 12 weeks for data 
collection (Hoddinott & Bass, 1986). 
4.5.4 Survey Section 1: Demographics and comorbidity 
Participant demographics included: age, gender, and ethnicity. Comorbidities 
assessed in the present study included health conditions identified on the Self-
Administered Comorbidity Questionnaire (Sangha, Stucki, Liang, Fossel, & Katz, 
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2003), extra-intestinal manifestation (EIM) checklist (described under IBD section), 
and conditions identified on part B of the CSI.  
Use of CSI as an indirect measure of central sensitization has been validated 
(AUC= 0.86, Sensitivity = 81%, Specificity = 75%) in a large population study in 
patients with central sensitivity syndromes (Mayer et al., 2012; Neblett et al., 2013). 
CSI (part A) evaluates 25 features across an array of somatic and emotional symptoms, 
with each item scored on a scale of 0 to 4, and overall scoring ranging from 0 to 100 
(Neblett, Hartzell, Mayer, et al., 2017).  Higher CSI scores indicate increased 
symptomology related to central sensitization, with scores ≥ 40 indicating the likely 
presence of central sensitivity syndromes (Mayer et al., 2012; Neblett et al., 2013).  
4.5.5 Survey Section 2: IBD status 
Indicators of IBD status included in the present study were: IBD subtype, IBD 
activity, health-related quality of life (HRQOL), and clinical features (number of 
hospitalizations and surgeries, current medications, and EIM status).  
4.5.5.1 IBD activity 
IBD activity in the present survey was evaluated by the patient Harvey 
Bradshaw Index (P-HBI) for Crohn’s disease and patient Simple Clinical Colitis 
Activity Index (P-SCCAI) for ulcerative colitis. P-HBI assesses five variables (general 
well-being, the severity of abdominal pain, number of liquid stools, presence of 
abdominal mass, and presence of complications) where scoring is based on symptoms 
from the previous day (Evertsz, Hoeks, et al., 2013; Walsh et al., 2016). The P-HBI is 
reported to highly correlate with the clinician administered HBI, with moderate to large 
agreement between clinicians and patients, and significant positive predictive value 
(96%) for identifying disease remission (Evertsz, Hoeks, et al., 2013).  
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The widely used clinician administered SCCAI demonstrated good to excellent 
psychometric and performance validity for detecting disease activity in ulcerative 
colitis (Higgins et al., 2007). The patient administered SCCAI (P-SCCAI) demonstrated 
substantial agreement (87%, κ=0.66) with the clinician administered SCCAI (Evertsz, 
Nieuwkerk, et al., 2013). P-SCCAI assesses six variables (daytime bowel frequency, 
night-time bowel frequency, blood in stool, general well-being, the urgency of 
defecation, and extra-colonic features) where scoring is based on symptoms from the 
previous week (Evertsz, Nieuwkerk, et al., 2013). Both P-SCCAI and P-HBI identify 
disease remission as scores of ≤ 4 (Evertsz, Nieuwkerk, et al., 2013; Walsh et al., 
2016).  
4.5.5.2 Severity of disease course 
Based on recommendations reported in the literature, the best practice to 
indicate disease severity includes evaluation of HRQOL and aspects of IBD course 
(Peyrin-Biroulet et al., 2016; Walsh et al., 2016). In the present survey, HRQOL was 
assessed through the validated Short IBD Questionnaire (SIBDQ) (E. Irvine, Zhou, & 
Thompson, 1996; Peyrin-Biroulet et al., 2016). SIBDQ demonstrated significant retest 
reliability (ICC = 0.65, Cronbach’s α = 0.78) with ability to detect clinically meaningful 
changes in HRQOL through the assessment of five heath dimensions (bowel symptoms, 
systemic symptoms, functional impairment, social impairment, and emotional function) 
(E. Irvine et al., 1996). SIBDQ scoring is interpreted as poor (10-29), moderate (30-49), 
and optimal (50-70) (E. Irvine et al., 1996; Peyrin-Biroulet et al., 2016). 
Assessment of disease course in the present study includes self-reports for: 
hospitalizations, surgical interventions, medications, and EIM status (Peyrin-Biroulet et 
al., 2016; Siegel et al., 2016). Medications were recorded under the following 
categories: immunosuppressant, biologic, gut-specific anti-inflammatory, and steroids. 
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EIM status was evaluated through a 20-item checklist developed from multiple EIM 
investigations, to include the European Crohn’s and Colitis Organisation Guidelines 
developed from expert consensus (Marcus Harbord et al., 2016; Huang, Mishra, 
Thanabalan, & Nguyen, 2013; Levine & Burakoff, 2011; Trikudanathan et al., 2012).  
4.5.6 Survey Section 3: Pain status 
MSK Pain dimensions evaluated in the present study included: location, 
severity, interference, and quality (nociceptive and neuropathic pain qualities). A body 
diagram demarcating 47 different body regions was used in the present study to record 
regional pain location and distribution, which previously demonstrated significant test-
retest reliability (r=0.85) in chronic pain patients (Margolis, Chibnall, & Tait, 1988; S. 
Van Erp et al., 2015; Zeitz et al., 2016). This diagram was developed from 
recommendations regarding MSK conditions in IBD (S. J. van Erp et al., 2016; Zeitz et 
al., 2016) and investigations reporting the use pain drawing instruments (Margolis et 
al., 1988). Generalized pain was distinguished from regional pain using the modified 
widespread pain criterion which requires an individual to report pain in 4 out of 5 pain 
regions (4 quadrants plus axial pain) (Wolfe et al., 2016). 
In the event that multiple painful regions were identified, participants were 
asked to nominate their ‘main area of pain’. Pain severity was then evaluated as “the 
strongest pain during the past 4 weeks”, solely for the regions identified as the ‘main 
area of pain’, using a numerical rating scale (NRS), with positive findings as mild (1-4), 
moderate (5-6), or severe (7-10) (Williamson & Hoggart, 2005). Evaluation of pain 
interference and nociceptive pain quality in the present survey were evaluated through 
Patient-Reported Outcomes Measurement Information System (PROMIS) Pain 
Interference 4a and Nociceptive Pain Quality 5a short forms (Gershon, Rothrock, 
Hanrahan, Bass, & Cella, 2010). PROMIS short forms, developed by the National 
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Institutes of Health, have undergone extensive qualitative expert and patient review, as 
well as quantitative analysis of data collected on general populations and clinical 
samples (Gershon et al., 2010). Scoring of PROMIS short forms identify findings as: 
mild (50-59), moderate (60-69), or severe (≥70). 
The presence of neuropathic pain quality was evaluated through PainDETECT, 
which has previously demonstrated significant sensitivity (85%), specificity (80%), and 
a positive predictive value (83%) for differentiating nociceptive from neuropathic pain, 
as well as identifying the contribution of neuropathic pain to overall pain experiences 
(Freynhagen, Baron, Gockel, & Tölle, 2006). PainDETECT identifies neuropathic pain 
through evaluation of three pain dimensions including: gradation of pain, pain course 
pattern, and radiating pain with possible scores ranging from 0 to 38 (Freynhagen et al., 
2006). Interpretation of PainDETECT scores identify neuropathic components as likely 
(≥ 19), unlikely (≤ 12), and unclear (13-18) (Freynhagen et al., 2006). 
Secondary evaluation of abdominal pain was also included in the present study. 
Abdominal pain was characterized through dimensions of intensity and interference, 
measured by NRS for both items. Positive findings for abdominal pain intensity and 
interference are identified as mild (1-4), moderate (5-6), or severe (≥7) (Williamson & 
Hoggart, 2005).  
 
4.5.7 Sample Size Estimation 
Sample size estimation for Study 1 was determined based on recommendations 
from current literature regarding LCAs (Chapter 5) and mediation-based analyses 
(Chapter 6). Current literature regarding subgrouping-based analyses offers no 
straightforward guidelines about the minimum nor maximum sample size necessary for 
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LCAs (Wurpts & Geiser, 2014). However, supporting evidence exists for a minimum 
sample size of N = 200 with respect to the number of present indicator variables and 
use of a medium to strong covariate (Finch & Bronk, 2011; Gudicha, Tekle, & 
Vermunt, 2016). Similarly, current literature recommends a sample size of N = 150 to 
200 required to detect mediating effects in the absence of type-II errors (Fritz & 
MacKinnon, 2007). Therefore, minimum sample size estimate for both the primary 
aims and sub-analysis of Study 1 was 200 participants. 
 
4.6 Chapter summary 
This chapter presented the full protocol for Study 1 of the present thesis, aimed 
at exploring self-reported MSK pain in IBD. Results and discussion for the primary aim 
and sub-analysis of Study 1 are present in Chapters 5 and 6, respectively. 
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5 Study One: Profiles of Musculoskeletal Pain in Individuals with IBD 
 
5.1 Chapter overview 
Chapter 4 presented the full protocol for Study 1 aimed at exploring self-
reported MSK pain in individuals with IBD. The following chapter presents the 
statistical analysis, results, and discussion related to the primary aims of Study 1.  
 
5.2 Primary Study Aims 
 To investigate profiles, or subgroups, of self-reported MSK pain in 
individuals with IBD through latent class analysis (LCA), exploring 
features of pain (location, intensity, quality, and interference), IBD 
(abdominal pain, IBD activity, and health-related quality of life (HRQOL)), 
and central sensitization symptomology (i.e. central sensitization inventory 
(CSI)). 
 To investigate differences between subgroup with respect to patient 
characteristics, including demographics, comorbidity, and IBD (subtype 
and IBD course).  
 
5.3 Hypothesis 
It was hypothesized that the exploration of multiple patient features through 
LCA will demonstrate distinct subgroups related to MSK pain, IBD, and central 
sensitization symptomology. It was further hypothesized that patient characteristics (i.e. 
demographics, comorbidity, and IBD features) will differ between subgroups.  
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5.4 Data Reduction 
Data collected during the present study was used to quantify variables used in 
LCA, including latent class indicators, potential latent class covariates, and external 
variables. As stated in Chapter 4, essential datasets for the present study required 
completion of all components related to the internal latent class variables. This includes 
all components necessary to calculate individual questionnaire scoring (e.g. 
PainDETECT and CSI) as well as composite scores (e.g. generalised pain). As such, 
LCA variables were characterized directly from raw data, scores from individual 
measures, or criteria identified from composite data. Measures used to characterize 
LCA variables is presented in Table 4.1, with parameters for each categorical variable 
defined in their respective subheadings in Chapter 4.  
Categorical indicator variables utilized in the present study included: strongest 
pain severity, average pain severity, pain interference, generalized pain, neuropathic 
quality, nociceptive quality, CSI, IBD activity, and presence of abdominal pain. The 
use of categorical indicators reflects the clinical utility of variables, such as IBD 
activity, whereby assessment scores are typically interpreted as active versus not active, 
as opposed to continuous values. Variables considered for covariate analysis included: 
IBD subtype and HRQOL (i.e. short inflammatory bowel disease questionnaire 
(SIBDQ)). The variable(s) not utilized as a covariate was included in the list of external 
variables used to explore differences between subgroups. External variables included: 
gender, age, number of extra-intestinal manifestations (EIMs), total comorbidity score, 
hospitalizations, surgeries, and current medications. 
To clarify: n=54 participants were excluded for incomplete survey responses, 
which was defined (page 71) in the thesis as: “Essential datasets for the present study 
were identified as completion of all components related to internal latent class variables 
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identified above.” As presented in the methodology (Section 5.4), these variables 
included composite scores of individual questionnaires (e.g. CSI and PainDETECT). 
Therefore, participants had to complete all of questions pertaining to the individual 
questionnaires in order for the composite to be calculated and defined for each variable 
(Data reduction for latent class indicator variables is outlined in Section 5.4). As such, 
individuals that did not complete these questionnaires thereby negating the ability to 
calculate overall composite scores were exclude. 
5.5 Statistical Analysis 
Descriptive statistics (frequencies, means, and standard deviations (SD)) were 
used to characterize demographic, comorbidity, IBD, and pain characteristics of study 
participants. LCA was performed in two stages using R statistical software. Initial LCA 
was used to identify models with 1 to 6 subgroups (or classes) across the sample using 
indicator variables quantified during data reduction. Model fit was assessed using 
model fit statistics (Akaike information criterion (AIC) and Bayesian information 
criterion (BIC)), the goodness of fit G2 which follows a chi-squared distribution, and 
model entropy (L. M. Collins & Lanza, 2013). Lower values for information criteria 
and higher values for G2 and entropy between models suggest models with optimal 
balance between fit and parsimony (L. M. Collins & Lanza, 2013). Interpretability was 
also considered along with fit statistics when selecting the final model. Further 
assessment of the final model included average posterior probabilities and classification 
error. Average posterior probabilities ≥ 0.70 (L. M. Collins & Lanza, 2013) and 
classification error ≤ 0.10 were considered acceptable. Participants were assigned class 
membership based on their highest posterior probability. Chi-squared tests were used to 
identify a covariate with significant association (p ≤ 0.05) with the final model. A 
subsequent LCA was then performed using the final model and the identified covariate 
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to predict indicator class membership. Conditional item probabilities of indicator 
variables reaching ≥ 0.500 were used to characterise each latent class (L. M. Collins & 
Lanza, 2013). 
Subgroup profiling of the identified latent classes was performed to further 
describe the association of internal variables (indicators and covariate) unique to each 
class. Additionally, investigation of between class differences for external variables was 
performed. Chi-squared tests of association (dichotomous variables) and one-way 
analyses of variance (ANOVAs)/Kruskal-Wallis ANOVAs (continuous variables) were 
used to investigate between class differences for both internal latent class variables, as 
well as external demographic and comorbidity variables. Univariate logistic regression 
analysis was used to explore the association of individual comorbidities (independent 
variable) with latent class membership (dependent variable). Where Peduzzi’s criteria 
for sample size allowed, variables demonstrating significance (p ≤ 0.05) were adjusted 
for the confounding effects of age, gender, and IBD subtype (Peduzzi, Concato, 
Kemper, Holford, & Feinstein, 1996). A confounder is understood to be a variable 
which may falsely accentuate the relationship between two factors of interest 
(MacKinnon, Krull, & Lockwood, 2000). As such, adjustment for potential 
confounders aims to provide an undistorted estimate of the relationship between the 
independent and dependent variables (MacKinnon et al., 2000). Assumptions for 
ANOVA and regression models were assessed where appropriate to ensure model fit, 
including: normality of scoring distribution (Shapiro-Wilk tests, significance ≤ 0.05)), 
collinearity diagnostics (variance inflation factor < 10 with tolerance > 0.2), and 




Results of this study are presented in two sections. The first section presents 
descriptive statistics for participant characteristics (demographics, IBD, and pain). The 
second section presents the results of the LCA and comparative analysis of the 
subgroup profiles. 
5.6.1 Participant characteristics 
5.6.1.1 Demographics 
A total of 370 individuals with IBD volunteered to participate in the online 
survey. Eleven respondents were excluded due to minimum age requirements. An 
additional 54 respondents were excluded due to incomplete survey response. Essential 
datasets for the present study were identified as completion of all components related to 
internal latent class variables identified above. The remaining 305 respondents were 
included as study participants. Demographics for the excluded participants are 
presented in Table G.1 (Appendix G). Demographics (age and gender), IBD subtype, 
comorbidity, and CSI scores of study participants are presented in Table 5.1. Of the 305 
participants, 201 (66%) individuals reported IBD subtype as Crohn’s disease, 94 (31%) 
reported ulcerative colitis, and 10 (3%) reported indeterminate colitis. Participants in 
the study represented the following ethnic groups: New Zealand European (n=274), 
Maori (n=18), Indian (n=4), English (n=5), Australian (n=5), North American (n=4), 
Fijian (n=3), Dutch (n=2), Scottish (n=1), German (n=1), South African (n=2), Croatian 







Table 5.1  
Demographic and Comorbidity Data  
Characteristic IBD (N = 305) CD (N = 201) UC/IC (N= 104) 
Gender  
   Male, n (%)    
   Female, n (%)    














   Range (years) 











   Total comorbidity 
      Range (n) 













  CSI 
      Range 










Note. Inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), 
indeterminate colitis (IC), standard deviation (SD), and central sensitization inventory 
(CSI). 
 
5.6.1.2 IBD status 
Results from questionnaires assessing aspects of IBD status in this study are 
presented in Table 5.2. Of the participants who reported Crohn’s disease (n=201), 4 
indicated the presence of an ileostomy and therefore were unable to utilize the patient 
Harvey Bradshaw Index (P-HBI), which requires evaluation of bowel habits not 
assessable in patients with intestinal stomas. Consequently, the results of the P-HBI to 





Summary of IBD characteristics  
Questionnaire N (%) 
IBD activity 
      P-HBI  
          Active  
          Inactive 
      P-SCCAI  
          Active  









       Optimum 
       Moderate 





Current medication use  
      Biologics  
      Immunosuppressants  
      Gut specific anti-inflammatories 
      Steroids  
         Previous steroid courses a  








Number of hospitalizations 
      None 
      1-5 
      6-10 






Extra-intestinal manifestations (mean (SD)) 0.98 (1.07) 
Number of surgeries (mean (SD)) 1.40 (2.78) 
Note. Inflammatory bowel disease (IBD), patient Harvey Bradshaw Index (P-HBI), 
patient Simple Clinical Colitis Activity Index (P-SCCAI), Short Inflammatory Bowel 
Disease Questionnaire (SIBDQ), and standard deviation (SD). 
a Steroid courses are indicated by use of 2 or more prescribed courses since IBD 
diagnosis 
 
5.6.1.3 Pain status 
Results from questionnaires assessing aspects of abdominal and MSK pain in 
this study are presented in Table 5.3 and 5.4, respectively. Of the included participants, 
80% (n = 244) reported the presence of abdominal and/or MSK pain. Of these 
82 
participants, 15% (n = 36) reported the presence of only abdominal pain, 33% (n = 82) 
reported the presence of only MSK pain, and 52% (n = 126) reported the presence of 
both abdominal and MSK pain. Of the MSK regions identified as painful by study 
participants, the low back was overall the most frequently reported region (n = 124, 
60%), while also identified most frequently as the ‘main area of pain’ (n = 41, 20%). A 
summary of all painful regions reported by participants is presented in Tables G.2 and 




Summary of Abdominal Pain Characteristics of Study Participants (n = 162) 
   Pain severity (NRS) 
        None         
        Mild 
        Moderate 






   Pain interference (NRS) 
        None         
        Mild 
        Moderate 










Summary of Musculoskeletal Pain Characteristics of Study Participants (n = 208) 
Questionnaire N (%) 
Pain location 
        Regional 




 Strongest pain severity (NRS) 
        Mild 
        Moderate 





Average pain severity (NRS) 
        None         
        Mild 
        Moderate 






Pain interference (PROMIS Pain Interference 4a) 
        None         
        Mild 
        Moderate 






   Neuropathic pain quality (PainDETECT) 
        Unlikely         
        Likely 





Nociceptive pain quality (PROMIS Pain Interference 4a) 
        None         
        Mild 
        Moderate 






Note. Numeric rating scale (NRS), and Patient-Reported Outcomes Measurement 




5.6.2.1 Latent class analysis 
Fit statistics for initial latent class models (1 to 6) are reported in Table 5.5. As 
indicated by the lowest BIC results, a 2-class model was most parsimonious, where 
AIC supported a 4-class model. Consideration of fit statistics along with interpretability 
of the models suggested that a 3-class model was optimal. Classification error of the 3-
class model was acceptable at 0.087. Average posterior probabilities (SD) of the 3-class 
model were 0.920 (0.13), 0.851 (0.14), and 0.892 (0.15), respectively.  
 
Table 5.5 
Fit Statistics for Six Latent Class Models  
Number of 
latent classes 
Log-likelihood df BIC AIC G2 Entropy 
1 -1478.92 186 3053.56 2993.84 964.46 - 
2 -1343.77 167 2884.32 2761.55 694.17 0.802 
3 -1312.52 148 2922.85 2737.04 631.66 0.754 
4 -1290.79 129 2980.44 2731.58 588.20 0.749 
5 -1274.81 110 3049.52 2737.62 556.25 0.809 
6 -1262.73 91 3126.41 2751.46 532.09 0.791 
Note. Degrees of freedom (df), Bayesian information criterion (BIC), Akaike information 
criterion (AIC), and goodness of fit (G2). 
 
 
Class 1 included 30.8% of study participants and was characterized as “mixed 
mechanism”. Class 1 represents a high probability for presenting with positive CSI 
scores, active IBD, abdominal pain, severe MSK pain, and moderate MSK pain 
interference. Additionally, Class 1 demonstrated increased probability of presenting 
with nociceptive and/or neuropathic pain qualities when compared to Class 2 and 3. 
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Class 2 was characterized as “central mechanism” and represented the largest group 
(42.1%). Class 2 represented a high probability for presenting with positive CSI scores, 
active IBD, mild MSK pain interference, and no additional pain qualities (nociceptive 
or neuropathic). Class 2 also presented with moderate probability for presenting with 
abdominal pain and moderate MSK pain severity. The third, and smallest (26.9%) 
latent class was characterized as “regional & remission”. Class 3 represented a low 
probability for demonstrating positive CSI scores, active IBD, abdominal pain, or 
additional pain qualities (nociceptive or neuropathic). Additionally, Class 3 
demonstrated a high probability of presenting with mild to no MSK pain interference, 
and a moderate probability of presenting with regional MSK pain and moderate MSK 
pain severity. Conditional item responses of indicator variables for each class are 




Table 5.6  
Conditional Item Response Probabilities of Three Latent Classes  
Indicator variable  Probability of categorical presentation 
 Yes No Mild Moderate Severe 
Class 1 “Mixed mechanism” (n=63, 30.8%) 
    Strongest pain severity  0.000 0.000 0.093 0.907 
    Average pain severity  0.000  0.024 0.764 0.213 
    Pain interference  0.016  0.070 0.784 0.130 
    Generalized pain 0.625 0.375     
    Neuropathic 0.229 0.532  0.240   
    Nociception  0.239 0.409 0.255 0.097 
    Abdominal pain 0.881 0.119     
    Central Sensitization Inventory 0.903 0.097     
    IBD activity 0.804 0.196    
Class 2 “Central mechanism” (n=86, 42.1%) 
    Strongest pain severity  0.000  0.053 0.688 0.259 
    Average pain severity  0.000  0.536 0.454 0.009 
    Pain interference  0.000  0.764 0.236 0.000 
    Generalized pain 0.535 0.465     
    Neuropathic 0.070 0.798  0.133   
    Nociception  0.746  0.168 0.086 0.000 
    Abdominal pain 0.581 0.419     
    Central Sensitization Inventory 0.916 0.084     
    IBD activity 0.782 0.219    
Class 3 “Regional & remission” (n=55, 26.9%) 
    Strongest pain severity  0.017  0.303 0.608 0.072 
    Average pain severity  0.035  0.748 0.199 0.019 
    Pain interference  0.449  0.487 0.047 0.017 
    Generalized pain 0.334 0.666     
    Neuropathic 0.000 1.000  0.000   
    Nociception  0.905  0.095 0.000 0.000 
    Abdominal pain 0.390 0.610     
    Central Sensitization Inventory 0.396 0.604     
    IBD activity 0.404 0.596     
Note. Bold font indicates variables that characterize each class (> 0.500). 
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5.6.2.2 Subgroup profiles 
Descriptive statistics with between class differences for external variables 
(demographics, total comorbidity, EIMs, and clinical IBD features) and internal latent 
class variables (indicator and covariate) are shown in Tables 5.7 to 5.9. Additionally, 
descriptive statistics with between class differences for individually assessed 
comorbidities are presented in Appendix H. No significant differences between latent 
classes were found for gender, age, EIMs, IBD subtype, hospitalizations, surgeries, or 
medications. All internal latent class variables (indicator and covariate) demonstrated 
significant between class differences (p ≤ 0 .05) (Table 5.8), while total comorbidity 
score was the sole external variable demonstrating significance (p = 0 .005) (Table 5.7). 
Univariate logistic regression analysis for individual comorbidities, to include EIMs, 
identified statistically significant differences (p ≤ 0.05) between latent classes for: 
osteoarthritis (p = 0.027), osteoporosis (p = .045), depression (p = 0 .001), anxiety (p = 
0.025), and chronic fatigue syndrome (p = 0.020). Peduzzi’s criteria  for sample size 
was solely met by depression and anxiety variables (Peduzzi et al., 1996). As such, 
subsequent logistic regression analysis adjusting for age, gender, and IBD subtype 
indicated gender as a confounder for both depression and anxiety, and age as a 
confounder for anxiety (Table 5.9).   
Table 5.7 
Demographic and Comorbidity Data of Three Latent Classes  
Variable Class 1 Class 2 Class 3 P Association 
Age, mean (SD) 46.60 (13.71) 43.19 (13.19) 43.40 (13.77) 0.224 2.99 a 
Female gender, n (%) 52 (83) 74 (86) 42 (76) 0.471 0.13 b 
Comorbidity, mean (SD) 3.17 (1.91) 0.80 (0.87) 2.12 (1.66) 0.005* 10.44 a 
EIMs, mean (SD) 2.03 (1.47) 1.71 (1.27) 1.60 (1.44) 0.184 3.38 a 
Note. Standard deviation (SD), extra-intestinal manifestation (EIM), inflammatory 
bowel disease (IBD), ulcerative colitis (UC), and indeterminate colitis (IC). 
a Kruskal-Wallis one-way analysis of variance, b chi-squared test. 
* p ≤ .05.  
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Table 5.8 
Categorical Latent Class Variable Frequencies of Three Latent Classes  







Strongest MSK pain severity (NRS) 
  
<0.001* 0.844 a 
     None 0(0) 0(0) 1 (2)   
     Mild 0(0) 2 (2) 20 (36)   
     Moderate 5 (8) 64 (74) 30 (55)   
     Severe 58 (92) 20 (23) 4 (7)   
Average MSK pain severity (NRS) 
  
<0.001* 0.674 a 
     None 0(0) 0(0) 2 (4)   
     Mild 1 (2) 46 (54) 43 (78)   
     Moderate 49 (78) 39 (45) 9 (16)   
     Severe 13 (21) 1 (1) 1 (2)   
PROMIS Pain Interference  
   
<0.001* 0.943 a 
     None 1 (2) 0(0) 26 (47)   
     Mild 3 (5) 68 (79) 26 (47)   
     Moderate 51 (81) 18 (21) 2 (4)   
     Severe 8 (13) 0(0) 1 (2)   
PROMIS Nociceptive Pain Quality 
  
<0.001* 0.614 a 
     None 14 (22) 65 (76) 51 (93)   
     Mild 27 (43) 14 (16) 4 (7)   
     Moderate 16 (25) 7 (8) 0(0)   
     Severe 6 (10) 0(0) 0(0)   
PainDETECT 
   
<0.001* 0.419 a 
     Unlikely neuropathic  35 (56) 68 (79) 55 (100)   
     Likely neuropathic  13 (21) 7 (8) 0(0)   
     Uncertain 15 (24) 11 (13) 0(0)   
Generalized MSK pain  40 (64) 45 (52) 18 (33) 0.003* 0.236 a 
CSI  55 (87) 82 (95) 19 (35) <0.001* 0.606 b 
IBD activity 50 (79) 66 (77) 23 (42) <0.001* 0.344 b 
Abdominal pain 55 (87) 50 (58) 21 (38) <0.001* 0.389 a 
SIBDQ c 
   
<0.001* 0.528 a 
     Optimal 7 (11) 23 (27) 37 (67)   
     Moderate 47 (75) 62 (72) 18 (33)   
     Poor 9 (14) 1 (1) 0(0)   
Note. Musculoskeletal (MSK), numeric rating scale (NRS), Patient-Reported Outcomes 
Measurement Information System (PROMIS), Short Inflammatory Bowel Disease 
Questionnaire (SIBDQ), central sensitization inventory (CSI), and inflammatory bowel disease 
(IBD). 
a large effect size, b moderate effect size, c latent class covariate. 
* p ≤ 0.05. 
 
Table 5.9 
Associations of Depression and Anxiety with Latent Class Membership Adjusted for Age, Gender, and IBD Subtype 
 
Note. Class 1 – reference class. Confidence interval (CI), inflammatory bowel disease (IBD). 
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Variable Unadjusted Adjusted (age) Adjusted (gender) Adjusted (IBD subtype) 
 Exp (β) (95% CI) P Exp (β) (95% CI) P Exp (β) (95% CI) P Exp (β) (95% CI) P 
Depression  0.001*  0.001*  0.007*  0.001* 
   Class 2 0.43 (0.22, 0.85) 0.014* 0.41 (0.21, 0.82) 0.011* 0.47 (0.16, 1.37) 0.166 0.43 (0.22, 0.85) 0.015* 
   Class 3 0.21 (0.09, 0.49) <0.001* 0.20 (0.09, 0.47) <0.001* 0.07 (0.12, 0.36) 0.002* 0.21 (0.09, 0.48) <0.001* 
Anxiety  0.054*  0.025*  0.078  0.054* 
   Class 2 0.52 (0.24, 1.12) 0.097 0.61 (0.29, 1.27) 0.187 0.51 (0.16, 1.61) 0.251 0.61 (0.29, 1.27) 0.187 
   Class 3 0.26 (0.10, 0.71) 0.008* 0.31 (0.12, 0.81) 0.017* 0.09 (0.01, 0.78) 0.029* 0.31 (0.12, 0.82) 0.017* 
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5.7 Discussion
Primary aims of this cross-sectional study were to explore MSK-related pain in 
individuals with IBD, in order to describe distinct patient subgroups and identify 
differences between the subgroups based on profiles of external variables. Current 
study results describe three distinct and clinically relevant subgroups characterized as 
“mixed mechanism” for Class 1, “central mechanism” for Class 2, and “regional & 
remission” for Class 3. Both Classes 1 and 2 demonstrated high probabilities of 
presenting with positive CSI scores (≥ 40) and active IBD states. However, Class 1 was 
the only class to demonstrate an increased probability of presenting with neuropathic 
and/or nociceptive pain qualities. Class 1 also presented with the highest MSK pain 
severity and pain interference scores, as well as the highest probability for presenting 
with abdominal pain. Class 3 was the only class to demonstrate increased probability 
for IBD remission and regional MSK pain, while also demonstrating low probability for 
positive CSI scores and abdominal pain. 
In the current study, positive CSI scores were a dominant feature in Classes 1 
and 2, thereby identifying significant symptomology commonly seen in patients 
presenting with underlying mechanisms of central sensitization. Additionally, Classes 1 
and 2 also presented with increased MSK pain severity and interference profiles 
compared to Class 3 presenting with a low probability of positive CSI scores. As 
described by Woolf (Clifford J Woolf, 2011, 2014), the increased responsiveness of 
neurons within the central nervous system as a result of central sensitization leads to 
pain hypersensitivity. Previous studies of persistent pain in other populations, such as 
osteoarthritis, have shown an increase in pain severity in individuals demonstrating 
central sensitization (Akinci et al., 2016; Arendt‐ Nielsen et al., 2018; Lluch, Torres, 
Nijs, & Van Oosterwijck, 2014). Central sensitization is a broad concept that includes 
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numerous and complex pathophysiological mechanisms, including changes to pain 
facilitation, inhibition, and sensory processing (Clifford J Woolf, 2011, 2014). 
Of the two classes presenting with central sensitization symptomology, Class 1 
demonstrated a 91% probability of presenting with severe MSK pain, whereas Class 2 
demonstrated a 69% probability of presenting with moderate pain. The presence of 
central sensitization has been described as different degrees over a continuum (Lluch et 
al., 2014), as opposed to simply present or not. The question then becomes: to what 
extent is central sensitization contributing to the clinical picture (Lluch et al., 2014)? 
Differences in pain profiles described here may be the result of greater contribution 
from mechanisms of central sensitization and/or additional factors (i.e. psychological 
and behavioural features) to the overall clinical picture of Class 1, leading to worse pain 
experiences. Previous investigation of chronic spinal pain found that higher CSI scores 
correlated with depressive symptoms, perceived disability, sleep disturbance, and 
increased pain severity (Neblett, Hartzell, Williams, et al., 2017). Similarly, current 
results demonstrated that higher CSI scores corresponded with the presence of 
depression and anxiety, as well as higher pain severity across subgroups.  
In addition to higher CSI scores and greater pain severity, individuals in Class 1 
were also more likely to present with multiple pain mechanisms, greater total 
comorbidity, as well as a higher prevalence of abdominal pain, osteoarthritis, and 
osteoporosis. Incidentally, the presence of central sensitization is thought to be an 
important contributor to increased painful comorbidities in chronic pain populations, as 
hypersensitivity due to central sensitization may result in pain from minimal 
nociceptive input of other structures (e.g. arthritic joints) (Arendt‐ Nielsen et al., 2018). 
As such, the presence of multiple comorbidities and/or overlapping peripheral 
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mechanisms in the presence of central sensitization, may have a cumulative effect 
leading to worse pain experiences in Class 1. 
The current study demonstrated a notable pattern between CSI and IBD activity 
scores, suggestive of a directional relationship between these measures. Results 
indicated that a high probability of demonstrating positive CSI also represented a high 
probability of active IBD (Class 1 and 2), with the opposite being true in Class 3. IBD 
literature has previously described animal models of central sensitization and IBD 
activity, specifically with regards to the development and maintenance of chronic 
abdominal pain (Bielefeldt et al., 2009; K. E. Farrell, Callister, & Keely, 2014). These 
models describe modulation of neural activity as a consequence of pro-inflammatory 
mediators present in active IBD states leading to sensitized nervous systems (Bielefeldt 
et al., 2009; K. E. Farrell et al., 2014). Results from the present study suggest that 
contributions of central sensitization to pain in IBD may extend beyond models of 
abdominal pain to include MSK-related pain as well.  
Subgroup profiling in the present study indicated no between-class differences 
for observed demographics, EIMs, IBD subtype, and clinical IBD features. In fact, of 
the variables assessing IBD in this study, IBD activity and HRQOL were the only ones 
to demonstrate a significant association. Determination of IBD severity is reported to 
consider the presence of mucosal lesions, as well as the accumulation of: IBD-related 
hospitalizations and surgeries, multiple EIMs, use of disease-modifying medications, 
and multiple steroid courses following IBD diagnosis (Peyrin-Biroulet et al., 2016; 
Siegel et al., 2016). Therefore, although the present study indicated that the majority of 
the observed IBD features in isolation did not predict subgroup membership, current 
literature would suggest that the combined consideration of these features to describe 
overall disease severity may be more useful. The relationship of active IBD and 
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HRQOL demonstrated during subgroup profiling would highlight the potential for 
influences from overall disease severity to MSK pain presentations. Therefore, future 
research should explore the construct of IBD severity as an independent risk factor for 
MSK pain experiences in this population.  
Total comorbidity scores were the sole external variable to demonstrate an 
association with class membership, with increased prevalence in Class 1. Although 
comorbidities have shown to be independent predictors of several outcomes, such as 
mortality and disability, relatively little is known about the effect of disease 
combinations on outcomes (de Groot, Beckerman, Lankhorst, & Bouter, 2003). 
Investigation of individual disease combinations on disability indicated that the effects 
of some combinations were additive, while other effects were synergistic, leading to 
increased disability (de Groot et al., 2003). Results from the present study indicate that 
an increase in total comorbidity (e.g. disease count) is predictive of membership to the 
subgroup demonstrating worse MSK pain profiles (Class 1). However, it is unknown 
whether specific disease combinations would demonstrate differing effects on subgroup 
membership.  
Analysis of individual comorbidities identified significant between class 
differences for osteoarthritis, osteoporosis, chronic fatigue syndrome, depression, and 
anxiety. Distribution of these comorbidities followed the total comorbidity distribution, 
with increased prevalence in Class 1. Similar to previous IBD investigations (Geng et 
al., 2018), the present study identified gender as a confounder for both depression and 
anxiety. Rates of mood disorders have been shown to be higher in IBD compared to 
other diseases and the general population (M. Regueiro, Greer, & Szigethy, 2017). 
Pooled incidence rates for anxiety and depression in IBD patients were reported to be 
19% and 21%, respectively, was almost double those of healthy individuals (Mikocka-
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Walus, Knowles, Keefer, & Graff, 2016). The presence of depression and anxiety, 
along with poor HRQOL, has shown significant correlation with increased number of 
relapses (Kendall’s Tau = -0.40, p <0.001), suggesting mood disorders may be a risk 
factor in IBD (Mittermaier et al., 2004; M. Regueiro et al., 2017). However, it is 
unclear whether the temporal presentation and fluctuation of mood disorders in relation 
to the relapsing-remitting nature of IBD are significant beyond chance (Mikocka‐
Walus et al., 2007).  
The current sample population is similar to current New Zealand 
epidemiological IBD data where approximately 97% of IBD patients identified as New 
Zealand Eurpeans, with significantly reduced representation of Māori (Su, Gupta, Day, 
& Gearry, 2016). This is the first study to characterize self-reported MSK pain through 
subgrouping analysis of multiple IBD and pain features. The present study included 
numerous standalone questionnaires, validated to assess respective pain and disease 
features. Face and content validity of survey questionnaires was provided by experts in 
the field of gastroenterology and chronic pain. Subgroups in the present study represent 
categorical interpretation of included questionnaires to reflect the clinical utility of 
these measures. However, subgrouping analysis performed on continuous indicator 
variables may lead to different subgrouping results. 
A common limitation of online surveys relates to the assessment of IBD activity 
through self-reported measures. Standard clinical practice for estimating IBD activity 
typically includes clinical investigations, such as colonoscopies and serum biomarkers, 
alongside measures used in the present study (Peyrin-Biroulet et al., 2016; Siegel et al., 
2016; Walsh et al., 2016). Therefore, estimation of IBD activity in the present study 
may not fully reflect findings from more invasive clinical assessments. Although the 
present study recorded all MSK pain regions reported by each participant, exploration 
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of pain features were solely recorded for regions identified as the participant’s ‘main 
area of pain’. Therefore, results may not characterize features specific to all painful 
regions reported in the present study. Similarly, as it was not possible to externally 
confirm the presence of IBD diagnosis through medical records, the current study 
utilized self-reports for previous IBD diagnosis. However, recruitment for the current 
sutyd was primarily through Crohn’s and Colitis New Zealand to increase access to the 
target population. 
However, as the primary source for recruitment of study participants was 
through Crohn's and Colitis New Zealand, study results may overly represent 
individuals who have previously or are currently seeking support in managing their 
IBD (Šimundić, 2013). Further, the present study represents individuals who have 
digital and online access, and may not be generalizable to the broader IBD population. 
Future research should explore the presence and implications of central 
sensitization in IBD patients with and without persistent MSK pain, in order to provide 
further insight into the complex relationship between central sensitization, persistent 
MSK pain, and IBD. For instance, investigations exploring somatosensory functioning 
as a measure of central sensitization, as well as influences from psychological, 
comorbidity, and IBD features may reveal mechanisms as well as risk factors for 
ongoing painful experiences in patients. Future research of this nature would further 
develop and support the new model for MSK pain proposed in the present thesis, 
leading to targeted assessment and treatment pathways for MSK pain in IBD. 
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5.8 Chapter Summary 
Exploration of self-reported MSK pain experiences through subgrouping in the 
current chapter provides evidence for the possibility of multiple mechanisms 
contributing pain experiences in IBD, including nociceptive, neuropathic, and central 
mechanisms. Study results describe three clinically relevant subgroups where 
individuals with worse MSK pain experiences also presented with active IBD and 
increased CSI scores, suggesting the potential modulation of pain experiences by 
shared mechanisms of central sensitization. Results from the sub-analysis aim of Study 
1, exploring causal relationships between these variables are presented in Chapter 6.  
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6 Study One: IBD Activity, Central Sensitization Inventory, and Worse 
Musculoskeletal Pain Experiences 
 
6.1 Chapter overview 
The positive predictive relationship between active IBD and the presence of 
certain MSK conditions is well-documented in IBD literature (Brakenhoff et al., 2011; 
Vavricka et al., 2015). Additionally, literature exploring the gut-brain-axis paradigm 
(Chapter 2) suggests that intestinal inflammation results in changes to visceral afferent 
pathways, triggering a cascade of central nervous system, endocrine, and immune 
responses. However, IBD literature is unable to suggest whether IBD activity 
influences MSK pain experiences (e.g. severity and interference). Results from the 
previous chapter indicated that patients with active IBD and higher central sensitization 
inventory (CSI) scores, also demonstrated an increased probability of presenting with 
worse MSK pain experiences. However, subgrouping results are unable to determine 
whether these variables are co-dependant or simply co-exist in patients. Therefore, the 
following chapter presents the statistical analysis, results, and discussion of a causal 
model exploring the relationship between active IBD, increased CSI scores, and worse 
MSK pain experiences (Study 1 – sub-analysis). 
 
6.2 Sub-analysis Study Aims 
 To investigate the predictive relationship between IBD activity and MSK 
pain experiences (severity and interference). 
 To investigate the mediating effects of CSI scores between IBD activity and 
MSK pain experiences.  
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6.3 Hypothesis 
It was hypothesized that active IBD is associated with worse MSK pain 
experiences and this relationship is mediated by greater symptoms of central 
sensitization (i.e. higher CSI scores). 
6.4 Statistical Analysis 
Descriptive statistics (frequencies, means, and standard deviations (SD)) were 
used to characterize demographic, IBD, and pain characteristics of study participants. 
Univariate linear regression analyses (IBM SPSS Statistics 25) were used to explore the 
relationship between: independent variables (IBD activity scores) and dependent 
variables (pain severity scores and pain interference scores). Assumptions for linear 
regression models were assessed to ensure model fit, including: normality of scoring 
distribution (Shapiro-Wilk tests, significance ≤ 0.05)), collinearity diagnostics (variance 
inflation factor < 10 with tolerance > 0.2), and homoscedasticity (scatterplot of 
residuals). 
Mediation analysis (PROCESS version 3) in the present study included: 1) 
simple mediation analysis (PROCESS - model 4) to assess the relationship between 
independent variable (IBD activity scores), dependent variable (pain severity scores), 
and mediator (CSI scores); and 2) serial mediation analysis (PROCESS - model 6) to 
assess the relationship between independent variable (IBD activity scores), dependent 
variable (pain interference scores), and mediators (CSI and pain severity scores). Both 
mediation models were adjusted for a priori confounders, including age, gender, and 
self-reported anxiety and depression, with significant confounding identified as >10% 
change in the regression coefficient from the unadjusted model. All three potential 
confounders have previously been shown to influence CSI scores and/or MSK pain 
experiences (Bair, Wu, Damush, Sutherland, & Kroenke, 2008; Fillingim, King, 
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Ribeiro-Dasilva, Rahim-Williams, & Riley III, 2009; Mayer et al., 2012). 
Heteroscedasticity-consistent standard errors were used and the statistical significance 
of mediation (i.e. indirect effects) was identified through bootstrapping of 5,000 
samples (95% confidence intervals). 
 
6.5 Results 
A total of 305 individuals with IBD provided informed consent to participate in 
the online survey. Out of the survey respondents, 208 individuals reported the presence 
of MSK pain and were included as study participants. A summary of demographic data 
(age and gender) and IBD subtype are presented in Table 6.1. Of the 208 participants, 
143 individuals reported IBD subtype as Crohn’s disease, 59 reported ulcerative colitis, 
and six reported indeterminate colitis.  
 
Table 6.1  
Demographics and IBD Subtype of Survey Participants (N=208) 
Characteristic n (%) 
Gender *  
   Male  
   Female 






   Range (years) 
   Mean (SD) 
 
18 – 88 
44.26 (13.89) 
IBD subtype 
   Crohn’s disease 
   Ulcerative colitis 





Note. *Gender was identified by n = 207 participants. 
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6.5.1 Survey measures 
Results from questionnaires assessing IBD activity, MSK pain severity and 
interference, and CSI scores are presented in Table 6.2. Of the participants who 
reported Crohn’s disease (n = 143), 4 indicated the presence of an ileostomy and 
therefore did not meet the criteria for completing the patient Harvey Bradshaw Index 
(P-HBI), which requires evaluation of bowel habits not assessable in patients with 
intestinal stomas. Consequently, results of the P-HBI are reported for the remaining 139 
participants with Crohn’s disease. Active IBD as indicated by scores > 4 for both the P-
HBI and the patient Simple Clinical Colitis Activity Index (P-SCCAI), were found in 
69% of survey participants (64% of Crohn’s disease participants and 78% of 
ulcerative/indeterminate colitis participants). 
Of the MSK regions identified as painful by study participants, the low back 
was the most frequently reported region (n = 124), and most frequently identified as the 
‘main area of pain’ (n = 41). Pain severity scores ranged from 0 to 10 (numeric rating 
scale (NRS)), with only one participant reporting an NRS score of 0. PROMIS Pain 
Interference scores ranged from 41.6 to 75.6, with 93% of study participants 
demonstrating positive pain interference as scores > 50. CSI scores in the present study 







Self-reported Clinical Features of Survey Participants (N=208) 
Questionnaire Range Mean (SD) 
IBD activity 
      P-HBI (n=139) 














      Pain severity (NRS) 0-10 6.89 (2.06) 
      PROMIS Pain Interference 41.6-75.6 58.48 (6.97) 
Central Sensitization Inventory 12 - 82 47.87 (13.70) 
Note. Standard deviation (SD), Patient Harvey Bradshaw Index (P-HBI), Patient Simple 
Clinical Colitis Activity Index (P-SCCAI), numeric rating scale (NRS), and Patient-
Reported Outcomes Measurement Information System (PROMIS). 
 
 
6.5.2 IBD and musculoskeletal pain experiences 
Unadjusted univariate linear regression analysis indicated that IBD activity was 
a significant predictor of both increased MSK pain severity (R2 = 0.039, F (1,202) = 
8.235, p < 0.005) and increased MSK pain interference (R2 = 0.067, F (1,202) = 14.542, 
p < 0.001). 
6.5.3 Mediation models 
6.5.3.1 IBD activity and musculoskeletal pain severity 
Simple mediation analysis indicated that IBD activity was a significant 
predictor of increased CSI scores (β = 7.456, SE = 1.930, p < 0.001) and CSI scores 
were a significant predictor of increased MSK pain severity (β = 0.047, SE = 0.012, p < 
0.001). Furthermore, IBD activity was no longer a significant predictor of MSK pain 
severity after controlling for CSI scores (β = 0.481, SE = 0.314, p = 0.127). The greater 
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participation of females compared to males in the present study precluded the ability to 
control for gender confounding; however, neither age nor self-reported anxiety or 
depression demonstrated confounding effects on the mediation model. Approximately 
14% of the variance in MSK pain severity was accounted for by IBD activity mediated 
by CSI scores (R2 = 0.145). Results indicated the indirect effect was significant (β = 
0.352, SE = 0.139, CI [0.127, 0.664]). Summary of mediation results is described in 
Table 6.3 and Figure 6.1. 
 
Table 6.3 
Simple Mediation Model for Active IBD and Musculoskeletal Pain Severity (N=208) 
 β SE t P CI 
Mediation model summary: R2 = 0.145, F(5,197) = 4.875, p < 0.001*   
Effect: IBD activity on CSI 7.456 1.930 3.864 <0.001*  
Effect: CSI on pain severity 0.047 0.012 3.861 <0.001*  
Total effect 0.833 0.316 2.638 0.009*  
Direct effect 0.481 0.314 1.535 0.127  
Indirect effect 0.352 0.139   [0.127, 0.664] 
Notes. Inflammatory bowel disease (IBD), central sensitization inventory (CSI), 
standard error (SE), confidence interval (CI). 




Figure 6.1. Simple Mediation Model for Active IBD and Musculoskeletal Pain Severity 
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6.5.3.2 IBD activity and musculoskeletal pain interference. 
Serial mediation analysis indicated that IBD activity was a significant predictor 
of increased CSI scores (β = 7.456, SE = 1.930, p < 0.001) and CSI scores 
independently (β = 0.143, SE = 0.032, p < 0.001), as well as in series with MSK pain 
severity (β = 1.846, SE = 0.173, p < 0.001), were significant predictors of MSK pain 
interference. Furthermore, IBD activity was no longer a significant predictor of MSK 
pain interference after controlling for CSI and MSK pain severity scores (β = 1.337, SE 
= 0.826, p = 0.107). Similar to the simple mediation model, the greater participation of 
females compared to males in the present study precluded the ability to control for 
gender confounding. However, neither anxiety nor depression was found to have no 
effect, whereas age demonstrated a significant effect (regression coefficient change = 
14%) on the serial mediation model (β = 0.078, SE = 0.023, p < 0.001). Approximately 
54% of the variance in MSK pain interference was accounted for by IBD activity 
mediated in series by CSI and pain severity scores (R2 = 0.537). Results indicated the 
indirect effect was significant (β = 2.606, SE = 0.755, CI [1.201, 4.164]). Summary of 





Serial Mediation Model for Active IBD and Musculoskeletal Pain Interference (N=208) 
 β SE t P CI 
Mediation model summary:  R2 = 0.537, F(6,196) = 46.151, p < 0.001* 
Effect: IBD activity on CSI 7.456 1.930 3.864 <0.001*  
Effect: IBD activity on pain severity 0.481 0.314 1.532 0.127  
Effect: CSI on pain severity 0.049 0.012 4.054 <0.001*  
Effect: CSI on pain interference 0.143 0.032 4.421 <0.001*  
Effect: pain severity on interference 1.846 0.173 10.675 <0.001*  
Total effect 3.943 1.030 3.828 <0.001*  
Direct effect 1.339 0.826 1.619 0.107  
Indirect effect                                      2.606 0.755   [1.201, 4.164] 
Note. Inflammatory bowel disease (IBD), central sensitization inventory (CSI), 
standard error (SE), confidence interval (CI). 









The first aim of the sub-analysis for Study 1 was to explore the predictive 
relationship between IBD activity and MSK pain experiences (severity and 
interference). Results demonstrated a significant positive predictive relationship 
between active IBD and worse MSK pain severity and interference, thereby confirming 
the primary sub-analysis hypothesis. Unsurprisingly, the univariate analysis suggests 
the possibility for additional influences on MSK pain experiences in IBD patients, as 
active IBD explained less than 10% of the variance in pain measures used in the present 
study. The second aim of the sub-analysis was to explore mediating effects of CSI 
scores in the relationship between IBD activity and MSK pain experiences, to include 
serial mediation by CSI and pain severity to MSK pain interference. The study results 
support the secondary hypothesis as CSI scores demonstrated significant mediation in 
the relationship between active IBD and MSK pain severity. Similarly, the analysis 
showed that CSI scores, both independently and in series with MSK pain severity, 
demonstrated significant mediation of the relationship between active IBD and MSK 
pain interference. 
Exploration of how, for instance, a third variable affects the relationship 
between two other variables is the cornerstone of mediation analysis (MacKinnon et al., 
2007). Although the consideration of a third variable may appear simple, the 
interactions in a three-variable system can be very complicated (MacKinnon et al., 
2007). However, in exploratory investigations, such as the present sub-analysis, 
mediation-based analysis offers valuable insight into potential intervening variables 
when attempting to understand theoretical and causal pathways in relationships. Results 
in the present study suggest that the link between active IBD and worse MSK pain 
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experiences is significantly explained by symptoms related to central sensitization (i.e. 
CSI scores).  
CSI has been validated to assess an array of symptoms and risk factors 
associated with the development of central sensitization  (Mayer et al., 2012). This 
screening tool is unable to identify which central mechanisms are participating in an 
individual’s clinical picture, but rather indicates that consideration of central 
sensitization may guide practitioners to appropriate diagnostic testing (Mayer et al., 
2012). Although Study 1 of the present thesis is the first study to describe the potential 
for central mechanisms in MSK pain in this population, influences of central 
sensitization have been proposed in IBD-related postsurgical and abdominal pain 
(Bielefeldt et al., 2009; Bruce & Krukowski, 2006; Kristen E Farrell et al., 2014; Joris 
et al., 2015). Investigations of chronic postsurgical pain indicate that IBD patients are 
two to three times more likely to develop chronic pain following gastrointestinal 
surgery than non-IBD populations (Bruce & Krukowski, 2006; Joris et al., 2015). 
Central sensitization has been found to play a major role in the pathophysiology of 
chronic postsurgical pain, with its potentiation from prior disease inflammation thought 
to explain the increased prevalence of chronic pain in IBD patients (Bruce & 
Krukowski, 2006; Joris et al., 2015). 
Investigations of abdominal pain in IBD have described pain experiences 
persisting beyond active inflammation seen in IBD flares, as well as pain experienced 
in other body regions, such as the back and legs (Bielefeldt et al., 2009; Kristen E 
Farrell et al., 2014). This referred pain is thought to be the result of central sensitization 
causing an overlap in activity between visceral and somatosensory neurons within the 
spinal cord (Bielefeldt et al., 2009; Kristen E Farrell et al., 2014). In addition to these 
changes in neural activity, chronic abdominal pain models describe the modulation of 
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descending inhibitory mechanisms as a result of affective and cognitive features in IBD 
(Bielefeldt et al., 2009). Increased stress, anxiety, and hypervigilance have been 
suggested as factors which may exacerbate not only clinical features of IBD but 
visceral pain states as well (Bielefeldt et al., 2009). Consequently, current sub-analysis 
results, as well as previous reports of chronic pain models in IBD, suggest that 
exploration of central mechanisms is worthy of further investigation, to include altered 
somatosensory function and affective/cognitive features in IBD patients with MSK 
pain. 
Current sub-analysis results indicate that worse pain interference in active IBD 
is mediated in series by increased CSI and pain severity scores, thereby confirming the 
second study hypothesis. Additionally, increased CSI scores also demonstrated direct 
mediation of pain interference independent of pain severity scores. Similar to reports in 
the literature, pain interference in the present sub-analysis describes multiple and 
complex pathways by which pain may hinder one's engagement in physical, emotional, 
and social activities, also commonly described as one’s function. Previous pain models 
describe interference with daily activities resulting from ongoing painful experiences, 
with the assumption that relief from pain correlates with an improvement in function 
(Dworkin et al., 2005). However, exploration of interference constructs indicates that 
although severity, interference, and function are related to each other, they are distinct 
domains each requiring consideration (Amtmann et al., 2010; Karayannis et al., 2017). 
Although current sub-analysis measures (i.e. CSI, severity, and interference) are 
understood to assess distinct constructs, the closely related nature of these constructs 
creates the potential for some inter-item overlap between measures. However, as 
mediation analysis does not require complete local independence as a statistical 
assumption, the small amount of variance potentially created by this overlap likely has 
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nominal effects. As such, the multiple pathways mediating pain interference in the 
present sub-analysis further suggests the unique complexity and likely independent 
nature for each of these constructs.  
Of the potential confounders explored in the present sub-analysis, age 
demonstrated relationship to pain experiences. Specifically, increased age was 
identified as a significant confounder in the relationships with worse pain interference. 
A large investigation utilizing a PROMIS assessment of pain interference in IBD 
patients demonstrated slightly improved scores in older adults (> 60 years) compared to 
younger individuals (Kappelman et al., 2014). However, the authors did not identify 
which PROMIS Pain Interference assessment was used, nor whether results were 
statistically significant. Reports from the literature regarding the directional influence 
of age on pain interference in other populations are conflicting, with some reports of 
worse interference in older adults within the general population (Thomas et al., 2007), 
whereas chronic pain populations demonstrated greater interference in younger 
individuals (Blyth et al., 2001). These studies further highlight the complexity of 
interference constructs. Further investigation is needed in order to better understand the 
components for how increasing age influences pain interference in active IBD and 
MSK pain experiences. 
In the present sub-analysis, increased CSI scores accounted for 14% of the 
variance in the relationship between active IBD and pain severity. Furthermore, CSI 
scores and pain severity accounted for 54% of the variance in the relationship between 
active IBD and pain interference. These results suggest that traditional inflammatory 
models, which exclude central mechanisms, in the context of MSK pain may be 
insufficient to explain the prevalence of pain in this population. This has implications 
for the management of MSK pain in IBD patients, where common pharmaceutical 
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approaches aimed at reducing inflammation may not be a successful strategy for a 
significant proportion of patients (Fornaciari et al., 2001; Levine & Burakoff, 2011; 
Zeitz et al., 2016). Furthermore, in a large study exploring pain in IBD, where over 
50% of patients reported pain duration of more than five years, results indicated that 
one in four patients did not receive any pain management (Zeitz et al., 2016). Given this 
large symptom burden and evidence for inadequate pain management, further research 
into the participation of central mechanisms in ongoing MSK pain experiences is 
warranted to develop new assessment and treatment frameworks in IBD.  
Standard clinical practice for assessing IBD activity typically includes clinical 
investigations, such as colonoscopies and serum biomarkers, alongside measures used 
in the present study (Peyrin-Biroulet et al., 2016; Siegel et al., 2016; Walsh et al., 
2016). Therefore, IBD activity in the present sub-analysis may not reflect findings from 
clinical assessments. Similarly, as self-reported measures used in the present study are 
unable to differentiate between primary inflammatory versus non-inflammatory MSK 
conditions, the presence of inflammatory arthropathies in the present study was solely 
based on self-reports of previous diagnoses. The present sub-analysis explored pain 
severity and interference solely for regions identified as the participant’s ‘main area of 
pain’. Therefore, results may not be generalizable to all painful regions reported in the 
present study. 
Although Crohn's and Colitis New Zealand and the social media groups targeted 
for recruitment in the present study are large, they are not restricted to IBD patients and 
include additional persons such as IBD providers, support networks, and family. 
Therefore, it is difficult to speculate the overall size of the source population. Current 
literature indicates significant gender effects with regards to measures of central 
sensitization and additional psychosocial factors, such as mood disorders. The 
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increased participation of females to males in the present sub-analysis did not allow for 
exploration nor controlling for gender effects of these measures. However, as this is the 
first study to explore the scope of MSK in IBD, it is unknown whether the increased 
female representation in the present sub-analysis represents true gender distribution in 
IBD, or is the result of sampling bias. However, current literature acknowledges an 
overall increased response rate of females over males typically seen in online survey 
based investigations (G. Smith, 2008). Therefore, determination of whether or not 
gender distribution in Study 1 represents true MSK pain demographics in IBD, or are 
simply due to response/sampling bias is uncertain. 
As the present sub-analysis is cross-sectional by design, temporal causality 
between mediators and variables cannot be explored. However, the significant 
associations demonstrated in the present study highlight potentially important 
relationships between these variables. As such, future investigations utilizing 
longitudinal designs should explore the directional and temporal nature of these 
relationships in order to better understand the stated associations. 
Future research should explore objective measures of central sensitization in 
IBD patients, as well as possible gender effects and modulating factors, such as 
psychosocial features. Additionally, investigation of clinical IBD activity (e.g. serum 
biomarkers and colonoscopies), as well as the severity of IBD alongside assessments of 
central sensitization would provide further insight and context into the nature of central 
pain mechanisms in this population. Such investigations may allow for individualised 
and targeted treatment pathways to improve MSK pain experiences in IBD.  
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6.7 Chapter Summary 
The sub-analysis in the current chapter builds on results from the primary aims 
of Study 1 (Chapter 5) by demonstrating that subgrouping variables (i.e. active IBD, 
CSI scores, and MSK pain experiences) do not simply co-exist in the identified 
subgroups, but rather demonstrated significant predictive relationships. The mediation 
of MSK pain experiences by CSI scores in patients with active IBD further implicates 
the presence and participation of shared mechanisms of central sensitization in IBD 
patients.  
Study 2 of the present thesis investigates assessments of central sensitization 
(i.e. symptomology and somatosensory functioning) in patients with IBD. Chapter 7 
presents the full protocol for Study 2, with the results and discussion for primary and 




7 Study Two: Assessment of Central Sensitization in Patients with 
IBD and Healthy Controls – Study Protocol 
 
7.1 Chapter overview 
Study 1 in the present thesis characterized the multidimensional nature of self-
reported MSK pain in IBD through the identification of distinct mechanistic profiles 
(Chapter 5), where features of active IBD and greater symptoms of central sensitization 
demonstrated positive predictive relationships to worse pain severity and interference 
(Chapter 6). Symptoms of central sensitization in Study 1 demonstrated a significant 
association with multiple patient features, including IBD, worse MSK pain experiences, 
and multiple pain types. An additional sub-analysis from Study 1 (Appendix H) 
indicated that CSI scores were significantly different in participants based on the 
presence of different pain states, such as solely abdominal pain versus abdominal and 
MSK pain. This suggests that additional measures of central sensitization in this 
population may be influenced simply based on the presence of IBD and/or the presence 
of MSK pain. Furthermore, the pattern of CSI scoring in relation to the variables 
characterizing the MSK pain profiles of Study 1, such as the presence of 
anxiety/depression, total comorbidity, active IBD, and IBD health-related quality of life 
(HRQOL), suggests that measures of central sensitization in this population may be 
influenced by these diverse features. Therefore, Study 2 of the present thesis explores 
assessments of central sensitization in IBD patients with and without MSK pain and 
healthy controls, in order to investigate: whether the presence of IBD and MSK pain 
influences assessments of central sensitization (Chapter 8), and whether individual 
patient characteristics influence assessments of central sensitization (Chapter 9). 
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The current chapter presents the protocol for Study 2: Assessment of central 
sensitization in patients with IBD and healthy controls. This was conducted at the IBD 
Center of Dartmouth-Hitchcock Medical Center in New Hampshire, USA. Results and 
subsequent discussions for the primary and secondary aims of Study 2 are presented in 
Chapters 8 and 9, respectively.  
 
7.2 Background 
As previously described, assessments of central sensitization commonly 
examine various clinical and experimental characteristics related to symptomology, 
somatosensory functioning, and factors influencing pain perceptions (Clifford J Woolf, 
2011). Somatosensory functioning is widely used to evaluate the excitability of 
different nociceptive pathways within the central nervous system (CNS) through static 
sensory tests, such as pressure pain threshold (PPT), and dynamic sensory tests, such as 
temporal summation (TS) and conditioned pain modulation (CPM) (Arendt-Nielsen & 
Yarnitsky, 2009; Arendt‐ Nielsen et al., 2018). Along with the investigation of 
common symptomology, these assessments may act as surrogate markers suggesting 
the presence of central sensitization mechanisms (Arendt-Nielsen & Yarnitsky, 2009; 
Arendt‐ Nielsen et al., 2018).  
In addition to these measures of central sensitization, cognitive and affective 
features are commonly explored as modulators of pain perceptions and nociceptive 
transmission in chronic pain (Villemure & Bushnell, 2002). Results from Study 1 
indicated that the presence mood disorders (i.e. anxiety and depression), as well as 
features of IBD (i.e. activity and HRQOL) were strongly correlated with MSK pain 
profiles in IBD (Chapter 5). Interestingly, the presence of psychological features have 
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long been reported in IBD patients (Andrews et al., 1987; Charles N Bernstein et al., 
2010; Farrokhyar et al., 2006; Guthrie et al., 2002; Simrén et al., 2002), with 
consequences ranging from decreased HRQOL, symptomatic flares, to speculations for 
an aetiological role in IBD (Chapter 3). Similarly, influences from lifestyle factors, 
such as substance use (i.e. smoking and alcohol) and sleep quality, have been described 
as predictors of worse IBD severity (Ali & Orr, 2014; Siegel et al., 2016) and 
modulators of central sensitization assessments (Finan, Goodin, & Smith, 2013; 
Gierthmühlen et al., 2015; Nijs et al., 2017). Consequently, results from Study 1 along 
with reports from pain and IBD literature suggests that exploration of influences from 
psychological, IBD, lifestyle, and comorbidity features may provide a deeper 
understanding to measures of central sensitization in this population. 
 
7.3 Study Aims 
7.3.1 Primary aims 
 To investigate differences in measures of central sensitization (i.e. central 
sensitization inventory (CSI), PPT, CPM, and TS) across three groups: 1) 
IBD patients with MSK pain, 2) IBD patients without MSK pain, and 3) 
healthy controls. 
 To investigate whether between-group differences demonstrated above are 
confounded by psychological factors (perceived stress, affect style, anxiety, 
depression, and pain catastrophizing). 
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7.3.2 Secondary aim 
 To investigate the association between measures of central sensitization (i.e. 
CSI, PPT, TS, and CPM) and IBD features, as well as psychological, 
demographic, comorbidity, and lifestyle features in patients with IBD. 
 
7.4 Study Hypotheses 
7.4.1 Primary hypothesis 
It was hypothesized that IBD patients with MSK pain will demonstrate greater 
symptomology related to central sensitization (i.e. CSI scores) and altered 
somatosensory functioning (i.e. PPT, CPS, and TS) compared to IBD patients without 
pain, and to healthy controls. It was further hypothesized that psychological factors will 
demonstrate a degree of confounding in the measures of central sensitization found to 
be statistically significantly different between the study groups described above. 
7.4.2 Secondary hypothesis 
It was hypothesized that IBD features will demonstrate a positive association 
with measures of central sensitization. It was further hypothesized that models 
predicting measures of central sensation will represent influences from multiple patient 
features, including worse IBD, psychological, lifestyle, and comorbidity status. 
 
7.5 Methods 
7.5.1 Research Design 
The present cross-sectional study was granted ethical approval by the 
Institutional Review Board for Dartmouth College, Committee for the Protection of 
Human Subjects (STUDY00031471) (Appendix J).  
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7.5.1.1 Participants 
Individuals aged 18 years or older presenting to Dartmouth-Hitchcock Medical 
Center (USA) were invited to participate across three study groups: (1) IBD with MSK 
pain, (2) IBD without MSK pain, and (3) healthy controls (Appendix K). Patients with 
a previously establish IBD diagnosis by a gastroenterologist were identified through the 
Dartmouth-Hitchcock’s electronic medical records with written approval obtained by 
each treating physician prior to all recruitment efforts. Healthy controls were recruited 
through email invitations to staff members of Dartmouth-Hitchcock Medical Center, as 
well as friends/family members of Dartmouth-Hitchcock patients.  
7.5.1.2 Exclusion criteria 
IBD patients (with and without MSK pain) were excluded if they reported any 
of the following: pregnancy, current history of drug or alcohol abuse, any condition 
resulting in altered sensation such as: nerve injuries, neurological conditions (e.g. 
stroke, multiple sclerosis, and Parkinson’s disease), or surgery within the last 3 months. 
Healthy controls were excluded if they reported any of the following: pregnancy, 
history of drug or alcohol abuse, a history of pain experiences lasting longer than 24 
hours in the past 3 months, and/or a diagnosis of acute or chronic health conditions (e.g. 
neurological, cardiovascular, gastrointestinal, hepatobiliary, urogenital, psychological, 
and cancer) (Gierthmühlen et al., 2015).  
7.5.1.3 Data collection 
Participants meeting inclusion/exclusion criteria were invited to attend one 
examination session at Dartmouth-Hitchcock Medical Center. Participants were 
provided with detailed information related to the study and signed a consent form to 
participate (Appendix J). Examination included somatosensory testing, followed by 
completion of digitized questionnaires (Appendix M). The order of somatosensory 
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testing was standardized, whereas the order of questionnaires was randomized to reduce 
test order effects, with skip patterns to direct participants toward relevant questionnaires 
where applicable. Outcome measures used during the examination session are presented 
in Table 7.1. Following the examination sessions, data extraction from the patients’ 
medical records was performed to further characterize IBD features (Table 7.2). Details 
of the constructs related to features included in the present study are presented in 
Chapter 3, with assessment scoring and psychometrics presented below. 
7.5.2 Demographic, lifestyle, and comorbidity features 
Participant demographics included: age, gender, and ethnicity. Lifestyle factors 
assessed included: smoking, alcohol consumption, cannabis use, and sleep quality. 
Sleep quality was assessed using a single item of the Pittsburgh Sleep Quality Index 
(Carpenter & Andrykowski, 1998). Participants were asked to respond to the question: 
During the past month, how would you rate your sleep quality overall? (Very good, 
fairly good, fairly bad, and very bad). Total comorbidity scores were calculated as 
disease counts using health conditions identified on the Self-Administered Comorbidity 
Questionnaire (Sangha et al., 2003), a 20-item extra-intestinal manifestation (EIM) 
checklist developed from multiple EIM investigations (Marcus Harbord et al., 2016; 
Huang et al., 2013; Levine & Burakoff, 2011; Trikudanathan et al., 2012), and 
conditions identified on the CSI (part B). HRQOL was assessed using the EuroQoL 
five-dimensional (EQ-5D) questionnaire (Buchholz, Janssen, Kohlmann, & Feng, 
2018). The EQ-5D questionnaire descriptive system comprises five domains (mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression), each one with five 
possible levels: no problems (level 1), slight problems (level 2), moderate problems 
(level 3), severe problems (level 4), and extreme problems (level 5), as well as a visual 
analogue scale ranging from 0 to 100.  
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Table 7.1 
Outcome Measures used to Evaluate Central Sensitization, IBD, and Pain Features  
Domain Outcome measure 
Primary Outcomes 
 Somatosensory function Pressure pain threshold 
Conditioned pain modulation 
Temporal summation  
 Central sensitization symptoms Central Sensitization Inventory (part A) 
Secondary Outcomes 
 Psychological factors Hospital Anxiety and Depression Scale 
Perceived Stress Scale (10-item) 
Positive and Negative Affective Schedule 
Pain Catastrophizing Scale 
 Health-related quality of life Short Inflammatory Bowel Disease Questionnaire 
EuroQoL five-dimensional questionnaire 
 Abdominal pain  
 
PROMIS Pain Interference 4a 
Numeric rating scale (severity) 
 Musculoskeletal pain Regional location (body diagram)  
PROMIS Pain Interference 4a 
Numeric rating scale (severity) 
 Sleep quality Pittsburgh Sleep Quality Index (single item) 
 Total comorbidity score Self-Administered Comorbidity Questionnaire 
Extra-intestinal manifestation checklist 
Central Sensitization Inventory (part B) 
Note. Inflammatory bowel disease (IBD), and Patient-Reported Outcomes 
Measurement Information System (PROMIS). 
 
 
7.5.3 Psychological features 
Psychological features examined included: anxiety/depression, perceived stress, 
positive and negative emotional styles, and pain catastrophizing. Details of these 
psychological constructs are presented in Chapter 3, with assessment scoring and 
psychometrics presented below. 
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Anxiety and depression were assessed using the Hospital Anxiety and 
Depression Scale (HADS). Correlation between subscales (anxiety and depression) of 
HADS, and the internal consistency of the subscales were found to be strong with 
Cronbach’s α values of 0.83 and 0.82, respectively (Bjelland, Dahl, Haug, & 
Neckelmann, 2002). Scores for each subscale range from 0 to 21, with a score of ≥ 8 
representing clinically meaningful levels of anxiety or depression (Bjelland et al., 
2002). Scores for the entire scale (emotional distress) range from 0 to 42, with higher 
scores indicating more distress. 
Perceived stress in the present study was explored through the 10-item 
Perceived Stress Scale (PSS-10). The PSS-10 evaluates the degree to which individuals 
believe their life has been unpredictable, uncontrollable, and overloaded during the 
previous month, using a Likert scale (0-4) for each item (Cohen et al., 1983). A review 
of the psychometric evidence for the PSS-10 indicated good internal consistency and 
test-retest reliability with coefficients reaching > 0.70 in all cases (E.-H. Lee, 2012). 
PSS-10 scores can range from 0 to 40 with higher scores indicating higher perceived 
stress (Cohen et al., 1983). Categorical interpretation of PSS-10 scoring, includes: low 
stress (0-13), moderate stress (14-26), and high stress (27-40). 
Emotional styles were explored through the Positive and Negative Affective 
Schedule (PANAS). This scale includes words describing 10 positive and 10 negative 
emotions, and requires participants to indicate on a Likert scale (1-5) the extent to 
which they felt each emotion during the previous week. Items included in PANAS were 
designed to allow independent positive and negative scoring, in acknowledgement that 
having, for instance, a low negative affect does not equate to having a high positive 
affect (Watson et al., 1988). PANAS subscales demonstrated very high correlation 
(α=.89 to .95) with their corresponding regression-based factor analysis scores, whereas 
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the discriminant correlations (α= -.02 to -.18) were quite low (Watson et al., 1988). 
Similarly, reliability of the positive (α=.86) and negative (α=.87) subscales were found 
to be high, while correlation between the scales (α= -.09) remained low. 
Catastrophizing relative to pain experiences in the present study was explored 
through the Pain Catastrophizing Scale (PCS). This measure assesses three different 
domains of pain catastrophizing, including rumination, magnification, and helplessness 
(Michael JL Sullivan, Bishop, & Pivik, 1995). Participants are asked to indicate the 
degree to which they experience various thoughts and feelings when they are in pain 
using Likert scales ranging from (0) ‘not at all’ to (4), with total possible scores ranging 
from 0 to 52 (Michael JL Sullivan et al., 1995). Clinically relevant levels of pain 
catastrophizing are identified as PCS scores > 30. The Cronbach alpha values reported 
for the total PCS (α=.87) and factor scales (rumination, α= .87; magnification, α=.60; 
helplessness, α=.79) were found to be satisfactory and acceptable (Michael JL Sullivan 
et al., 1995). Subsequent investigations found that the PCS showed strong temporal 
stability and validity. Evidence for convergent validity was demonstrated with the 
moderate correlation of the PCS to scores on self-report measures of anxiety (r=.32; 
p<.001) and negative affect (r=.32; p<001). Test–retest reliability estimates for six 
weeks (r=.75) and 10 weeks (r=.70) in college undergraduates (Michael JL Sullivan et 
al., 1995), as well as in clinical adult populations (Osman et al., 2000), showed strong 
evidence for the stability of responses on the PCS. 
7.5.4 IBD characteristics 
The following IBD features were characterised in the present study: IBD 
subtype (Crohn’s disease, ulcerative colitis, or indeterminate colitis), duration, 
medication use, abdominal pain, and disease severity.  
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Table 7.2 









Crohn’s disease, ulcerative colitis, indeterminate colitis 
Months/years 
Age at diagnosis (≤ 16 years, 17-40 years, > 40 years) 
Disease behaviour (penetrating, stricturing, perianal) 
Surgical history (resection and/or perianal) 
Stoma or j-pouch history 
Steroids, biologics, and immunosuppressants 
 
 
Medication use in IBD participants included consideration of previous and 
current use of steroids, biologics, and immunosuppressants. Abdominal pain was 
evaluated in terms of interference and severity. Abdominal pain interference was 
evaluated through Patient-Reported Outcomes Measurement Information System 
(PROMIS) Pain Interference 4a short form, developed by the National Institutes of 
Health. PROMIS short forms have undergone extensive qualitative expert and patient 
review, as well as quantitative analysis of data collected on general populations and 
clinical samples (Gershon et al., 2010). Positive findings for abdominal pain 
interference include: mild (50-59), moderate (60-69), or severe (≥70). Abdominal pain 
severity was evaluated using numeric rating scales recorded for worst, average, and 
current pain levels, with positive findings as mild (1-4), moderate (5-6), or severe (7-
10) (Williamson & Hoggart, 2005). 
Disease severity was assessed including: previous surgery, history of a stoma, 
age at diagnosis, disease behaviour, disease extent, and HRQOL. The Montreal 
classification system was used to describe phenotypes of IBD (Gomollón et al., 2016), 
to include: age at diagnosis (≤ 16 years old, 17-40 years old, and > 40 years old), 
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disease behaviour (penetrating, stricturing, and/or perianal disease), and disease extent. 
Disease extent for Crohn’s disease was defined as limited disease (<40 cm ileal 
involvement or absence of pancolitis) or extensive disease (ileal involvement of at least 
40 cm or presence of pancolitis) (Siegel et al., 2016). Disease extent for ulcerative 
colitis was defined as limited disease (distal to the splenic flexure) or extensive disease 
(beyond the splenic flexure) (Satsangi et al., 2006; Siegel et al., 2016).  
HRQOL was assessed using the validated Short IBD Questionnaire (SIBDQ) 
(E. Irvine et al., 1996; Peyrin-Biroulet et al., 2016). SIBDQ demonstrated significant 
retest reliability (ICC = 0.65, Cronbach’s α = 0.78) with ability to detect clinically 
meaningful changes in HRQOL through the assessment of five health dimensions 
(bowel symptoms, systemic symptoms, functional impairment, social impairment, and 
emotional function) (E. Irvine et al., 1996). SIBDQ score ranges from 10 (poor 
HRQOL) to 70 (optimum HRQOL), with scoring interpreted as poor (10-29), moderate 
(30-49), and optimal (50-70). 
7.5.5 MSK Pain characteristics 
Characteristics of MSK pain evaluated included: location, duration, 
interference, and severity. Pain location was recorded regionally (n=47) using a body 
diagram, which previously demonstrated significant test-retest reliability (r=0.85) in 
chronic pain patients (Margolis et al., 1988; S. Van Erp et al., 2015; Zeitz et al., 2016). 
Individuals with multiple pain regions were instructed to identify their “main” area of 
pain. Assessments of MSK pain interference and severity related to an individual’s 
“main” area of pain, using PROMIS Pain Interference 4a and numeric rating scales, 
respectively. Positive findings for the PROMIS Pain Interference 4a, include: mild (50-
59), moderate (60-69), or severe (≥70). Numeric rating scales for pain severity were 
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recorded for worst, average, and current pain levels, with positive findings as mild (1-
4), moderate (5-6), or severe (7-10) (Williamson & Hoggart, 2005). 
7.5.6 Measures of central sensitization 
Surrogate markers of central sensitization utilized in the present study included 
investigation of symptomology (i.e. CSI) and somatosensory functioning (i.e. PPT, 
CPM, and TS). Assessment of constructs related to central sensitization is presented in 
Chapter 3, with assessment scoring and psychometrics presented below. 
7.5.6.1 Symptoms of central sensitization 
 The use of CSI as an indirect measure of central sensitization has been 
validated previously (AUC= 0.86, Sensitivity = 81%, Specificity = 75%) in a large 
population with central sensitivity syndromes (Mayer et al., 2012; Neblett et al., 2013). 
CSI (part A) evaluates 25 features across an array of somatic and emotional symptoms, 
with each item scored on a scale of 0 to 4, and overall scoring ranging from 0 to 100 
(Neblett, Hartzell, Mayer, et al., 2017).  Higher CSI scores indicate increased 
symptomology related to central sensitization, with scores ≥ 40 indicating the likely 
presence of central sensitivity syndromes (Mayer et al., 2012; Neblett et al., 2013).  
7.5.6.2 Somatosensory functioning 
7.5.6.2.1 Sensory testing conditions 
All three study groups underwent the same standardized examination protocol 
(Appendices M & N), performed by a single investigator (CF). This investigator 
received training by a senior investigator (RM) for all testing procedures, and 
performed repeat pilot testing of all procedures on n = 5 healthy individuals prior to all 
data collection. Testing was performed in a quiet room, with participants positioned in 
comfortable prone lying for PPT and in supine for screening assessments, TS, and 
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CPM. All participants were provided a trial of each assessment to familiarize 
themselves with the procedure at remote body locations before data collection was 
initiated.  
7.5.6.2.2 Screening assessments 
Screening assessments used to detect the presence of peripheral neuropathies in 
the present study included Semmes-Weinstein monofilament examination (SWME) 
(Feng, Schlösser, & Sumpio, 2009; Olaleye, Perkins, & Bril, 2001) and vibration 
detection threshold (VDT) (Whitton, Johnson, & Lovell, 2005). The SWME 
demonstrated high sensitivity (93.1%) and specificity (100%) for identifying decreased 
sensation confirmed by gold standard nerve conduction tests (Feng et al., 2009). 
SWME of the upper limb was performed using a 4.56 (4 g) monofilament at six 
locations divided over the palm and fingers, bilaterally (Schreuders, Selles, van 
Ginneken, Janssen, & Stam, 2008). SWME of the lower limb was performed using a 
5.07 (10 g) monofilament at the pulp of the great toe, as well as the first, third, and fifth 
metatarsal heads, bilaterally (Feng et al., 2009). VDT was assessed using a Rydel–
Seiffer graded tuning fork (64 Hz, 8/8 scale) placed over bony prominences (styloid 
process of the ulna and medial malleolus), bilaterally. Participants were instructed to 
verbally indicate the moment they could no longer feel the sensation of vibration, and 
this value was recorded. VDT of each site was described as the mean of three trials 
(Rolke et al., 2006). 
7.5.6.2.3 Pressure pain threshold 
PPT was assessed at two locations for all groups: 1) low back (local) – at the 
middle of a horizontal line drawn between the upper border of the iliac crest and the 
corresponding spinous process, divided randomly between the left/right sides of the 
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body; and 2) contralateral Tibialis anterior (5 cm distal to the Tibial tuberosity) (Neziri 
et al., 2013).  
Previous reports of chronic abdominal pain have hypothesized the presence of 
central sensitization as a consequence of relapsing/remitting courses of peripheral 
inflammation (Bielefeldt et al., 2009). Periods of active inflammation typically result in 
acute abdominal pain, which often refers to the low back region as a result of neural 
sensitivity between visceral and somatosensory neurons within the spinal cord 
(Bielefeldt et al., 2009; Kristen E Farrell et al., 2014). Reports of abdominal pain 
experienced in periods beyond active inflammation is thought to demonstrate enduring 
mechanisms of central sensitization along these same neural pathways (Bielefeldt et al., 
2009; Kristen E Farrell et al., 2014). Therefore, the low back may represent the MSK 
region most likely to demonstrate changes in neural sensitivity (i.e. peripheral and 
central sensitization) in this population. Conversely, sensitivity demonstrated at a 
remote region (e.g. Tibialis anterior) may be suggestive of widespread versus regional 
sensitivity, characteristic of mechanisms related to central sensitization (den Boer et al., 
2019; Clifford J Woolf, 2011). 
PPT was assessed using an electronic handheld algometer (Wagner Force 
One™ FDIX), by a series of three ascending stimulus intensities with a 60 second 
interval between trials. Each stimulus was given as a slowly increasing ramp 
(approximately 50 kPa/s) from 0 to a maximum pressure of 1000 kPa (Neziri et al., 
2013; Rolke et al., 2006). If the participant did not indicate pain at 1000 kPa, this value 
was considered as the PPT. Participants were instructed to verbally stop the test when 
the sensation of pressure alone changed to one of pressure and pain, with the 
corresponding pressure recorded for each trial. PPT for each region was described as 
the mean of three trials. Lower scores indicate greater pain sensitivity.  
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Assessment of PPT in the low back region previously demonstrated positive 
test–retest reliability and agreement using electronic algometers (Vuilleumier et al., 
2015). Specifically, PPT assessments demonstrated excellent intra-examiner reliability 
at the Tibialis anterior muscle (ICC=0.91; 95 % CI 0.31–0.95) and lumbar muscles 
(ICC=0.82; 95 % CI 0.65–0.97) (Corrêa, Costa, de Oliveira, Sluka, & Liebano, 2015). 
PPT similarly demonstrated strong discriminative validity between chronic pain 
patients and healthy controls (OR=0.10; 95% CI 0.04-0.24), p<.001) (Neziri et al., 
2012). 
7.5.6.2.4 Conditioned pain modulation 
Assessment of CPM was performed immediately following the assessment of 
PPT described above. PPT of Tibialis anterior was used as the test stimulus and a 
standardized ice bath to the contralateral hand as the conditioning stimulus. The 
magnitude of the CPM effect in the present study was defined as the percent change 
score between PPT after compared to before the conditioning stimulus. A higher CPM 
change score suggested greater pain modulation and the participant is said to be a CPM 
responder. CPM has previously demonstrated positive evidence of test–retest reliability 
and agreement using PPT and an ice bath as test and conditioning stimulus, respectively 
(Vuilleumier et al., 2015). 
Pressure stimulation 
PPT on Tibialis anterior was performed as described above, prior to and 
immediately following the conditioning stimulus.  
Conditioning stimulus 
Participants were asked to submerge their hand contralateral to the test site 
(Tibialis anterior), wide open and up to the wrist, in a container of circulating ice water, 
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for a maximum of 2 minutes. The temperature of the ice water was maintained below 
3°C, monitored by a thermometer with a digital display (Mlekusch et al., 2016; Neziri 
et al., 2013; D Yarnitsky et al., 2015). Participants were instructed to withdraw their 
hand when the pain perceived became intolerable or when the 2 minute maximum was 
reached. Participants were asked to give a numeric pain rating (0-10) at the time of 
hand removal. Total immersion time and pain rating of the conditioning stimulus were 
recorded. 
7.5.6.2.5 Mechanical temporal summation 
Mechanical TS was assessed on the volar aspect of the non-dominant arm using 
a Semmes-Weinstein monofilament (no. 6.65) (LeResche, Turner, Saunders, Shortreed, 
& Von Korff, 2013). The perceived intensity of a single stimulus was compared with 
that of a series of 10 repetitive stimuli of the same physical intensity (1/s applied within 
an area of 1 cm2) (Rolke et al., 2006). Participants were asked to give a pain rating for 
the single stimulus and a pain rating for the series of 10 stimuli as a whole, using a ‘0–
10’ numerical rating scale. This procedure was repeated for three trials, with 1 minute 
between trials, and performed at different areas of the volar forearm for each trial. 
Mechanical TS in the present study was defined as the percent change score between 
the mean pain rating of 10 series and the mean pain rating of the single stimuli. Higher 
percent change scores indicated greater TS, indicating an increased gain or facilitation 
into the CNS. Assessments of TS have previously demonstrated positive evidence of 
test–retest reliability and agreement (Vuilleumier et al., 2015), with strong 
discriminative validity between chronic pain patients and healthy controls (OR=0.30; 
95% CI 0.17-0.54), p<.001) (Neziri et al., 2012). 
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7.5.7 Sample size 
A priori sample size estimation for the between-group comparison in the present 
study (Chapter 8) was calculated using G*Power based on the mean and standard 
deviation (SD) of PPTs previously reported for the low back region in chronic low back 
pain, chronic widespread pain, central sensitivity syndromes, and health populations 
(Gerhardt et al., 2016; Marcuzzi, Wrigley, Dean, Adams, & Hush, 2017; Meeus, 
Roussel, Truijen, & Nijs, 2010; Vuilleumier et al., 2015). Given the available data, total 
sample size of N=120 was estimated as able to demonstrate between group differences 
at 80% power and 5% level of significance.  
7.6 Chapter summary 
This chapter presents the full protocol for Study 2 of the present thesis, aimed at 
exploring measures of central sensitization across three groups, as well as associations 
of IBD, psychological, demographic, comorbidity, and lifestyle factors to measures of 
central sensitization. The results and discussion related to the primary and secondary 






8 Study Two: Between-group Comparisons for Measures of Central 
Sensitization 
 
8.1 Chapter overview 
The following chapter presents the statistical analysis, results, and discussion 
related to the primary aim of Study 2 to assessing central sensitization in IBD patients 
with MSK pain.  
8.2 Study Aims 
1. To investigate differences in measures of central sensitization (i.e. CSI, PPT, 
CPM, and TS) across three groups: 1) IBD patients presenting with MSK 
pain, 2) IBD patients without MSK pain and 3) healthy controls. 
2. To investigate whether between-group differences demonstrated above are 
confounded by psychological factors (PSS, PANAS (positive), PANAS 
(negative), HADS (anxiety), HADS (depression), and PCS). 
8.3 Hypotheses 
1. IBD patients presenting with MSK pain will demonstrate greater 
symptomology related to central sensitization (i.e. CSI scores) and altered 
somatosensory functioning (i.e. PPT, CPS, and TS) when compared to IBD 
patients without MSK pain and to healthy controls. Similarly, IBD patients 
without MSK pain will demonstrate greater symptomology related to central 
sensitization (i.e. CSI scores) and altered somatosensory functioning (i.e. 
PPT, CPS, and TS) when compared to health controls.  
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2. Psychological factors will demonstrate a degree of confounding in the 
measures of central sensitization demonstrating between-group differences 
described above. 
8.4 Statistical Analysis 
All statistical analyses were performed using IBM SPSS Statistics (version 26). 
Descriptive statistics were used to characterize IBD, pain, psychological, demographic, 
comorbidity, lifestyle, and measures of central sensitization evaluated in the present 
study. Where appropriate, Chi-square/Fisher’s exact tests (categorical variables) and 
independent t-tests (continuous variables) were used to characterize differences 
between the two IBD groups with regards to IBD features. Similarly, where 
appropriate, Chi-square/Fisher’s exact tests (categorical variables) and one-way 
analyses of variance (ANOVAs)/Kruskal-Wallis ANOVAs (continuous variables) were 
used to characterize differences between the three groups for psychological, 
demographic, lifestyle, and comorbidity features. Significance was identified at P ≤ .05. 
ANOVAs/Kruskal-Wallis ANOVAs were used to investigate between-group 
differences for measures of central sensitization as the primary aim of the current study. 
Assumptions for all ANOVA models were assessed to ensure model fit, including: 
normality of scoring distribution (Shapiro-Wilk tests) and homoscedasticity (scatterplot 
of residuals). Bonferroni and Mann Whitney’s tests were used to explore post hoc 
comparisons for measure of central sensitization, with significance identified at P ≤ .05. 
One-way Analyses of covariance (ANCOVAs) were used to investigate 
potential confounding by psychological features for measures of central sensitization 
demonstrating significant between-group differences (P ≤ .05). Adjustment for 
potential confounders aims to provide an undistorted estimate of the relationship 
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between the independent and dependent variables (MacKinnon et al., 2000). Additional 
assumptions for ANCOVAs were explored, including tests of normality listed above 
and Levene’s test for homogeneity. 
8.5 Results 
A total of 77 individuals (53 IBD patients and 24 healthy controls) volunteered 
to participate in Study 2 of the present thesis. Of the patients with IBD, 24 reported no 
history of MSK pain and 29 reported the presence of MSK pain lasting longer than 3 
months within the past year. None of the IBD patients nor the healthy controls were 
indicated as having features of peripheral neuropathy during screening assessments (i.e. 
SWME and VDT). However, two IBD patients were later diagnosed with neurological 
conditions and were therefore excluded from the present analysis. Similarly, 2 healthy 
controls were excluded due to a diagnosis of diabetes mellitus. With the exception of 
one participant representing an 8 year age gap, the remaining participants were age (± 5 
years) and gender matched across the following three study groups: IBD patients with 
MSK pain (n=22), IBD patients without MSK pain (n=22), and healthy controls (n=22).  
Results of Study 2 (primary aims) are presented below under the subheadings: 
1) demographics, comorbidity, and lifestyle factors (descriptive statistics), 2) IBD 
features (descriptive statistics), 3) MSK pain features (descriptive statistics), 
Psychological features (descriptive), and 4) measures of central sensitization 
(descriptive and between-group comparisons).  
8.5.1 Demographics, comorbidity, and lifestyle factors 
Demographic, lifestyle, and comorbidity status of the study participants are 
presented in Table 8.1. Participants represented the following ethnic groups, with one 
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participant identifying with two groups: White (n=63), African American (n=1), and 
Asian American (n=3).  
 
Table 8.1 
Participant Characteristics across the Three Study Groups (N = 66) 
Characteristic IBD with 
MSK pain    
(n = 22) 
IBD without 
MSK pain  
(n = 22) 
Healthy 
controls 
(n = 22) P 
Gender  
     Male, n (%)    












      Range (years) 
      Mean (SD) 
 
18 - 68 
37.64 (11.50) 
 
21 - 67 
37.95 (12.97) 
 




      Range (n) 
      Mean (SD) 
 
1 - 6 
3.14 (1.73) 
 






Smoking (yes, n (%)) 1 (5) 1 (5) 0 (0)  
Alcohol consumption 
      Yes, occasionally 
      Yes, regularly 















Cannabis use (yes, n (%)) 9 (41) 4 (18) 2 (9) 0.048b* 
Poor sleep quality 10 (45) 4 (18) 0 (0) 0.012a* 
EuroQol-5D-5L  
    Total (mean (SD)) 














Note. Inflammatory bowel disease (IBD), musculoskeletal (MSK), standard deviation 
(SD), health-related quality of life questionnaire (EuroQol-5D-5L), and visual analogue 
scale (VAS). 
a Fisher’s exact test. 
b Chi-squared. 
c Kruskal-Wallis analysis of variance.  




8.5.2 IBD features 
A summary of IBD features observed in the current study are presented in 
Tables 8.2 to 8.4. No significant differences were found between the two IBD groups 
for any of the observed IBD features.  
 
Table 8.2 
IBD Features of Study participants across Two Study Groups (n = 44) 
Assessment IBD with MSK 
pain (n = 22) 
IBD without MSK 
pain (n = 22) P 
IBD subtype 
   Crohn’s disease (n (%)) 
   Ulcerative colitis (n (%)) 










IBD duration, years (mean (SD)) 
   Range 
13.77 (10.47) 
1-42 
14.45 (10.38)  
2-41 
0.985 b 
Surgical history, yes (n (%)) 10 (45) 8 (36) 0.540 c 
SIBDQ 51.50 (6.47) 55.77 (9.38) 0.355 b 
Abdominal pain (n (%)) 13 (59) 7 (32)  0.069 c 
   Severity (NRS) (mean (SD)) 






Note. Inflammatory bowel disease (IBD), musculoskeletal (MSK), standard deviation 
(SD), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), numeric rating scale 
(NRS), and Patient-Reported Outcomes Measurement Information System (PROMIS). 
a Fisher’s exact test. 






Montreal Classification of Two Study Groups (n = 44) 
Characteristic IBD with MSK 
pain (n = 22) 
IBD without MSK 
pain (n = 22) P 
   Age at diagnosis (n (%)) 
        ≤ 16 years old 
        17-40 years old 










   Location (n (%)) 
        Crohn’s disease  
            Terminal ilium 
            Colon 
            Ileocolon 
        Ulcerative colitis 
            Proctitis  
            Left-sided 




















     Behaviour (n (%)) 
        Stricturing 
        Penetrating 
        Both stricturing/penetrating 













Note. Inflammatory bowel disease (IBD) and musculoskeletal (MSK). 
a Fisher’s exact test. 





IBD Medication Use of Study Participants (n = 44) 
Characteristic IBD with MSK pain 
(n = 22) 
IBD without MSK pain 
(n = 22) P 
Steroids (n (%)) 
      Never  
      Previous  
      Current use 
 
3 (14) 







Biologic (n (%)) 
      Never 
      Previous 










Immunosuppressant (n (%)) 
      Never 
      Previous 















8.5.3 Musculoskeletal Pain features 
MSK pain features of IBD patients are presented in Tables 8.5. Of the 
participants reporting the presence of MSK pain, 59% (n = 13) also reported the 
presence of abdominal pain. Of the MSK regions identified as painful by study 
participants, the low back (n = 11, 31%) and mid back (n = 11, 31%) were the most 
frequently reported regions, while the posterior neck (n = 4, 27%) was most frequently 
identified as the ‘main area of pain’. A summary of all painful regions reported by 





Summary of Musculoskeletal Pain Characteristics of Study Participants 
Characteristic Range Mean (SD) 
Body map, painful regions (n) 2-17 8.32 (4.61) 
Strongest pain severity (NRS) 0-9 4.86 (2.55) 
Average pain severity (NRS) 0-7 3.14 (2.05) 
PROMIS Pain Interference 4a 41.6 - 66.6 53.83 (7.54) 
Note. Standard deviation (SD), numeric rating scale (NRS), and Patient-Reported 
Outcomes Measurement Information System (PROMIS).   
 
 
8.5.4 Psychological features 
8.5.4.1 Descriptive statistics 
Psychological features of the study participants are presented in Table 8.6. The 
majority of participants in both IBD groups (n = 12, 55%) demonstrated moderate 
levels of perceived stress, while the majority of healthy controls (n = 14, 64%) 
demonstrated mild perceived stress. Only one IBD patient without MSK pain reached a 
clinically meaningful score (>30) of pain catastrophizing. HADS subscales indicated 
45% (n = 10) of IBD patients with MSK pain demonstrated clinically meaningful 
scores for the presence of anxiety (≥ 8), whereas only 14% (n = 3) of these same 
patients demonstrated clinically meaningful scores for depression (≥ 8). Conversely, 
23% (n = 4) of IBD patients without MSK pain and 23% (n = 4) of healthy controls 
demonstrated clinically meaningful scores for anxiety, with no IBD patients without 
MSK pain and 5% (n = 1) of the healthy controls demonstrating clinically meaningful 





Psychological Features across Three Study Groups (N = 66) 
Assessment 
IBD with MSK pain 
Mean (SD) 
IBD without MSK pain 
Mean (SD) 
Healthy controls 
Mean (SD) P 
HADS    
  Anxiety 













10-PSS 15.55 (7.58) 13.55 (7.35) 10.18 (5.88) 0.043b* 
PANAS  









  Negative affect 19.18 (6.90) 16.27 (4.23) 16.18 (3.70) 0.270a 
PCS 8.76 (7.53) 7.45 (9.26) 1.95 (2.98) 0.001a* 
Note. Inflammatory bowel disease (IBD), musculoskeletal (MSK), standard deviation 
(SD), Hospital Anxiety and Depression Scale (HADS), 10-item Perceived Stress Scale 
(PSS), Positive and Negative Affective Schedule (PANAS), and Pain Catastrophizing 
Scale (PCS). 
a Kruskal-Wallis analysis of variance 
b One-way analysis of variance 
* Significant at p ≤ 0.05. 
 
 
8.5.5 Measures of central sensitization 
8.5.5.1 Descriptive statistics 
A summary of participant scores for CSI, PPT, CPM, and TS are presented in 
Table 8.7. CSI scores were normally distributed (Shapiro-Wilk, p ≥ 0.05), with an 
overall range of 3 to 56 in study participants. Within the three study groups, 45% (n = 
10) of IBD patients with MSK pain demonstrated benchmarked CSI scores (≥40) 
representing patients with the likely presence of central sensitivity syndromes. 
Conversely, 18% (n = 4) of patients without MSK pain and no healthy controls 
demonstrated benchmarked CSI scores. PPT of the Tibialis anterior region was 
normally distributed (Shapiro-Wilk, p ≥ 0.05), with an overall range of 118.01 to 
754.13 kPa in study participants. PPT of the low back, CPM, and TS were not normally 
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distributed (Shapiro-Wilk, p < 0.05) within study groups. PPTs of the low back region 
ranged from 115.06 to 793.36 kPa, CPM scores ranged from - 43% to 185%, and TS 
scores ranged from 0% to 4% in study participants 
 
8.5.5.2 Between group comparisons 
Results for one-way ANOVAs to examine between-group differences for 
measures of central sensitization are summarised in Table 8.7. There was a statistically 
significant difference between groups for mean CSI scores (F(2,63) = 19.835, p < 
0.001, r = .62), with an observed power of greater than 90%.  A Bonferroni post hoc 
test revealed that mean CSI scores were significantly (p ≤ 0.05) different between 
groups (mean difference ± standard error, [95% confidence intervals]), including IBD 
patients with MSK pain compared to without MSK pain (10.64 ± 3.15, [2.89, 18.38], p 
= 0.004), IBD patients with MSK pain compared to healthy controls (19.82 ± 3.15, 
[12.07, 27.56], p <0.001), and IBD patients without MSK pain compared to healthy 
controls (9.18 ± 3.15, [1.44, 16.93], p = 0.015). There were no statistically significant 
differences between group means for remaining measures of central sensitization, 
including: PPT of Tibialis anterior (F(2,63) = 0.906, p = 0.409), PPT of the low back 






Measures of Central Sensitization across Three Study Groups (N = 66) 
Measure 











CSI 36.86 (9.63) 26.23 (12.68) 17.05 (8.58) F(2,63)=19.84, p <0.001* 
PPT (LB) a 370.07 (168.14)  369.98 (215.77)  432.29 (182.12)  H(2) = 1.62, p = 0.445 
PPT (TA) a 381.94 (178.77) 398.77 (174.17) 450.05 (171.50) F(2,63) = 0.91, p = 0.409 
TS b 100 [54 - 146] 133 [100 - 200] 100 [62 - 144] H(2) = 2.67, p = 0.263 
CPM a b c      20 [8 - 29] 29 [13 - 47] 24 [16 - 30] H(2) = 3.13, p = 0.209 
Note. Inflammatory bowel disease (IBD), musculoskeletal (MSK), standard deviation 
(SD), analysis of variance (ANOVA), central sensitization inventory (CSI), pressure 
pain threshold (PPT), low back (LB), Tibialis anterior (TA), temporal summation (TS), 
and conditioned pain modulation (CPM). 
a Values represent raw scoring for measures. 
b Values represent percent change for dynamic somatosensory measures.  
c Median [interquartile range] 
* Significant at p ≤ 0.05. 
 
Results for one-way ANCOVAs comparing CSI scores between study groups 
while controlling for individual psychological features are presented in Table 8.8. There 
was a significant difference in mean CSI scores between study groups when 
individually controlling for PSS (F(2,62) = 15.445, p < 0.001, r = .75), PANAS 
(positive) (F(2,62) = 15.058, p < 0.001, r = .71), PANAS (negative ) (F(2,62) = 15.058, 
p < 0.001, r = .75), HADS (anxiety) (F(2,62) = 18.173, p < 0.001 r = .73), HADS 
(depression) (F(2,62) = 18.978, p < 0.001, r = .76), and PCS and F(2,55) = 12.488, p < 
0.001, r = .78). Post hoc comparisons indicated that after controlling for psychological 
variables, CSI scores were still significantly different (p ≤ 0.05) between IBD patients 
with and without MSK pain, as well as healthy controls. However, adjustment for PSS 
and PCS no longer demonstrated significant differences in CSI scores between IBD 





Mean differences for Central Sensitization Inventory Scores between Three Study Groups Adjusted for Psychological Features 
CSI 
 IBD with MSK pain compared to  
IBD without MSK pain 
IBD with MSK pain compared to  
healthy controls 
IBD without MSK pain compared to 
healthy controls 
 Model summary MD (SE), [95% CI] P MD (SE), [95% CI] P MD (SE), [95% CI] P 
Unadjusted R=0.62, F(2,63)=19.84, p<.001* 10.64 (3.15), [2.89, 18.38] .004* 19.82 (3.15), [12.07, 27.56] <.001* 9.18 (3.15), [1.44, 16.93] .015* 
Adjusted         
 PSS R=0.75, F(2,62)=15.45, p<.001* 9.01 (2.68), [2.41, 15.62] .004* 15.46 (2.80), [8.57,22.35] <.001* 6.45 (2.72), [-0.243, 13.14] .063 
 PANAS-positive R=0.71, F(2,62)=15.06, p<.001* 8.60 (2.91), [1.44, 15.76] .013* 16.44 (3.00), [9.07, 23.82] <.001* 7.84 (2.88), [0.75, 14.94] .025* 
 PANAS-negative R=0.75, F(2,62)=18.17, p<.001* 7.45 (2.75), [0.69, 14.21] .026* 16.53 (2.75), [9.76, 23.31] <.001* 9.08 (2.68), [2.50, 15.66] .004* 
 HADS-anxiety R=0.73, F(2,62)=17.25, p<.001* 8.41 (2.81), [1.50, 15.33] .012* 16.74 (2.85), [9.73, 23.76] <.001* 8.33 (2.77), [1.51, 15.15] .011* 
 HADS-depression R=0.76, F(2,62)=18.98, p<.001* 7.82 (2.67), [1.26, 14.38] .014* 16.52 (2.69), [9.91, 23.13] <.001* 8.70 (2.62), [2.26, 15.14] .004* 
 PCS R=0.78, F(2,55)=12.49, p<.001* 10.56 (2.81), [3.63, 17.49] .001* 14.17 (2.95), [6.88, 12.47] <.001* 3.61 (2.77), [-3.23, 10.45] .593 
Note. Central sensitization inventory (CSI), inflammatory bowel disease (IBD), musculoskeletal (MSK), standard error (SE), perceived stress scale (PSS), 
positive and negative affect schedule (PANAS), hospital anxiety and depression scale (HADS), and pain catastrophizing scale (PCS). 
* p ≤ 0.05. 
  




The primary aim of Study 2 was to explore between-group differences for 
measures of central sensitization (i.e. CSI, PPT, CPM, and TS). Analysis indicated that 
CSI was the only measure of central sensitization to demonstrate a significant 
difference between study groups. Investigation of confounding factors for between-
group differences demonstrated a significant influence on CSI scores from all of the 
psychological features explored in the present study. However, CSI scores remained 
significantly different between all study groups even after controlling for psychological 
confounding, with the exception of perceived stress and pain catastrophizing. Models 
controlling for PSS and PCS demonstrated that mean CSI scores were no longer 
significantly different between IBD patients without MSK pain and healthy controls. 
However, the modest sample size may have resulted in a type II error causing analysis 
for PSS and PCS to falsely not reach significance. Future research utilizing a larger 
sample size would help to confirm whether PSS and PCS influence differences in CSI 
scoring between IBD patients without MSK and healthy controls. 
The present study did not demonstrate significant differences in somatosensory 
functioning (i.e. PPT, CPM, and TS) between the three study groups. These results may 
suggest that either altered somatosensory functioning is not contributing to persistent 
MSK pain in IBD patients, or that altered somatosensory functioning represents a more 
complex construct than is simply identified by the presence of IBD and/or MSK pain. 
Current literature suggests measures of somatosensory functioning may be influenced 
by additional features, such as specific pain presentations (Blumenstiel et al., 2011; 
Maier et al., 2010). Previous studies investigating a variety of discrete pain types, 
including neuropathic conditions, fibromyalgia, and chronic back pain, have indicated 
that different conditions present with different somatosensory profiles (Blumenstiel et 
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al., 2011; Maier et al., 2010). Similarly, different neurological conditions demonstrated 
a mixed profile of altered somatosensory functioning, suggesting that somatosensory 
assessments vary within as well as between pain types (Maier et al., 2010). Therefore, 
the diversity of MSK pain types represented in the present study may have contributed 
to variability in somatosensory assessments, resulting in a lack of statistical difference 
between the current study groups.  
In addition to MSK pain types, influences from various lifestyle factors to 
somatosensory assessments have been documented for both pain and healthy 
populations (Gierthmühlen et al., 2015; Mani, Adhia, Leong, Vanneste, & De Ridder, 
2019; Schuh-Hofer et al., 2013). An ongoing challenge of investigations utilizing 
current somatosensory assessments relates not only to identify, for instance, lifestyle 
factors which influence assessments but also in recruiting healthy participants across 
demographic spectrums which adhere to the strict exclusion of common factors stated 
in current guidelines, such as sleep disturbances, (Gierthmühlen et al., 2015). Although 
the present study attempted to closely follow these guidelines for healthy controls, strict 
adherence was not feasible. Therefore, results may reflect influences from factors, such 
as sleep disturbances, across all study groups, thus contributing to the variability in 
somatosensory assessments. Similarly, IBD patients in the present study did not differ 
significantly based on individual IBD factors. As such, results are unable to suggest 
whether certain IBD factors may have influenced measures of central sensitization in 
the present study, such as previous surgical history and/or abdominal pain experiences. 
Although central sensitization has been proposed in the generation and 
maintenance of chronic abdominal and post-surgical pain in IBD patients, (Bielefeldt et 
al., 2009; Kristen E Farrell et al., 2014; Hains et al., 2010), there have been few 
investigations of somatosensory functioning in IBD (Huehne et al., 2009; Munster et 
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al., 2015). These investigations were limited in their scope, assessing the dorsum of 
bilateral hands in patients specifically with Crohn’s disease. Similar to current study 
results, Munster, et al. (2015) reported no difference in PPT and TS between Crohn’s 
disease patients and healthy controls. Conversely, the same authors reported a 
significant decrease in heat detection, vibration detection, and mechanical pain 
thresholds in Crohn’s disease patients compared to healthy controls (Munster et al., 
2015). However, authors did not report on factors known to influence somatosensory 
assessments, such as psychological and lifestyle factors, as well as the use of biologic 
therapies, which are recognized as a cause of peripheral neuropathy (i.e. altered 
somatosensory functioning) in IBD patients (Burger & Florin, 2009; Singh, Kumar, 
Loftus Jr, & Kane, 2012).  
The between-group differences for CSI scoring seen in current results are 
similar to those in Study 1 of this thesis, where the presence of persistent MSK pain 
demonstrated greater symptoms of central sensitization (higher CSI scores). Previous 
studies report similar findings, with higher CSI scoring in chronic MSK pain patients 
when compared to healthy controls (Kregel et al., 2017; Mayer et al., 2012). In fact, a 
study exploring subpopulations of MSK pain (i.e. fibromyalgia, chronic widespread 
pain, and chronic regional low back pain) showed that all MSK pain types presented 
with greater symptoms of central sensitization compared to healthy controls (Mayer et 
al., 2012). However, in addition to MSK pain, the between-group differences for CSI 
scoring in the current study indicate that the presence of IBD independent of MSK pain 
was also associated with higher CSI scoring. These results highlight the need for further 
investigation to understand the relationship between IBD and central sensitization 
outside of MSK pain experiences. 
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The influences of psychological features on CSI scoring in the present study are 
similar to previous reports in the literature. Psychometric validation of CSI indicated 
that symptoms of emotional distress accounted for over 7% of the variance in CSI 
scoring and consequently have been identified as one of the four primary domains of 
this measure (Mayer et al., 2012). However, in the current study, it was interesting to 
note that CSI scores remained significantly different between all of the study groups 
after controlling for psychological features. This suggests that the relationship between 
greater symptoms of central sensitization and the presence of MSK pain and IBD is not 
explained by psychological functioning alone, therefore implicating participation from 
other CSI domains. 
As previously described, the CSI questionnaire was developed with the 
intention of producing a screening assessment to identify patients whose presenting 
symptoms are related to an underlying presence of central sensitization (Mayer et al., 
2012; Neblett et al., 2015). CSI explores features of psychological distress, sleep 
disturbances, fatigue, pain, and hyperalgesia/allodynia (i.e. visceral and somatic) in 
order to quantify the sensitivity of the somatosensory system (Kregel et al., 2017; 
Mayer et al., 2012; Verne et al., 2001; Yunus, 2008). Therefore, in addition to 
psychological features, interpretation of current study results within the domains of CSI 
would suggest that IBD patients with and without MSK pain may demonstrate a greater 
influence from features such as sleep quality, multiple pain sources (i.e. abdominal and 
MSK), as well as visceral hypersensitivity (i.e. functional bowel changes). 
Interestingly, sleep quality was found to be significantly different between the three 
study groups, where IBD patients with MSK pain demonstrated worse sleep quality 
(Table 8.1). Future research should explore the contributions of additional patient 
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features to overall CSI scores in order to better understand the nature of somatosensory 
sensitivity in IBD patients. 
As previously described, the use of CSI has been promoted in chronic pain 
algorithms as a method of identifying the need for further mechanistic investigation 
(Nijs et al., 2015; Nijs et al., 2014). Therefore, although the present study did not 
identify differences in somatosensory functioning across the study groups, the fact that 
CSI scores were significantly higher in IBD patients, increasingly so in those with 
MSK pain presentations, supports continued investigation of central mechanisms in this 
population. However, future research should employ methodologies to account for the 
variability in measures described above, such as investigation of targeted MSK pain 
subtypes, as well as an exploration of influences from additional participant features, 
such as lifestyle and clinical IBD features.  
Additionally, although the present study included age and gender matching 
across all of the groups, interpretation of study results should consider the modest 
sample size. The sample size estimate (N = 120) in the present thesis was based on the 
mean (SD) of PPTs previously reported for the low back region. However, due to 
restrictions during the data recruitment phase of this study, the resultant sample size (N 
= 66) suggests the current results are likely significantly underpowered. Post hoc 
analysis for CSI scores (>90%) suggest that the current sample may be sufficient to 
detect between-group differences for CSI, while remaining insufficient to detect 
differences in PPT, CPM, and TS assessments. The consequence of the resultant small 
sample size is primarily a reduced probability of detecting a difference between groups, 
where a difference exists for these assessments (type II error). Therefore, future IBD 
research should explore PPT, CPM, and TS assessments in adequately powered 
investigations to confirm current study findings. Similarly, the sample size in the 
138 
present study did not allow for a final ANCOVA to present a model of best fit, 
controlling for the combined psychological variables reaching significance.  
Assessment of somatosensory functioning in the current study did not include 
the full battery of quantitative sensory testing. Therefore, interpretation of 
somatosensory functioning in the current study relates only to PPT, mechanical TS, and 
CPM, without indication of additional sensory modalities, such as thermal and pain 
tolerance thresholds. PPT investigated in the present thesis included assessments at the 
low back and Tibialis anterior regions only. While the low back region was overall the 
most frequently reported pain region among IBD patients, it was not the most 
frequently reported “main” region of pain. Therefore, between-group comparison for 
this measure does not reflect differences for the most painful region in most patients. 
8.7 Chapter summary 
The present study is the first to investigate differences in measures of central 
sensitization between three groups: IBD patients with and without MSK pain, and 
healthy controls. Study results indicate that IBD patients demonstrated significantly 
greater symptoms of central sensitization compared to healthy controls. Furthermore, 
results indicated that the additional presence of persistent MSK pain in IBD 
demonstrated the greatest magnitude of central sensitization symptoms compared to 
patients without MSK pain and healthy controls. Study results also suggest that 
somatosensory assessments may be influenced by additional patient features, such as 
IBD, psychological, pain, demographics, comorbidity, and lifestyle factors. Therefore 
Chapter 9 presents the statistical analysis, results, and discussion related to the 
secondary aims of Study 2, to investigate associations between measures of central 
sensitization and IBD, as well as features within additional patient domains (i.e. 
psychological, demographic, comorbidity, and lifestyle). 
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9 Study Two: Associations between Measures of Central 
Sensitization and Multiple IBD Patient Domains 
 
9.1 Chapter overview 
The current chapter presents the statistical analysis, results, and discussion 
related to the secondary aims of Study 2: to investigate associations between measures 
of central sensitization and IBD, as well as features within additional patient domains 
(i.e. psychological, demographic, comorbidity, and lifestyle). Therefore, the results 
presented below relate to data collected solely on IBD patients (n = 51) in Study 2, who 
are thus referred to as the “participants” in this chapter.  
 
9.2 Secondary Study Aim 
 To investigate the association between measures of central sensitization (i.e. 
CSI, PPT, TS, and CPM) and IBD features, as well as psychological, 
demographic, comorbidity, and lifestyle features in patients with IBD. 
 
9.3 Hypothesis 
It was hypothesized that IBD features will demonstrate a positive association 
with measures of central sensitization. It was further hypothesized that models 
predicting measures of central sensitization will demonstrate influences from multiple 




9.4 Statistical Analysis 
All statistical analysis was performed using IBM SPSS Statistics (version 26). 
Descriptive statistics were used to characterize IBD, pain, psychological, demographic, 
comorbidity, lifestyle, and central sensitization features evaluated in the present study.  
A 2-step procedure was used to investigate the relationship between IBD 
features and measures of central sensitization. Step 1 included calculation of correlation 
coefficients (Pearson product-moment, Spearman rank-order, and point-biserial) to 
assess bivariate relationships between independent variables (IBD, psychological, 
demographics, comorbidity, and lifestyle features) and dependent variables (CSI, PPT, 
CPM, and TS). Significant correlations were identified as p ≤ 0.05 and strength of 
correlation defined as: very strong (≥ 0.80), strong (0.50 – 0.79), moderate (0.30 – 
0.50), weak (0.20 – 0.30), and very weak (< 0.19). 
Step 2 involved multiple linear regression analyses for each dependent variable 
(CSI, PPT, CPM, and TS) and primary independent variables (IBD features), if they 
demonstrated significant correlation (p ≤ 0.05). Secondary independent variables 
demonstrating significant correlations were individually assessed for their overall 
impact to step 2 modelling through stepwise entry into the model. Secondary variables 
resulting in a ≥ 10% change in R2 were included in the final backward regression 
model. Due to the modest sample size (n = 51), a maximum of 5 independent variables 
was added into the multiple regression models. Assumptions for correlation and linear 
models were assessed where appropriate, including: normality of scoring distribution 
(Shapiro-Wilk tests), collinearity diagnostics (variance inflation factor < 10 and 
tolerance > 0.2), and homoscedasticity (scatterplot of residuals). 
 




A total of 53 patients with IBD volunteered to participate in Study 2. Two IBD 
patients reported the presence of neurological conditions and were therefore excluded 
from the present analysis. Therefore, the final sample size included 51 IBD patients. 
Results of this secondary analysis are presented in three sections. The first section 
presents descriptive statistics for participant demographics, comorbidity, lifestyle, 
psychological, pain and IBD features, as well as measures of central sensitization (CSI, 
PPT, TS, and CPM). The second section presents correlation analyses of IBD, pain, 
psychological, demographic, comorbidity, and lifestyle features to measures of central 
sensitization. The third section presents multiple linear regression analyses between 
independent variables (IBD, psychological, demographic, comorbidity, and lifestyle 
features) and dependent variables (CSI, PPT, and CPM). 
 
9.5.1 Section 1: Descriptors of participant characteristics 
9.5.1.1 Demographics, comorbidity, and lifestyle factors 
The demographic, lifestyle, and comorbidity status of study participants are 
presented in Table 9.1. Participants in the study self-identified as the following ethnic 





Participant Demographic, Lifestyle, and Comorbidity Characteristics (N = 51) 
Characteristic N (%) 
Gender  
     Male  





      Range (years) 




Smoking (yes) 8 (16) 
Alcohol consumption 
      Yes, occasionally 
      Yes, regularly 





Cannabis use  16 (31) 
Poor sleep quality 18 (35) 
Total comorbidity (mean (SD)) 
      Range (n) 
2.63 (1.93) 
0 - 8 
Note. Standard deviation (SD). 
 
 
9.5.1.2 Psychological features 
Psychological features assessed in study participants are presented in Table 9.2. 
In total, 57% (n = 29) of participants demonstrated moderate levels of perceived stress, 
although only 1 participant reached a clinically meaningful score (>30) of pain 
catastrophizing. HADS subscales indicated 37% (n = 19) of study participants 
demonstrated clinically meaningful scores for the presence of anxiety (≥8), whereas 
only 8% (n = 4) demonstrated clinically meaningful scores for the presence of 
depression (≥8). 
 





Psychological Features of Study participants (N = 51) 
Measure Mean (SD) 
Perceived stress scale  15.02 (7.46) 
PANAS (positive affect) 32.70 (7.12) 
PANAS (negative affect) 17.94 (5.77) 
HADS (anxiety) 6.98 (3.64) 
HADS (depression) 3.49 (3.21) 
Pain catastrophizing scale (median (IQR)) 6.5 (7.75) 
Note. Standard deviation (SD), Positive and Negative Affective Schedule (PANAS), 
Hospital Anxiety and Depression Scale (HADS), and interquartile range (IQR). 
 
 
9.5.1.3 Pain features 
Pain features identified in study participants are presented in Table 9.3. In total, 
71% (n = 36) of participants reported the presence of MSK and/or abdominal pain. Of 
these participants, 26% (n = 13) reported the presence of only MSK pain, 16% (n = 8) 
reported the presence of only abdominal pain, and 29% (n = 15) reported the presences 
of both abdominal and MSK pain. Of the MSK regions identified as painful by study 
participants, the low back was overall the most frequently reported region (n = 15, 
35%), while the right knee (n = 4, 24%) and posterior neck (n = 4, 24%) were most 
frequently identified as the ‘main area of pain’. A summary of all painful regions 




Pain Features of Study participants (N = 51) 
Feature Mean (SD) 
Musculoskeletal pain (yes (n (%)) 
      Duration (years, median (IQR)) 
      Regions  
      Strongest severity (NRS) 
      Average severity (NRS) 







Abdominal pain (yes, n (%)) 23 (45) 
      Strongest severity (NRS) 
      Average severity (NRS) 




Note. Standard deviation (SD), interquartile range (IQR), numeric rating scale (NRS), 
and Patient-Reported Outcomes Measurement Information System (PROMIS). 
 
 
9.5.1.4 IBD features 
IBD features of study participants are presented in Tables 9.4 and 9.5. The 
majority of study participants were diagnosed with Crohn’s disease (59% (n = 30)), 
with a mean IBD duration of 13.77 years (SD = 10.47). Of the participants, 45% (n = 
23) had previously received surgical management of their IBD, and 63% (n = 32) 
identified as having extensive disease. The majority (n = 39, 76%) of study participants 
were taking biologic medication at the time of data collection, whereas significantly 
fewer participants were taking immunosuppressant medication (n = 7, 14%) and 
steroids (n = 5, 10%). 
 
 






IBD Features of Study participants (N = 51) 
Feature N (%) 
IBD subtype 
   Crohn’s disease  
   Ulcerative colitis  





IBD duration (years, mean (SD)) 
      Range 
13.77 (10.47) 
1 - 42 
Age at diagnosis, (years, mean (SD)) 25.41 (13.24) 
Surgical input (yes) 23 (45) 
      Stoma (yes) 10 (20) 
Disease behaviour  
      Stricturing disease (yes) 13 (25) 
      Penetrating disease (yes) 19 (37) 
      Perianal disease (yes) 21 (41) 
Disease extent (extensive) 32 (63) 
SIBDQ (mean (SD)) 53.10 (8.46) 
Note. Inflammatory bowel disease (IBD), standard deviation (SD), and Short 




Medication use of Study participants (N = 51) 
Medication N (%) 
Steroids 
      Never  
      Previous  






      Never 
      Previous 






      Never 
      Previous 








9.5.1.5 Measures of central sensitization 
Summary of participant scoring for CSI, PPT, CPM, and TS are presented in 
Table 9.6. CSI scores were normally distributed among study participants (Shapiro-
Wilk, p ≤ 0.05), with 31% (n = 16) of participants demonstrating CSI scoring (≥ 40) 
representative of patients with central sensitization syndromes. PPT of the low back and 
Tibialis anterior regions were normally distributed among study participants (Shapiro-
Wilk, p ≤ 0.05), whereas TS and CPM scores were not normally distributed (Shapiro-
Wilk, p > 0.05), and therefore were logarithmically converted prior to multiple linear 
regression modelling.  
 




Mean Scores for Measures of Central Sensitization in Study Participants (N = 51) 
Assessment Mean (SD) Range 
Central sensitization inventory 
   Benchmark score ≥ 40 (n (%)) 
32.55 (12.54) 
16 (31) 
8 - 62 
Pressure pain threshold  
   Low back 
   Tibialis anterior 
368.23 (189.82) 
383.25 (174.26) 
115.06 - 793.36 
118.33 - 754.13 
Temporal summation a  1.00 (0.83) 0 - 5 
Conditioned pain modulation a 24 (28) -52 - 178 
Note. Standard deviation (SD). 
a Median (interquartile range) for percentage change scores. 
 
 
9.5.2 Section 2: Correlation analysis 
Results of the analysis examining the correlation between IBD, psychological, 
demographic, comorbidity, and lifestyle features to measures of central sensitization are 
presented in Tables 9.7 – 9.0. 
9.5.2.1 IBD features 
TS was the only measure of central sensitization which did not demonstrate a 
significant correlation with at least one IBD feature (Table 9.7). The presence of 
abdominal pain (rpb = -0.332, p = 0.009) and worse HRQOL (SIBDQ, rho = -0.552, p < 
0.001) was significantly correlated with greater symptoms of central sensitization 
(higher CSI scores). Conversely, better HRQOL (SIBDQ, rho = 0.441, p = 0.001) 
correlated with greater pain modulation (higher CPM scores). Previous surgical input 
(rpb = 0.257, p = 0.034) was correlated with increased pressure sensitivity (lower PPT 
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of the low back), whereas the presence of a stoma was correlated with lower PPT in the 
low back (rpb = 0.386, p = 0.003) and Tibialis anterior (rpb = 0.289, p = 0.017).  
 
Table 9.7 
Spearman Rank-order Correlations of IBD Features to Measures of Central 
Sensitization in IBD Participants (N = 51) 
 CSI PPT (LB) PPT (TA) CPM TS 
Feature Rho P Rho P Rho P Rho P Rho P 
IBD subtype a .085 .554 .151 .145 .095 .505 -.168 .135 .022 .443 
IBD duration .054 .353 -.224 .057 -.182 .101 .066 .334 -.012 .470 
Age at diagnosis b -.095 .253 .132 .177 .028 .423 -.012 .468 .117 .225 
Disease extent a -.028 .423 -.039 .417 -.014 .462 -.015 .460 -.082 .258 
Surgical input a .081 .570 .257 .034 .152 .286 -.097 .263 .017 .445 
Stoma a -.006 .483 .386 .003 .298 .017 -.087 .284 .094 .227 
Stricturing a .251 .076 .142 .160 .069 .629 .116 .224 .038 .380 
Penetrating a .132 .355 .161 .129 .024 .867 -.007 .481 .149 .167 
Perianal a .063 .662 .107 .228 -.020 .889 -.045 .384 .188 .111 
SIBDQ -.557 <.001 .111 .219 .034 .406 .441 .001 .002 .496 
Abdominal pain a -.334 .007 .158 .134 .180 .103 .196 .099 .128 .152 
Note. Bold font indicates significant correlation (p ≤ .05). Central sensitization inventory (CSI), 
pressure pain threshold (PPT), low back (LB), Tibialis anterior (TA), conditioned pain 
modulation (CPM), temporal summation (TS), inflammatory bowel disease (IBD), and Short 
Inflammatory Bowel Disease Questionnaire (SIBDQ). 
a Point-biserial coefficient (rpb). 
b Montreal classification. 
 
9.5.2.2 Psychological features 
 CSI was the sole measure of central sensitization to demonstrate significant 
association with all psychological factors, where worse psychological functioning 
correlated with greater symptoms of central sensitization (Table 9.8). Conversely, 
higher CPM scores demonstrated significant correlation with decreased stress (rho = -
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0.303, p = 0.022), negative affect (PANAS) (rho = -0.253, p = 0.047), anxiety (HADS) 
(rho = -0.350, p = 0.009), and depression (rho = -0.332, p = 0.013).  
 
Table 9.8 
Spearman Rank-order Correlations of Psychological Features to Measures of Central 
Sensitization in IBD Participants (N = 51) 
Feature 
CSI PPT (LB) PPT (TA) CPM TS 
Rho P Rho P Rho P Rho P Rho P 
PSS a .524 <.001 .036 .400 .039 .394 -.303 .022 -.131 .147 
PANAS (p) a -.389 .002 .001 .498 .049 .367 .141 .178 .164 .094 
PANAS (n)  .485 <.001 -.004 .490 .048 .369 -.253 .047 -.048 .352 
HADS (a) .517 <.001 -.090 .265 -.084 .278 -.350 .009 -.131 .148 
HADS (d) .523 <.001 .006 .484 -.013 .464 -.332 .013 -.081 .258 
PCS .571 <.001 -.210 .091 -.174 .136 -.198 .117 .176 .092 
Note. Bold font indicates significant correlation (p ≤ .05). Central sensitization inventory (CSI), 
pressure pain threshold (PPT), low back (LB), Tibialis anterior (TA), conditioned pain 
modulation (CPM), temporal summation (TS), perceived stress scale (PSS), positive and 
negative affect schedule (PANAS), hospital anxiety and depression scale (HADS), pain 
catastrophizing scale (PCS). 
a Pearson’s coefficient (r). 
 
 
9.5.2.3 Demographic, lifestyle, and comorbidity features 
Demographic, lifestyle, and comorbidity features most frequently demonstrated 
correlation with CSI scores, with 4 out of 7 characteristics reaching significance (Table 
9.9). Poor sleep quality (rho = 0.379, p = 0.003), higher total comorbidity (rho = 0.429, 
p = 0.001), lack of current cannabis use (rpb = -0.399, p = 0.029), and the presence of 
MSK pain (rpb = -0.427, p = 0.001) were correlated with higher CSI scores. Male 
gender was significantly correlated with higher PPT scores for both the low back (rpb = 
-0.418, p = 0.001) and Tibialis anterior (rpb = -0.563, p < 0.001). Improved sleep quality 
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was significantly correlated with both higher CPM scores (rho = -0.314, p = 0.006) and 
higher PPT of Tibialis anterior (rho = -0.232, p = 0.050).  
 
Table 9.9 
Spearman Rank-order Correlations of Demographic, Lifestyle, and Comorbidity 
Features to Measures of Central Sensitization in IBD Participants (N = 51) 
Feature 
CSI PPT (LB) PPT (TA) CPM TS 
Rho P Rho P Rho P Rho P Rho P 
Age a -.002 .495 -.120 .201 -.218 .063 .070 .325 .060 .317 
Gender b  .207 .079 -.418 .001 -.576 <.001 .172 .130 .040 .374 
Smoking -.161 .129 .055 .351 .055 .351 .174 .127 .028 .412 
Alcohol  -.051 .361 .005 .485 -.040 .391 .136 .186 -.119 .170 
Cannabis b -.399 .029  .023 .436 -.083 .484 .068 .329 .133 .143 
Sleep quality .379 .003 -.088 .269 -.232 .050 -.374 .006 .061 .314 
Comorbidity  .456 <.001 -.198 .082 -.198 .082 -.143 .175 -.001 .497 
MSK Pain b -.427 .001 .029 .419 .141 .162 .082 .296 .031 .402 
Note. Bold font indicates significant correlation (p ≤ .05). Central sensitization inventory (CSI), 
pressure pain threshold (PPT), low back (LB), Tibialis anterior (TA), conditioned pain 
modulation (CPM), temporal summation (TS), and musculoskeletal (MSK). 
a Pearson’s correlation (r).  
b Point-biserial coefficient (rpb). 
 
 
9.5.3 Section 3: Multiple linear regression analysis 
Results of the multiple linear regression analyses between independent variables 
(IBD, psychological, demographic, comorbidity, and lifestyle features) and dependent 
variables (CSI, PPT, and CPM) are presented in Table 9.10. 
9.5.3.1 CSI 
Individual stepwise multiple regression analysis for CSI scores (dependent 
variable) and SIBDQ (primary independent variable) indicated a ≥ 10% R2 change 
      
 
151 
score for the following secondary independent variables: PSS, PANAS (positive), 
PANAS (negative), HADS (anxiety), HADS (depression), PCS, sleep quality, MSK 
pain, and total comorbidity.  The final backward multiple regression model for CSI 
showed significant positive associations of poor HRQOL (SIBDQ), greater pain 
catastrophizing, the presence of MSK pain, poor sleep quality, and greater total 




Associations between Participant Features and Measures of Central Sensitization 
 β SE t P 
CSI model summary: R2 = 0.74, F(4,36) = 20.16, p < 0.001*   
   SIBDQ -0.42 0.14 -3.01 0.005* 
   Pain catastrophizing 0.70 0.14 4.97 <0.001* 
   Musculoskeletal pain -5.37 2.49 -2.15 0.038* 
   Sleep quality 4.33 1.36 3.19 0.003* 
   Total comorbidity 1.39 0.64 2.18 0.036* 
PPT (low back) model summary: R2 = 0.32, F(3,47) = 7.33, p < 0.001*   
   Stoma 160.67 56.41 2.85 0.006* 
   Gender -170.64 45.51 -3.75 0.000* 
PPT (Tibialis anterior) model summary: R2 = 0.43, F(2,48) = 18.26, p < 0.001*   
     Stoma 126.43 47.27 2.68 0.010* 
   Gender -205.47 38.14 -5.39 <0.001* 
CPM model summary: R2 = 0.27, F(2,44) = 7.88, p < 0.001*   
   SIBDQ 0.02 0.01 2.19 0.034* 
   HADS (depression) -0.04 0.02 -2.12 0.040* 
Note. Standard error (SE), pressure pain threshold (PPT), conditioned pain modulation 
(CPM), Hospital Anxiety and Depression Scale (HADS), Short Inflammatory Bowel 
Disease Questionnaire (SIDBQ), and central sensitization inventory (CSI). 




The backward regression model for PPT of the low back and Tibialis anterior 
regions showed significant positive associations from female gender and history of a 
stoma to increased pressure sensitivity at both regions (Table 9.10). 
9.5.3.3 CPM 
Individual stepwise multiple regression analysis for CPM scores (dependent 
variable) and SIBDQ (primary independent variable) indicated a ≥ 10% R2 change 
score for the following secondary independent variables: HADS (anxiety), HADS 
(depression), and sleep quality.  The final backward multiple regression model for CPM 
showed significant positive associations of better HRQOL (SIBDQ) and lower 
depression scores to greater pain modulation (higher CPM scores) (Table 9.10). 
 
9.6 Discussion 
The secondary aim of Study 2 was to investigate the association between 
measures of central sensitization and IBD features, as well as features within additional 
patient domains (i.e. psychological, demographic, comorbidity, and lifestyle). TS was 
the only measure of central sensitization to not correlate with any of the participant 
features examined in the current study, whereas CSI demonstrated the greatest number 
of correlations and was the only measure to demonstrate significant relationships within 
each feature domain. The final regression models indicated that women with a history 
of a stoma demonstrated increased pressure sensitivity in both the low back and Tibialis 
anterior regions. This study also showed that less effective pain modulation was 
demonstrated in patients with poor HRQOL and greater depression scores. Patients 
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with poor HRQOL, greater pain catastrophizing, MSK pain, poor sleep quality, and 
greater total comorbidity were shown to have greater symptoms of central sensitization.  
Along with female gender, the history of a stoma positively predicted lower 
PPT of both low back and Tibialis anterior regions. Although the surgical formation of 
stomas is generally considered a simple undertaking, the consequences can be complex 
and life‐ threatening, ranging from early (i.e. leakage, retraction, and necrosis) to late 
complications (i.e. herniation, prolapse, and stenosis) reported in 20-70% of patients 
(Shabbir & Britton, 2010). Furthermore, although stomas differ, for instance in type 
and duration, their presence is suggestive of overall worse disease severity (Siegel et 
al., 2016). Therefore, the relationship between a history of stoma formation and 
increased pressure pain sensitivity may reflect somatosensory changes as a consequence 
of worse IBD severity and/or complications directly related to the stoma itself. 
Interestingly, patients with a history of stomas in the present study demonstrated 
decreased PPT at two regions, where regions were always located in opposing body 
quadrants (e.g. left low back and right Tibialis anterior). Distribution of sensitivity in 
this manner is suggestive of widespread versus regional sensitivity, characteristic of 
mechanisms related to central sensitization (den Boer et al., 2019; Clifford J Woolf, 
2011).  
The pattern of association between patient features (i.e. worse psychological 
functioning, the presence of pain, greater overall comorbidity, etc.) and higher CSI 
scores found in the current study is similar to reports in the literature. CSI broadly 
assesses features across multiple dimensions (e.g. physical symptoms and emotional 
distress), in order to quantify the presence of central sensitization related 
symptomology (Mayer et al., 2012; Neblett, Hartzell, Williams, et al., 2017). Therefore, 
it is unsurprising that current features related to these dimensions were found to 
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correlate with higher CSI scores. However, higher CSI scores have also previously 
demonstrated association to additional factors not directly assessed in the measure, such 
as greater number of painful regions and greater comorbidity (Neblett, Hartzell, 
Williams, et al., 2017).  
CSI and CPM were the only measures of central sensitization to correlate with 
IBD HRQOL (i.e. SIBDQ). Similarly, these measures demonstrated the most 
correlations to psychological features. The final models for both CSI and CPM retained 
the positive associations of both SIBDQ and a psychological feature. Current literature 
reports significant influences from primary psychological features to both CSI and 
CPM scoring in pain populations, as well as healthy controls (Mayer et al., 2012; 
Nahman-Averbuch et al., 2016). Similarly, reports of IBD HRQOL have indicated that 
worse psychological functioning is a significant determinant of poor HRQOL in 
patients (Guthrie et al., 2002; van der Eijk et al., 2004). As such, the relationship 
between IBD HRQOL and measures of central sensitization demonstrated in the present 
study, may represent complex mediating pathways from psychological factors within 
these domains. 
Although sleep quality was the feature which most frequently correlated with 
measures of central sensitization, it was only retained in the model associated with CSI 
scores. Altered sleep behaviour has been well described in pain and immune 
populations (Finan, Goodin, et al., 2013; Y. C. Lee et al., 2013; M. T. Smith & 
Haythornthwaite, 2004). Consequently, research regarding influences of sleep 
disturbances has moved from simple associations towards mechanistic explorations, for 
instance examining changes in neurotransmitter signalling, mediating pathways through 
psychological features, and changes in CNS cell activation (Finan, Goodin, et al., 2013; 
Nijs et al., 2017).  
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Disturbed sleep is a well-described clinical observation in IBD patients, 
particularly during active IBD (Ali & Orr, 2014). A review of sleep disturbances in 
IBD described associations with gastrointestinal symptoms, suggesting that altered 
sleep quality increases immune activity, and in turn, worsening IBD severity (Ali & 
Orr, 2014). A large prospective study reporting on the association between active IBD 
and worse sleep quality also found a strong correlation between sleep quality, 
psychological functioning, and IBD HRQOL (Graff et al., 2010). These reports are 
similar to findings in the current study for patient features associated with CSI scores. 
Similarly, findings from Study 1 in the present thesis (Chapter 6) showed positive 
associations between active IBD and higher CSI scores. Therefore, CSI may represent a 
mediating pathway in the complex relationship between these patient features and 
active IBD. 
Interpretation of current study results should consider the potential bias related 
to limitations of the statistical modelling from the modest sample size. Additionally, 
measures of central sensitization in the present study included a limited range of 
somatosensory assessments, and as such, not representative of the full battery of 
available quantitative sensory testing. Therefore, future research should include a more 
comprehensive exploration of quantitative sensory testing suggested in current 
literature to provide the best evidence for altered somatosensory functioning in this 
population.  
An ongoing challenge in IBD research continues to be predicting how 
individual clinical IBD features contribute to overall patient outcomes (Siegel et al., 
2016). Several of the IBD features explored in the present study were not found to be 
significantly correlated with measures of central sensitization. However, correlations 
with structural IBD features found in the present study, such as a history of stomas, 
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suggests that further investigation of structural changes in IBD patients (e.g. number 
and/or extent of bowel resections) may reveal additional relationships to measures of 
central sensitization. Additionally, the present study did not include IBD features 
characterized by common clinical assessments (i.e. biomarker, endoscopic, and 
histologic investigations). Therefore, future research should consider the exploration of 
these assessments of immune and structural characteritics, and their potential 
association to measures of central sensitization in IBD patients. 
9.7 Chapter summary 
The current chapter presents analysis, results, and discussion from the 
secondary aims of Study 2. Current study results are the first to describe correlations of 
multiple participant features across IBD, psychological, demographic, comorbidity, and 
lifestyle domains, to measures of central sensitization in IBD patients. Findings from 
this study highlight the need, not only for the ongoing investigation of central 
mechanisms in IBD (i.e. comprehensive quantitative sensory testing), but also into the 
complexity of how multiple features are related to these assessments in order to identify 
targeted assessment and treatment pathways.  
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10 General Discussion 
 
10.1 Chapter overview 
This thesis proposes a new framework to consider and explore persistent MSK 
pain in IBD (Chapter 1). This framework integrates models described in IBD and 
chronic pain literature, describing common constructs and the potential for shared 
mechanisms leading to worse pain experiences (Chapter 2). The present thesis explored 
MSK pain in individuals with IBD within this framework through two primary studies. 
The current chapter integrates results from these studies to present overall thesis 
findings situated within current literature, highlight the strengths while acknowledging 
the limitations of this thesis, and present recommendations for future research. 
Contributions to research and clinical practice are presented throughout the sections of 
this chapter together with concluding statements. 
10.2 Summary of thesis findings  
Overall, findings from the present thesis suggest that a sub-population of IBD 
patients with and without MSK pain present with features indicative of central 
sensitization. Thesis findings further suggest that central sensitization in IBD represents 
a spectrum of symptom severity levels, whereby worse severity is associated with 
worse morbidity. Additionally, results suggest that MSK pain experiences, together 
with the presence of central sensitization, are potentially associated with IBD severity. 
Key results from the two primary thesis studies are discussed below within the broader 
context of these main findings.  
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10.2.1 Central sensitization in IBD 
This thesis is the first to describe the presence of symptoms and potential risk 
factors for central sensitization, assessed through CSI, in individuals with IBD. Results 
from an additional sub-analysis of Study 1 indicated that a proportion of patients with 
and without MSK and/or abdominal pain demonstrated CSI scores benchmarked (≥ 40) 
to suggest the dominant presence of central sensitization (Appendix I). There is 
uncertainty in the current literature as to why central sensitization presents in only sub-
populations for certain conditions, such as rheumatoid arthritis and low back pain, 
while presenting as the predominate feature in other populations, such as fibromyalgia 
and irritable bowel syndrome (Nijs et al., 2014). However, reports of influences from 
biopsychosocial factors have been implicated in the sub-populations presenting with 
features of central sensitization (Nijs et al., 2014; Phillips & Clauw, 2011). 
Interestingly, the results presented in this thesis indicated that measures of central 
sensitization were most commonly associated with patient characteristics, including 
historic or the current presence of a stoma, psychological distress, greater comorbidity, 
and worse HRQOL (Chapter 9). Therefore, the sub-population of IBD patients 
demonstrating features of central sensitization may represent individuals with a unique 
profile of IBD-related risk factors for developing central sensitization. 
10.2.2 Central sensitization symptom severity   
Exploration of CSI scores in the present thesis suggests a scoring pattern similar 
to recent reports describing different CSI severity levels, where worse symptom 
severity correlated with worse pain severity, worse psychological functioning, and 
greater sleep disturbances in chronic pain populations (Neblett, Hartzell, Mayer, et al., 
2017). Investigation of CSI in the present thesis indicated that IBD patients presenting 
with both MSK and abdominal pain demonstrated significantly greater symptom 
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severity (higher CSI scores) compared to those presenting with a single type of pain 
(abdominal or MSK) or no pain (Appendix I). Additionally, greater symptom severity 
demonstrated associations with active IBD, greater psychological distress, and greater 
comorbidity (Chapters 5, 6, 8, and 9). Previous chronic MSK pain investigations have 
consistently reported similar directional relationships across these features in patients 
demonstrating mechanisms of central sensitization (Nijs et al., 2014; Smart, Blake, 
Staines, & Doody, 2012). Therefore, findings from the present thesis suggests that the 
presence of central sensitization in IBD may represent a spectrum of severity levels 
which correlate with overall patient morbidity.  
10.2.3 Links to IBD severity 
Thesis findings suggests that MSK pain experiences and measures of central 
sensitization in IBD are potentially linked to IBD severity, characterized by features 
such as: HRQOL, persisting and disabling symptoms, surgical input, and repeated 
flares (Gomollón et al., 2016; Peyrin-Biroulet et al., 2016; Satsangi et al., 2006; Siegel 
et al., 2016). This was first conceptualized through the subgrouping analysis of Study 1, 
where the pattern of IBD features presented across the subgroups was suggestive of 
different levels of IBD severity (Chapter 5). This implies that IBD severity may be the 
construct which informed the nature of the MSK pain profiles generated through this 
subgrouping analysis (Chapter 5). For instance, Study 1 characterized a MSK pain 
subgroup which demonstrated active IBD, the presence of abdominal pain, greater 
comorbidity, higher CSI scores, poor IBD HRQOL, and worse MSK pain experiences 
(Chapter 5). Conversely, another subgroup was characterised by IBD remission, no 
abdominal pain, fewer comorbidities, and better HRQOL. Interpretation of subgrouping 
results in this manner suggests that consideration of the MSK pain profiles described in 
the present thesis alongside additional features of IBD (i.e. colonoscopy reports) may 
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offer a meaningful dimension for further evaluating disease severity in patients with 
IBD. 
Findings from Study 2 indicated that somatosensory functioning in IBD patients 
is associated with other patient features such as a history of a stoma, the presence of 
abdominal pain, and poor HRQOL. As stated above, the presence of these features has 
been well-described in patients understood to have worse IBD severity (Gomollón et 
al., 2016; Peyrin-Biroulet et al., 2016; Satsangi et al., 2006). Similar to MSK pain 
profiles of Study 1, interpretation of these relationships suggests that somatosensory 
functioning, a surrogate marker of central sensitization, may also be influenced by the 
construct of IBD severity. Therefore, future investigation of somatosensory functioning 
based on different levels of disease severity may identify potential risk factors for 
developing central sensitization in IBD.  
10.3 Clinical implications 
The current research provides evidence for potential abnormal central nervous 
system functioning in patients with IBD. This could influence clinical practice by 
making clinicians more aware of potential mechanisms, such as central sensitization, 
leading to the development of targeted management pathways. As in many conditions, 
clinical decision-making regarding management of IBD patients is related to clinicians’ 
perspectives regarding symptomology and results from clinical assessments. Identifying 
patients whose clinical presentation (i.e. history of a stoma) and/or current symptoms 
(i.e. poor sleep and decreased HRQOL) which are understood to be correlated to 
measures of central sensitization may impact management strategies. Similarly, results 
from Study 1 offers clinicians a guide for identifying the probability that patients may 
present with certain mechanistic profiles of MSK pain. Recognition of risk factors and 
MSK pain profiles may trigger the use of screening tools, such as CSI, and/or referral to 
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pain specialists for further evaluation and treatment. Although literature in other 
chronic pain populations has explored treatments, such as psychological interventions 
(Hoffman, Papas, Chatkoff, & Kerns, 2007), brain stimulation (Leo & Latif, 2007), and 
acupuncture (MacPherson et al., 2017), these concepts have not been investigation in 
the treatment of persistent MSK pain in patients with IBD. Future research should 
explore targeted treatment strategies in patients with IBD to identify appropriate and 
effective treatement pathways.  
10.4 Strengths  
10.4.1 Statistical analysis 
 Exploring complex disease and pain constructs through investigation of 
individual characteristics may not provide insight into developmental pathways for 
worse pain experiences (Bergman & Magnusson, 1997). In view of this, the present 
thesis utilized subgrouping-based analysis to characterize profiles of MSK pain in over 
200 patients with IBD.  The use of subgrouping analysis provides the opportunity to 
observe patterns of multiple IBD and pain characteristics across a sampling of patients, 
in order to draw broad conclusions and identify important constructs which influence 
pain presentations. Therefore, the use of subgrouping analysis in the present thesis not 
only provided evidence for distinct profiles of MSK pain, but it also identified both 
IBD and pain features which accounted for their distinctiveness. Characterising MSK 
pain profiles in this manner may, therefore, provide a useful clinical framework to 
identify patients with an increased probability of presenting with central sensitization. 
Individuals with active IBD, multisite pain, and severe MSK pain experiences can be 
seen as presenting with a high risk for central sensitization, thereby signifying the need 
for further investigation. The use of self-reported measures to characterize IBD and 
pain features within these MSK pain profiles increases the clinical utility beyond 
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gastroenterology, allowing clinicians such as physiotherapists, who typically do not 
have access to more invasive clinical investigations, to better determine appropriate 
pain management pathways. Furthermore, the relationships between IBD, central 
sensitization, and pain features also provide direction for future research to explore 
predictors for patient outcomes. 
10.4.2 Study sampling and design 
The present thesis explored persistent MSK pain in two populations, including a 
population-based investigation (New Zealand) and a clinic-based investigation (United 
States of America). These two study populations also recruited different patient 
profiles, in terms of the proportion of patients who were currently being treated at a 
gastroenterology clinic, compared to those not actively under care. Thus, although these 
studies each have limitations from sampling biases inherent to each study design, the 
homogeneity in findings across the studies suggest external validity of overall thesis 
findings. 
10.4.3 Spectrum of MSK conditions 
Previous investigations of MSK pain in IBD have primarily reported on 
inflammatory arthropathies, with less consideration of additional MSK pain conditions 
in this population. Although the present thesis did not investigate clinical diagnoses of 
inflammatory versus non-inflammatory pain types, thesis studies ultimately described a 
broader spectrum of persistent MSK conditions in IBD, ranging from regional to 
multisite pain, where less than 30% of participants reported previous inflammatory 
joint diagnoses (Appendix G). The present thesis is the first to explore measures of 
central sensitization related to MSK pain in IBD, including the use of CSI and 
somatosensory assessments. Findings from both primary studies contribute to the 
growing body of evidence for the relationship between CSI and multiple patient 
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domains, including pain, psychological, lifestyle, and comorbidity factors, in IBD-
related MSK pain. Finally, the present thesis proposed a new framework for persistent 
MSK pain in IBD, where exploration of this framework indicated the participation of 
central sensitization in the modulation of painful experiences. 
 
10.5 Limitations 
Although specific limitations for each study have already been discussed in the 
previous chapters, this section highlights the limitations in the context of the whole 
thesis. 
10.5.1 Study methods 
The present thesis solely utilized quantitative methods for exploring and 
charactizing persistent MSK pain in individuals with IBD. Although this approach has 
been recommended for the objective assessment of the present research question 
(Arendt-Nielsen et al., 2012; Arendt‐ Nielsen et al., 2018; Catalano et al., 2017; Koop 
et al., 2015; Wu et al., 2013), the inclusion of a qualitative component may have 
provided a valuable context to thesis findings. Future research should consider utilizing 
mixed methodological approaches to allow for a deeper understanding of persistent 
MSK pain experiences in individuals with IBD. Similarly, the present thesis utilized 
narrative reviews of the literature to explore current research themes. Inclusion of 
systematic reviews of current literature may have further informed methodologies used 
in the present thesis. 
10.5.2 Surrogate markers of central sensitization 
Interpretation of study results should include consideration of measures used in 
the present thesis to assess central sensitization in patients with IBD. In the absence of a 
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gold standard to investigate mechanisms of central sensitization, current literature 
suggests the use of diagnostic surrogate markers to indicate the presence of central 
sensitization (Arendt‐ Nielsen et al., 2018; Clifford J Woolf, 2011). Therefore, 
assessment of central sensitization in the present thesis included investigation of 
symptomology (i.e. CSI) and somatosensory functioning (i.e. quantitative sensory 
testing (QST)). However, although CSI has been validated to evaluate an array of 
symptoms related to the sensitivity of the somatosensory system, thereby implicating 
changes to CNS processing, it does not assess individual mechanisms related to central 
sensitization. Therefore, CSI has been described as a screening tool to identify the need 
for further assessment of central sensitization mechanisms (Arendt‐ Nielsen et al., 
2018; Mayer et al., 2012; Nijs et al., 2015).  
Since instigating the work reported in the present thesis, the taxonomy used to 
describe pain mechanisms related to abnormal nociceptive neuronal activity in the CNS 
has evolved and now includes the term “nociplastic” pain (International Association for 
the Study of Pain (IASP) Taxonomy 2017). The term “central sensitization” is 
understood to specifically refer to an increase in nociceptive neuronal activity of the 
CNS, whereas “nociplastic” provides a broader understanding that abnormal changes 
can include an increase or decrease in nociceptive activity (IASP Taxonomy 2017). 
This distinction has important implications for future research investigating the 
complexity of chronic pain experiences described in this thesis and in current IBD 
literature (i.e. MSK, abdominal, and post-surgical pain). As such, future investigation 
of chronic pain in IBD should embrace this new taxonomy and the features which 
operationalize “nociplastic” as a pain mechanism (Aydede & Shriver, 2018). 
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10.5.3 Assessment of IBD 
Assessment of IBD features in this thesis utilized self-reported measures (i.e. 
symptomatic IBD activity, HRQOL, psychological, and lifestyle factors), as well as 
features extracted from patients’ charts (i.e. medication use, disease extent and 
behaviour, surgical history, subtype, and duration). Thesis investigations did not 
include clinical assessments of IBD activity (i.e. colonoscopy, histology, and 
biomarkers). Therefore, relationships between IBD features, MSK pain experiences, 
and measures of central sensitization described in the present thesis do not include these 
clinically important assessments of disease activity. Additionally, due to the differences 
in study design, characterization of IBD features differed somewhat between Study 1 
and 2 of the thesis. For instance, Study 1 utilized a self-reported measure of IBD 
activity, and Study 2 characterized structural IBD changes (i.e. stricturing, penetrating, 
stomas, surgical input, etc.) through investigations extracted from patient charts  
IBD literature and clinical practice reflects a longstanding interest in 
distinguishing IBD, representing an organic disease with strong genetic links, from 
irritable bowel syndome (IBS), which is a functional gastrointestinal disorder classified 
as a central sensitivity syndrome (Schoepfer et al., 2008). However, as previously 
stated, IBS is reported in 20% of IBD patients (Abdalla et al., 2017). Similarly, results 
from Study 1 in the present thesis indicated that approximately 30% of the participants 
had coexisting IBS (Table G.2, Appendix G). Future research should consider 
exploring constructs of central sensitization in IBD patients with and without IBS in 
order to understand the influence of comorbid central sensitivity syndromes to current 
thesis findings.  
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10.5.4 Validity of thesis findings 
A significant challenge of investigating MSK pain in patients with IBD relates 
to the often overlapping presence of abdominal pain. As previously described (Chapters 
1 and 2), abdominal pain is the most common pain complaint in this population, often 
signifying the presence of active disease. Therefore, stratifying patient groups, for 
instance, in Study 2 by the presence of MSK pain as well as the presence of abdominal 
pain would have been ideal to solely investigate influences of MSK pain to measures of 
central sensitization. However, stratifying patients in this manner is significantly less 
feasible and may unintentionally bias groups based on active versus non-active IBD. 
Participants in both thesis studies demonstrated that 60% of the participants with MSK 
pain also presented with overlapping abdominal pain, which may represent associations 
to active IBD. However, both thesis studies demonstrated that 30% of participants 
without MSK pain presented with abdominal pain. Therefore, the decision to only 
stratify patient groups based on the presence of MSK pain in Study 2 may have 
influenced the measures of central sensitization, particularly somatosensory 
assessments, causing an overall threat to the validity of present thesis findings.  
As previously stated, investigations utilizing somatosensory assessments in IBD 
have been limited in scope with focus solely on peripheral neuropathies (Huehne et al., 
2009; Munster et al., 2015). Additionally, although current literature exploring the 
psychometric properties of these assessments in other populations (i.e. low back pain) 
have demonstrated sufficient measurement properties (Vuilleumier et al., 2015), 
psychometric investigations specifically in IBD patients are lacking. Therefore, current 
literature is unable to suggest whether the somatosensory assessment procedures 
utilized in Study 2 demonstrate acceptable properties to explore somatosensory 
functioning in IBD patients. Future research should explore the psychometrics (e.g. 
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discriminative validity and test re-test reliability) of somatosensory assessments in IBD 
patients in order to make recommendations for their use in clinical and research 
practices. 
 
10.6 Recommendations for future research 
10.6.1 Risk factors for central sensitization  
Findings from the present thesis, as well as reports from current literature, 
suggest that a sub-population of IBD patients, with and without pain, may present with 
central sensitization. Thus, it is important to identify the risk factors for developing 
central sensitization in IBD. Current literature proposes a complex range of risk factors 
for presenting with central sensitization, including early childhood trauma, immune 
activity, and psychological stress (Kindler et al., 2010; Nijs et al., 2017). Similarly, 
findings from the present thesis indicated that measures of central sensitization are 
associated with a range of patient features (i.e. IBD, pain, psychological, and lifestyle) 
which have previously been described as determinants of IBD severity (Gomollón et 
al., 2016; Peyrin-Biroulet et al., 2016; Satsangi et al., 2006; Siegel et al., 2016). 
However, the development of a novel tool to assess IBD severity, indicated different 
weighted contribution from patient features in the overall determination of disease 
severity (Siegel et al., 2016). Therefore, future research should utilize a prospective 
study design to examine IBD severity, as a potential risk factor for patients presenting 
with central sensitization through the use of a novel assessment, such as the IBD 
Disease Severity Index (Siegel et al., 2016).  
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10.6.2 Chronic postsurgical pain in IBD 
Investigations of chronic postsurgical pain indicate that IBD patients are two to 
three times more likely to develop chronic pain following gastrointestinal surgery than 
non-IBD populations (Bruce & Krukowski, 2006; Joris et al., 2015). Although studies 
have postulated that chronic post-surgical pain may be the result of altered CNS 
processing in patients, this has yet to be investigated. The present thesis demonstrated 
an association between a history of stomas to increased somatosensory sensitivity (i.e. 
lower PPT scores) in IBD patients. Similarly, present investigations demonstrated 
higher CSI scoring (i.e. greater symptoms of central sensitization) in patients presenting 
with worse pain experiences. Previous investigations of post-surgical pain in other 
populations demonstrated that preoperative CSI scores predicted worse post-operative 
outcomes (i.e. worse pain severity, poor HRQOL, and longer hospital stays) (Bennett, 
Walsh, Thompson, & Krishnaney, 2017; M. S. Kim et al., 2019; S. H. Kim, Yoon, 
Yoon, Yoo, & Ahn, 2015). Therefore, future research utilizing prospective study 
designs should explore the predictive relationship between CSI and post-surgical 
outcomes as a tool to identify IBD patients at risk of greater pain (i.e. abdominal and 
MSK) and disability following bowel surgery.  
10.6.3 Targeted assessment of MSK pain types 
The results in Chapter 8 suggest that the observed somatosensory measures (i.e. 
PPT, CPM, and TS) applied at the specified body sites were not significantly different 
between this sampling of IBD patients with/without MSK pain and health controls. 
However, these results are unable to suggest whether the scope of somatosensory 
measures applied at different body sites would demonstrated similar findings. 
Additionally, in order to explore differences in somatosensory assessments in IBD 
patients, investigation for the discriminative validity of somatosensory assessments in 
      
 
169 
IBD is needed. Future research should consider the psychometric properties (i.e. 
discriminative validity and reliability) of the different assessment modalities and 
procedures in IBD patients in order to make recommendations for clinical and research 
practices. Additionally, the development of a composite score, comprised of the 
different assessment modalities meaningful to IBD, may offer a valuable way for 
considering central sensitization in future investigations. 
Current literature provides a growing body of knowledge surrounding measures 
of central sensitization specific to pain regions, often providing normative data for 
future use in research and clinical practice. However, the primary thesis studies did not 
aim to characterize measures of central sensitization by each pain region. Therefore, 
future research exploring the regional assessment of central sensitization would provide 
a better understanding of whether somatosensory functioning in IBD patients differs by 
pain location. 
The burden of inflammatory arthropathies has been well-described in IBD 
literature, where inflammation is the mechanism typically described in the generation of 
painful joint pain experiences. However, investigations of chronic pain in primary 
inflammatory arthritis conditions have implicated altered CNS processing in ongoing 
and worse pain experiences (Y. C. Lee, Nassikas, & Clauw, 2011). Results from the 
present thesis indicated that a profile of MSK pain in IBD suggested the participation of 
multiple pain mechanisms, such as nociceptive, neuropathic, and central mechanisms 
(Chapter 5). Incidentally, this particular profile presented with the worse MSK pain 
experiences when compared to the other profiles. Although MSK profiles did not 
demonstrate differences in the frequency of patients reporting previous inflammatory 
arthritis diagnoses, it is unknown whether arthritis patients presented with active 
arthritis at the time of investigation or not. Therefore, future research should explore the 
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role of central sensitization in IBD patients with inflammatory arthropathies to better 
understand the contributions of different mechanisms to pain experiences in this 
population. 
10.7 Conclusion 
Two primary thesis studies were conducted to explore the potential for shared 
mechanisms in individuals with IBD presenting with persistent MSK pain. A sub-
population of IBD patients with and without MSK pain presented with features 
suggesting the presence of central sensitization. Individuals with MSK pain and 
symptoms of central sensitization presented with worse IBD, HRQOL, and pain 
experiences. MSK pain in IBD presented as distinct profiles, suggesting influences 
from worse IBD severity to pain presentations and the presence of central sensitization. 
Measures of central sensitization in IBD were associated with a range of patient 
features (i.e. IBD, pain, psychological, lifestyle, and comorbidity), highlighting 
potential risk factors for the development of central sensitization leading to worse pain 
experiences in IBD patients. 
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As a member of Crohn’s and Colitis NZ, you are invited to participate in an 
online survey about ongoing pain in people with Inflammatory Bowel Disease. This 
survey is part of a larger study at the University of Otago, aimed at investigating why 
individuals with IBD develop persistent pain in order to help find targeted treatments. 
Attached to this email is an Information Sheet and Consent Form with details 
about this study, to include contact details if you have any additional questions.  
The survey takes approximately 10-15 minutes to complete. At the end of the 
survey you will be given the opportunity to enter in a prize draw for a $50 Prezzy 
card! There are 5 chances to win! 
Thank you for your time and interest in this study. After reviewing the 
Information Sheet and Consent Form, you can begin the survey by clicking the link 
below: 










You are invited to participate in an online survey about ongoing pain in people 
with Inflammatory Bowel Disease. This survey is part of a larger study at the 
University of Otago, aimed at investigating why individuals with IBD develop persistent 
pain in order to help find targeted treatments. 
The survey takes approximately 10-15 minutes to complete. At the end of the 
survey you will be given the opportunity to enter in a prize draw for a $50 Prezzy card 
with 5 chances to win! 
For more information regarding this study and to proceed to the survey - click 
the link below: 
NZ IBD Aches & Pains Survey 
 
  





New Zealand IBD Aches & Pains Survey 
 
What is this study about? 
The aim of this study is to investigate why individuals with IBD develop 
persistent pain in order to help find targeted treatments. 
Am I eligible for the study? 
You are eligible to participate if you are: 
 Living in New Zealand 
 Have been diagnosed with IBD (Crohn’s disease, ulcerative colitis, or 
unspecified colitis) 
 Not pregnant (to include less than 6 months post-partum) 
 Do not have any neurological diseases (i.e., multiple sclerosis, Parkinson’s 
disease, stroke) 
 Have not had a nerve injury 
 Have not had surgery in the last 3 months 
What will I be asked to do? 
You will be invited to complete and online survey that takes approximately 10-
15 minutes to complete. Please read the attached Information Sheet and Informed 
Consent carefully before you decide to participate in this survey.  
 
Upon completing the survey, you will be given the opportunity to enter in a prize draw 
for a $50 Prezzy card, with 5 chances to win.  
To participate click on the link below:  
 
NZ IBD Aches & Pains Survey 
 
Thank you for your time in supporting this study. The study has ethical approval from 
the University of Otago (Reference: H17/095). 
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New Zealand IBD “Aches & Pains” Survey 
INFORMATION SHEET FOR PARTICIPANTS 
 
Thank you for showing an interest in this project. Please read this information sheet carefully 
before deciding whether or not to participate.  If you decide to participate we thank you. If you 
decide not to take part there will be no disadvantage to you and we thank you for considering 
our request.   
 
 
What is the Aim of the Project? 
We are trying to understand the nature of musculoskeletal pain in people with 
Inflammatory Bowel Disease (IBD). More specifically, we are interested how different aspects 
of pain, IBD, and general health contribute to an individual’s overall pain experience. We will 
do this by asking a series of questions around these themes, and then identify how these 
themes relate to each other. The aim of this project is to better understand the mechanisms 
behind why people with IBD develop persistent pain, and also to identify targeted treatments. 
 
 
What Type of Participants are being sought? 
Adults that have been diagnosed with IBD (Crohn’s disease, ulcerative colitis, or unspecified 
IBD) living in New Zealand who have ongoing pain. 
 
Adults who have following conditions/situations will unfortunately not be able to take part in 
this study. This includes:  
 Neurological diseases (i.e., multiple sclerosis, Parkinson’s disease, stroke) 
 Nerve injuries 
 Surgery in the last 3 months 
 Pregnancy (to include less than 6 months post-partum)  
 
 
What will Participants be asked to do? 
Should you agree to take part in this project, you will be asked to complete an online survey 
(approximately 10-15 minutes). Hyperlink to the survey is included in the body of the original 
invitation email. You will be able to stop the survey at any time to withdraw from this study. 
Alternatively, you may decide not to take part in the project without any disadvantage to 
yourself of any kind. If you choose to participate in this survey, you will be offered the chance 
to enter in a prize draw for a $50 Prezzy card as reimbursement for your participation, with 5 
chances to win.  
 
 
Is there any Risk of Discomfort or Harm from Participation? 
This study consists of one online survey that requires approximately 10-15 minutes to 
complete. No risks of discomfort or harm have been identified for potential participants. 
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What Data or Information will be collected and What Use will be Made of it? 
This online survey asks questions relating to three categories: 1) participant information (age, 
gender, and ethnicity) & general health, 2) IBD related questions (type of IBD, disease activity, 
and disease severity), and 3) pain related questions (location, intensity, duration, and quality of 
pain).  
Identifying the relationship between pain and disease features will help indicate why 
individuals with IBD develop persistent pain and to identify possible treatment plans.  
 Who will have access to the data or information? 
The collected data will be securely stored in such a way that only the primary 
investigator and PhD candidate will be able to gain access to it for analysis.  
 
 How will data or information be securely managed, stored and destroyed?  
The data collected will be securely stored on a password protected computer 
located in the PhD candidate’s locked office. Data obtained as a result of the research 
will be retained for at least 10 years in secure storage. Any personal information 
(such as: name and contact details) you provide will only relate to prize draws and 
requests for study information. Personal information will be collected separately from 
health data and therefore not linked at any time with collected health data. Any 
personal information collected will be destroyed once the study is completed. 
Reasonable precautions will be taken to protect data gathered and documented by 
electronic means during the study period through password protected computer.  
 
 What data or information will be reflected in the completed research? 
Completed research will reflect only summary measures of the gathered data. 
Any personal information gathered during the survey will be collected separately and 
not at any time linked to health data. Every attempt will be made to preserve your 
confidentiality and anonymity. You will be given a computer generated identification 
code upon initiation of the survey, and data will be linked to that code only.   
 
 Will the participants have the opportunity to correct or withdraw the 
data/information? 
You will have full rights to correct or change the information until the 
completion of your online survey session. Once the survey session is complete, the 
anonymous data will no longer be accessible to participants. 
 
 Will participants be given the opportunity to view the data or information that relates 
to them either before or after the completion of the research? At what stage will this 
opportunity be given to them? 
You will have the opportunity to navigate through any portion of the survey 
until completion of your survey session. Once the survey session has ended, the 
anonymous data will no longer be accessible to participants.   
 
 Will participants be provided with the results of the study?  




Can Participants Change their Mind and Withdraw from the Project? 
You may withdraw from participation in the project at any time during the online survey and 
without any disadvantage to yourself of any kind. 
 
 




What if Participants have any Questions? If you have any questions about our 
project, either now or in the future, please feel free to contact either: 
Ms Carrie Falling  
PhD Candidate & Co-investigator 
Dr Ramakrishnan Mani  
Primary Investigator & Lecturer 
Centre for Health, Activity & 
Rehabilitation Research 
Centre for Health, Activity & 
Rehabilitation Research 
School of Physiotherapy School of Physiotherapy 
University of Otago University of Otago 
325 Great King Street 325 Great King Street 
Dunedin 9016 Dunedin 9016 
Email: carrie.falling@otago.ac.nz  Email: 
ramakrishnan.mani@otago.ac.nz   
Phone : 03 479 5422 Phone : 03 479 3485  
 
This study has been approved by the University of Otago Human Ethics Committee. If you 
have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph. 03 479 8256 or email 
gary.witte@otago.ac.nz). Any issues you raise will be treated in confidence and investigated 
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Appendix E – Study 1: Participant Consent Form 
 
New Zealand IBD Aches & Pains Survey 
Investigators:  
Carrie Falling, PhD candidate, School of Physiotherapy (carrie.falling@otago.ac.nz)   
Dr Ramakrishnan Mani, Principal Investigator, School of Physiotherapy 
(ramakrishnan.mani@otago.ac.nz) 
CONSENT FORM 
At the start of the survey you will be asked to provide your informed consent acknowledging 
the following: 
 
1. I have read the Information Sheet concerning this study and understand the 
aims of this research project. 
2. I have had sufficient time to talk with other people of my choice about 
participating in the study.   
3. I confirm that I meet the criteria for participation which are explained in the 
Information Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am 
free to withdraw from the project at any time during my survey session without 
disadvantage. 
6. I know that as a participant I will be asked to complete one online survey that 
explores questions regarding aspects of pain, IBD and general health.  
7. I understand that I may decline to answer any question(s), and/or may withdraw 
from the project during the active survey session without disadvantage of any 
kind. 
8. I understand the nature and size of the risks of discomfort or harm which are 
explained in the Information Sheet. 
9. I know that when the project is completed all personal identifying information 
will be destroyed, and anonymous health data will be placed in secure storage 
and kept for at least ten years.  
10. I understand that the results of the project may be published and be available 
in the University of Otago Library, but I understand that any personal 
identifying information will remain confidential between myself and the 
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researchers during the study, and will not appear in any spoken or written 
report of the study. 
11. I know that I will be offered the opportunity to voluntarily be entered into a 
prize draw for a $50 Prezzy card as reimbursement for my participant. 
12. I know that no commercial use will be made of data from this study.   
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Appendix F – Study 1: Survey 
 
New Zealand IBD Aches & Pains Survey 
 
Q1. I have read the study Information Sheet provide and consent to participate in:   
New Zealand IBD Aches & Pains National Survey 
 Yes  
 No  
Condition: No Is Selected. Skip To: End of Survey. 
 
 
The following are some questions about your IBD history and general health. 
 
Q2. Which form of Inflammatory Bowel Disease (IBD) have you been diagnosed with? 
 Crohn's Disease  
 Ulcerative colitis  
 IBD Unspecified  
 




Q4. How many times have you been admitted to hospital for IBD flares or 
complications of IBD (excluding surgeries)? ___________ 
 
Q5. How many IBD related surgeries have you had in total?   __________ 
 
Q6 Please indicate any of the following medication that you are currently taking: 
 Gut specific anti-inflammatories, such as:  
Mesalazine (Asacol®, Pentasa®, Asamax 500®)  
Sulphasalazine (Salazopyrin®)  
Olsalazine   
 Steroids, such as:  
Budesonide (Entocort®)  
Hydrocortisone acetate (Colifoam®)  
Prednisone Methylprednisone (Medrol®, Solu-Medrol®, Depo-Medrol®) 
 Immunosuppressants, such as:   
Methotrexate (Methoblastin®, Trexate®, Hospira®)  
Azathioprine (Imuran®, Azamun®, Imuprine®)  
Ciclosporin   
 Biologics (TNF inhibitors), such as:  
Infliximab (Remicade)  
Adalimumab (Humira)  
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Q7 Have you received 2 or more courses of steroids (eg. budesonide, hydrocortisone, 
prednisone, etc.) as treatment for your IBD since your initial diagnosis? 
 Yes  
 No  
 
Q8. Have you ever been diagnosed with any of the following: 
 Osteoporosis  
 Colorectal cancer  
 Sweet's Syndrome  
 Psoriasis  
 Episcleritis  
 Scleritis  
 Kidney stones (nephrolithiasis)  
 Primary sclerosing cholangitis  
 Rheumatoid arthritis  
 Ankylosing spondylitis  
 Sacroiliitis  
 Inflammatory arthritis  
 Osteoarthritis  
 Arthralgia  
 Uveitis  
 Erythema Nodosum  
 Mouth ulcers (Oral aphthous ulcers)  
 Pyoderma Gangrenosum  
 Anal fissure / fistula 
 Abscess  
 Heart Disease  
 Vascular disease  
 Respiratory disease 
 Diabetes  
 Kidney disease  
 Liver disease  
 Dementia  
 Cancer  









If Crohn's Disease is selected for Q2 “Which form of Inflammatory Bowel Disease 
(IBD) have you been diagnosed with?” 
 
The following are specific questions regarding your Crohn's disease: Please 
check one box per number. 
 
Q9. General well-being (yesterday) 
 Very well  
 Slightly below par  
 Poor  
 Very poor  
 Terrible  
 
Q10 Abdominal pain (yesterday) 
 None  
 Mild  
 Moderate  
 Severe  
 
Q11 Number of liquid or soft stools per day (yesterday) _______________ 
 
Q12. Abdominal mass: 
 None  
 Dubious  
 Definite  





If Crohn's Disease is not selected for Q2 “Which form of Inflammatory Bowel 
Disease (IBD) have you been diagnosed with?”  
 
The following questions concern your Ulcerative colitis. These questions refer to 
your symptoms during the PREVIOUS WEEK. 
 
Q13 On average per day (24 hours), how many times did you use the toilet for 
defecation during the previous week? Blood and slime discharge is also considered 
defecation. 
 0 to 3 times  
 4 to 6 times  
 7 to 9 times  
 More than 9 times  
 
Q14. On average per night, how many times did you get out of bed to use the toilet for 
defection during the previous week? 
 Never  
 1 to 3 times  
 More than 3 times  
 
Q15. During the previous week, were you able to hold up your stool for 15 minutes or 
longer, when you felt the urge to use the toilet? 
 Yes  
 No  
 I don't know  
 
Q16. During the previous week, did you have to make adjustments to your activities, to 
ensure that there was a toilet nearby? 
 Yes  
 No  
 I don't know  
 
Q17. During the previous week, have you found stool in your underwear? 
 Yes  
 No  
 I don't know  
 
Q18. During the previous week, how many times did you see blood in your stool? 
 Never  
 Much less than half of the times  
 A little less than half of the times  
 More than half of the times  
 
Q19. If you would have to rate your general well-being during the previous week by 
giving it a number, what number would you choose? (1 = very bad, 10 = perfect) 
___________ 
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Q20. During the previous week, did you have joint pain which was worse at rest than 
after activity? 
 Yes  
 No  
 I don't know  
 
Q21. During the previous week, were your joints red or swollen? 
 Yes  
 No  
 I don't know  
 
Q22. During the previous week, have you ever woken up from joint pain? 
 Yes  
 No  
 I don't know  
 
Q23. During the previous week, have you had a skin disorder that has been diagnosed 
as erythema nodosum by your treating specialist? 
 Yes  
 No  
 I have a skin disorder but have not seen my specialist for it or do not know what 
the disorder is called.  
 
Q24. During the previous week, have you had a skin disorder that has been diagnosed 
as pyoderma by your treating specialist? 
 Yes  
 No  
 I have a skin disorder but have not seen my specialist for it or do not know what 
the disorder is called.  
 
Q25. Do you momentarily have an eye infection, that you have seen an eye-specialist 
for and which your treating specialist diagnosed as uveïtis? 
 Yes  
 No  
 I have an eye infection but have not seen an eye specialist for it or do not know 




The following are questions regarding the impact of IBD on your quality of life. 
 























How often has the feeling 
of fatigue or being tired 
and worn out been a 
problem for you during the 
past 2 weeks? 
              
How often during the last 
2 weeks have you delayed 
or canceled a social 
engagement because of 
your bowel problem?  
              
How often during the past 
2 weeks have you been 
troubled by pain in the 
abdomen?  
              
How often during the past 
2 weeks have you felt 
depressed or 
discouraged?  
              
How often during the past 
2 weeks have you felt 
relaxed and free of 
tension?  
              
How much of the time 
during the past 2 weeks 
have you been troubled by 
a feeling of having to go to 
the bathroom even though 
your bowels were empty?  
              
How often during the past 
2 weeks have you felt 
angry as a result of your 
bowel problem?  
              
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Overall, in the past 2 
weeks, how much of a 
problem have you had 
with passing large 
amounts of gas?  
              
Overall, in the past 2 
weeks, how much of a 
problem have you had 
maintaining or getting to 
the weight you would like 
to be?  
              
 
 
Q28. As a result of your bowel problems, how much difficulty did you experience doing 
leisure or sports activities you would liked to have done during the past 2 weeks? 
 A great deal of difficulty; activities made impossible  
 A lot of difficulty  
 A fair bit of difficulty  
 Some difficulty  
 A little difficulty  
 Hardly any difficulty  
 No difficulty; the bowel problem did not limit sports or leisure activities  
 
 
Q29. Have you experienced abdominal pain that lasted longer than 1 week during the 
past year?  (Please do not report pain from feverish illness, menstruation, or from 
surgery within the past year) 
 Yes  









If yes is selected for Q29 “Have you experienced abdominal pain that lasted longer 
than 1 week during the past year? (Please do not report pain from feverish illness, 
menstruation, or from surgery within the past year)”   
 
Q30.  In the past 7 days… 
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How would you rate your abdominal 
pain on average?  
 
Q31.  In the past 7 days… 
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How much did abdominal pain 






Q32. Have you experienced any bodily aches or pains OTHER THAN abdominal pain, 
headaches and/or chest pain, such as pain from muscles, joints, or bones that has 
lasted longer than 1 week in the past year?  (Please do not report pain from feverish 
illness, menstruation, surgery within the past year, or acute injury within the past 3 
months) 
 Yes  
 No  
IF: No Is Selected. Skip To: Q45 
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Q33. Please mark all of the areas that you have had pain in the past 12 months that 
lasted longer than 1 week.(Please do not report pain from feverish illness, 




Q34. Please mark your MAIN area of pain. (Please do not report pain from feverish 




Q35. Have you ever been diagnosed with peripheral or diabetic neuropathy? 
 Yes  
 Maybe  
 No  
 
Q36. Does your pain radiate to other regions of your body? 
 Yes  
 No  
 
















How much did pain interfere with 
your day to day activities?            
How much did pain interfere with 
work around the home?            
How much did pain interfere with 
your ability to participate in social 
activities?  
          
How much did pain interfere with 




Q39.   
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How would you assess your pain 





 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How strong was the STRONGEST 





 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
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How strong was the pain during the 




Q42. Mark the picture that best describes the course of your pain: 
 Persistent pain with slight fluctuations  
 Persistent pain with pain attacks  
 Pain attacks without pain between them  




Q43. Please respond to each question or statement by marking one box per row.  
In the past 7 days... 
 Never  
Hardly 
noticed  
Slightly  Moderately  Strongly  
Very 
strongly  
Do you suffer from a 
burning sensation 
(e.g. stinging 
nettles) in the 
marked areas?  
            
Do you have a 
tingling or prickling 
sensation in the 
area of your pain 
(like crawling ants or 
electrical)?  
            
Is light touching 
(clothing, a blanket) 
in this area painful?  
            
Do you have sudden 
pain attacks in the 
area of your pain, 
like electrical 
shocks?  
            
Is cold or heat (bath 
water) in this area 
occasionally painful?  
            
Do you suffer from a 
sensation of 
numbness in the 
areas that you 
marked?  
            
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Q44. Please respond to each question or statement by marking one box per row. 











Did your pain feel sore?  
          
Did your pain feel tender?  
          
Did your pain feel achy?  
          
Did your pain feel deep?  
          
Did your pain feel steady?  









The following are questions about your general health and well-being: 
Q45. Please choose the best response to the right of each statement. 
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 Never  Rarely  Sometimes  Often  Always  
I feel tired and unrefreshed when I 
wake from sleeping.            
My muscles feel stiff and achy.  
          
I have anxiety attacks.  
          
I grind or clench my teeth.  
          
I have problems with diarrhea 
and/or constipation.            
I need help in performing my daily 
activities.            
I am sensitive to bright lights.  
          
I get tired very easily when I am 
physically active.            
I feel pain all over my body.  
          
I have headaches.  
          
I feel discomfort in my bladder 
and/or burning when I urinate.            
I do not sleep well.  
          
I have difficulty concentrating.  
          
I have skin problems such as 
dryness, itchiness, or rashes.            
Stress makes my physical 
symptoms get worse.            
I feel sad or depressed.  
          
I have low energy.  
          
I have muscle tension in my neck 
and shoulders.            
I have pain in my jaw.  
          
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Certain smells, such as perfumes, 
make me feel dizzy and 
nauseated.  
          
I have to urinate frequently.  
          
My legs feel uncomfortable and 
restless when I am trying to go to 
sleep at night.  
          
I have difficulty remembering 
things.            
I suffered trauma as a child.  
          
I have pain in my pelvic area.  
          
 
 
Q46. Have you been diagnosed by a doctor with any of the following disorders? 
 Restless Leg Syndrome  
 Chronic Fatigue Syndrome  
 Fibromyalgia  
 Temporomandibular Joint Disorder (TMJ)  
 Migraine or tension headaches  
 Irritable Bowel Syndrome  
 Multiple Chemical Sensitivities  
 Neck Injury (including whiplash)  
 Anxiety or Panic Attacks  
 Depression  
 
The following are a more few questions about you: 
 
Q47. Select your gender 
 Male  
 Female  
 Gender diverse (please specify)  ____________________ 
 
Q48. What is your age in years? ___________ 
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Q49. Which ethnic group do you belong to? Mark the space or spaces that apply to 
you 
 New Zealand European  
 Māori  
 Samoan  
 Cook Island  
 Tongan  
 Niuean  
 Chinese  
 Indian  
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Study One: Included and Excluded Participant Characteristics 
Characteristic Included (N = 305) Excluded (N = 54) 
Gender a 
   Male, n (%)    
   Female, n (%)    










   Range (years) 













 IBD type b 
   CD, n (%)  
   UC, n (%) 









Note. Inflammatory bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC), 
indeterminate colitis (IC), standard deviation (SD), and central sensitization inventory 
(CSI). 
a Answered by n = 22 excluded participants  
















n (%) P 
Depression 31 (49) 32 (37) 14 (26) 0.001* 
Anxiety 19 (30) 22 (26) 8 (15) 0.054 
Heart Disease 3 (5) 2 (2) 2 (4) 0.726 
Vascular disease 1 (2) 2 (2) 0(0) 0.952 
Respiratory disease 3 (5) 4 (5) 3 (6) 0.975 
Diabetes 6 (10) 3 (4) 4 (7) 0.337 
Kidney disease 2 (3) 1 (1) 0(0) 0.709 
Liver disease 2 (3) 4 (5) 2 (4) 0.894 
Dementia 0(0) 0(0) 0(0) - 
Cancer 1 (2) 5 (6) 0(0) 0.480 
AIDS/HIV 0(0) 0(0) 0(0) - 
Restless leg syndrome 6 (10) 3 (4) 3 (6) 0.322 
Chronic fatigue syndrome 9 (14) 2 (2) 2 (4) 0.020* 
Fibromyalgia 3 (5) 4 (5) 0(0) 0.999 
TMJ 2 (3) 4 (5) 0(0) 0.904 
Migraine 16 (25) 17 (20) 6 (11) 0.145 
Irritable bowel syndrome 18 (29) 28 (33) 16 (29) 0.847 
Multiple Chemical Sensitivities 1 (2) 4 (5) 0(0) 0.619 
Neck Injury (including whiplash) 12 (19) 9 (11) 3 (6) 0.080 









Extra-intestinal Manifestations of Three Latent Classes  










Inflammatory Arthritis 21 (33) 22 (26) 15 (27) 0.572 
Osteoarthritis 13 (21) 9 (11) 2 (4) 0.027* 
Arthralgia 19 (30) 21 (24) 9 (16) 0.222 
Osteoporosis 12 (19) 7 (8) 3 (6) 0.045* 
Colorectal cancer 0(0) 0(0) 1 (2) - 
Sweet's Syndrome 0(0) 1 (1) 0(0) - 
Psoriasis 6 (10) 6 (7) 3 (6) 0.693 
Episcleritis 0(0) 0(0) 1 (2) - 
Scleritis 0(0) 0(0) 0(0) - 
Nephrolithiasis 3 (5) 5 (6) 1 (2) 0.555 
Primary sclerosing cholangitis 2 (3) 2 (2) 2 (4) 0.897 
Uveitis 1 (2) 1 (1) 2 (4) 0.595 
Erythema Nodosum 1 (2) 4 (5) 2 (4) 0.619 
Oral aphthous ulcers 22 (35) 29 (34) 21 (38) 0.862 
Pyoderma Gangrenosum 1 (2) 0(0) 1 (2) 0.995 
Anal fissure or fistula 21 (33) 31 (36) 21 (38) 0.859 
Intestinal abscess 6 (10) 9 (11) 4 (7) 0.816 
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Appendix H – Study 1: Sub-analysis Poster Presentations  
Falling, C., Stebbings, S., Mani, R., Baxter, D., & Gearry, R. (2018). (424) Central 
Sensitization Mediates the Relationship between Inflammatory Bowel Disease Activity 
and Musculoskeletal Pain Severity. The International Association for the Study of Pain: 





Falling, C. L., Stebbings, S., Baxter, G. D., Gearry, R. B., & Mani, R. (2018) Central 
sensitization inventory mediates the relationship between inflammatory bowel disease 
activity and musculoskeletal pain experiences. NZ Society of Gastroenterology: Annual 
Scientific Meeting, held at: Dunedin, New Zealand. 
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Falling, C., Stebbings, S., Mani, R., Baxter, D., & Gearry, R. (2019). Central 
Sensitization Inventory Discriminates between Pain Groups in Individuals with 
Inflammatory Bowel Disease. American Pain Society: Annual Scientific Meeting, held 
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Appendix I – Study 1: Accepted abstract for Secondary Sub-analysis 
 
 
Falling, C., Stebbings, S., Mani, R., Baxter, D., & Gearry, R. (2019). (183) Central 
Sensitization Inventory Discriminates between Pain Groups in Individuals with 
Inflammatory Bowel Disease. The Journal of Pain, 20(4), S21. 
 
 
Central sensitization inventory discriminates between pain groups in individuals 
with inflammatory bowel disease   
 
Falling C, Stebbings S, Baxter GD, Gearry RB, Mani R 
Abdominal and musculoskeletal (MSK) pain experiences are common in 
inflammatory bowel diseases (IBD). Recent evidence suggests that MSK pain severity 
is influenced by IBD activity and it is mediated by symptoms commonly related to 
central sensitization syndromes. However, it is not known whether severity of central 
sensitization symptoms can discriminate the type of pain presentation in individuals 
with IBD. A cross-sectional online survey among 305 New Zealand adults with IBD 
(aged 18-88 years) was conducted. Features of IBD, abdominal pain, and MSK pain 
were examined using multiple validated questionnaires. Presence and severity of 
symptoms commonly seen in central sensitivity syndromes were assessed using the 
central sensitization inventory (CSI). One-way analysis of variance with post-hoc 
multiple comparisons, while controlling for age and gender, was used to determine 
differences in CSI scores based on the type of pain presentation: no pain (n=61), only 
abdominal pain (n=36), only MSK pain (n=82), and both abdominal/MSK pain 
(n=125). Analysis indicated significantly different CSI scores between identified pain 
presentations (F (3,298) = 32.187, p ≤ 0.000). Individuals reporting no pain 
demonstrated the lowest CSI scores (M = 31.25, SD = 12.39), while those with both 
abdominal/MSK pain demonstrated the highest (M = 51.48, SD = 13.22). Post-hoc 
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comparisons described significant differences (p ≤ 0.05) in CSI scores between all pain 
groups, except between individuals only reporting musculoskeletal pain and those only 
reporting abdominal pain (MD = 1.07, SE = 2.52). In the present study, CSI scores were 
able to discriminate pain presentations in IBD, with higher CSI scores in individuals 
with both abdominal/MSK pain. Future research should explore the relationship 
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Appendix K – Study 2: Participant Invitation Letters 
IBD Aches & Pains Study 
As a patient of Dartmouth-Hitchcock Medical Center who has been diagnosed 
with inflammatory bowel disease (IBD), you are invited to participate in a study 
investigating pain in people with IBD. This study is part of a larger study from the 
University of Otago (New Zealand), aimed at investigating why individuals with IBD 
develop ongoing pain in order to help find targeted treatments. 
In order to explore pain in IBD, we are looking for IBD patients WITH 
musculoskeletal pain (i.e. bones, joints, and/or muscles) as well as IBD patients 
WITHOUT pain.  
If you are 18 years or older, and would like more information about this study, 
please contact: Carrie Falling (email: carrie.falling@postgrad.otago.ac.nz). 
 
$20 amazon gift vouchers will be given to each 
eligible participant as reimbursement for your 
time. 
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IBD Aches & Pains Study 
As a patient of Dartmouth-Hitchcock Medical Center with a routine upcoming 
appointment, you are invited to participate as a healthy individual in a study 
investigating pain in patients with inflammatory bowel disease (IBD). This study is part 
of a larger study from the University of Otago (New Zealand), aimed at investigating why 
individuals with IBD develop ongoing pain in order to help find targeted treatments. 
In order to do this, we must also evaluate healthy individuals to better understand 
pain in patients with IBD.  
If you are 18 years or older, and would like more information about participating 
in this study as a healthy individual, please contact: Carrie Falling (email: 
carrie.falling@postgrad.otago.ac.nz).  
$20 amazon gift vouchers will be given to each 
eligible participant as reimbursement for your 
time. 
 
            
                                                         
  




Appendix L – Study 2: Questionnaires 
 
Q1-Q32: Questionnaires for all Participant groups 
 




(Q2: Situational Catastrophizing Questionnaire. To be completed immediately 
following Cold pressor assessment during sensory testing) 
 
Q2. For the following questions, we are interested in the type of thoughts and feelings 
that you had while you were participating in these pain procedures. Listed below 
are several statements describing different thoughts and feelings that may be 
associated with pain. Please indicate the degree to which you had these thoughts 















I worried about when it 
would end.           
I thought that the pain 
might overwhelm me.           
I felt that I couldn't stand 
it.           
I couldn't stop thinking 
about how much it hurt.           
I kept wishing that it 
would be over.           
I felt that the procedures 







 (Q3: Central Sensitization Inventory) 
 
Q3. The following are questions about your general health and well-being: 
     Please choose the best response to the right of each statement. 
 
 Never Rarely Sometimes Often Always 
I feel tired and unrefreshed when I wake 
from sleeping.           
My muscles feel stiff and achy.           
I have anxiety attacks.           
I grind or clench my teeth.           
I have problems with diarrhea and/or 
constipation.           
I need help in performing my daily 
activities.           
I am sensitive to bright lights.           
I get tired very easily when I am 
physically active.           
I feel pain all over my body.           
I have headaches.           
I feel discomfort in my bladder and/or 
burning when I urinate.           
I do not sleep well.           
I have difficulty concentrating.           
I have skin problems such as dryness, 
itchiness, or rashes.           
Stress makes my physical symptoms get 
worse.           
I feel sad or depressed.           
I have low energy.           
I have muscle tension in my neck and 
shoulders.           
I have pain in my jaw.           
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Certain smells, such as perfumes, make 
me feel dizzy and nauseated.           
I have to urinate frequently.           
My legs feel uncomfortable and restless 
when I am trying to go to sleep at night.           
I have difficulty remembering things.           
I suffered trauma as a child.           







(Q4: 10-item Perceived Stress Scale) 
 
Q4. The questions in this scale ask you about your feelings and thoughts during the 
last month. In each case, you will be asked to indicate by circling how often you 









In the last month, how often have you 
been upset because of something that 
happened unexpectedly? 
          
In the last month, how often have you 
felt that you were unable to control the 
important things in your life? 
          
In the last month, how often have you 
felt nervous and “stressed”?           
In the last month, how often have you 
felt confident about your ability to 
handle your personal problems? 
          
In the last month, how often have you 
felt that things were going your way?           
In the last month, how often have you 
found that you could not cope with all 
the things that you had to do? 
          
In the last month, how often have you 
been able to control irritations in your 
life? 
          
In the last month, how often have you 
felt that you were on top of things?           
In the last month, how often have you 
been angered because of things that 
were outside of your control? 
          
In the last month, how often have you 
felt difficulties were piling up so high 
that you could not overcome them? 








(Q5: Positive and Negative Affective Schedule) 
 
Q5. This scale consists of a number of words that describe different feelings and 
emotions. Read each item and then list the number from the scale below next to 




OR Not at all 




Interested           
Distressed           
Excited           
Upset           
Strong           
Guilty           
Scared           
Hostile           
Enthusiastic           
Proud           
Irritable           
Alert           
Ashamed           
Inspired           
Nervous           
Determined           
Attentive           
Jittery           
Active           
Afraid           
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(Q6-Q11: EuroQoL 5D) 
Under each heading, please tick the ONE box that best describes your health TODAY. 
Q6. MOBILITY 
 I have no problems walking around 
 I have slight problems walking around  
 I have moderate problems walking around  
 I have severe problems walking around  
 I am unable to walk around  
Q7. SELF-CARE 
 I have no problems washing or dressing myself   
 I have slight problems washing or dressing myself 
 I have moderate problems washing or dressing myself  
 I have severe problems washing or dressing myself  
 I am unable to wash or dress myself  
Q8. USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
 I have no problems doing my usual activities  
 I have slight problems doing my usual activities  
 I have moderate problems doing my usual activities  
 I have severe problems doing my usual activities  
 I am unable to do my usual activities  
Q9. PAIN / DISCOMFORT 
 I have no pain or discomfort 
 I have slight pain or discomfort  
 I have moderate pain or discomfort  
 I have severe pain or discomfort  
 I have extreme pain or discomfort  
Q10. ANXIETY / DEPRESSION 
 I am not anxious or depressed  
 I am slightly anxious or depressed  
 I am moderately anxious or depressed  
 I am severely anxious or depressed  
 I am extremely anxious or depressed  
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Q11. We would like to know how good or bad your health is TODAY 
This scale is numbered from 0-100. 
100 means the best health you can imagine 
0 means the worst health you can imagine 
 
 
Slide the bar to indicate how your health is TODAY 
 0 10 20 30 40 50 60 70 80 90 100 





(Q13-26: Hospital Anxiety and Depression Scale) 
 
Tick the box beside the reply that is closest to how you have been feeling in the past 
week.  
Don't take too long over your replies: your immediate answer is best. 
 
Q13. I feel tense or 'wound up': 
 Most of the time 
 A lot of the time 
 From time to time, occasionally 
 Not at all 
 
 
Q14. I still enjoy the things I used to enjoy: 
 Definitely as much 
 Not quite so much 
 Only a little 




Q15. I get a sort of frightened feeling as if something awful is about to happen: 
 Very definitely and quite badly 
 Yes, but not too badly 
 A little, but it doesn't worry me 
 Not at all 
 
 
Q16. I can laugh and see the funny side of things: 
 As much as I always could 
 Not quite so much now 
 Definitely not so much now 
 Not at all 
 
 
Q17. Worrying thoughts go through my mind: 
 A great deal of the time 
 A lot of the time 
 From time to time, but not too often 
 Only occasionally 
 
 
Q18. I feel cheerful: 
 Not at all 
 Not often 
 Sometimes 
 Most of the time 
 
 
Q19. I can sit at ease and feel relaxed: 
 Definitely 
 Usually 
 Not Often 
 Not at all 
 




Q20. I feel as if I am slowed down: 
 Nearly all the time 
 Very often 
 Sometimes 
 Not at all 
 
Q21. I get a sort of frightened feeling like 'butterflies' in the stomach: 
 Not at all 
 Occasionally 
 Quite Often 
 Very Often 
 
Q22. I have lost interest in my appearance: 
 Definitely 
 I don't take as much care as I should 
 I may not take quite as much care 
 I take just as much care as ever 
 
Q23. I feel restless as I have to be on the move: 
 Very much indeed 
 Quite a lot 
 Not very much 
 Not at all 
 
Q24. I look forward with enjoyment to things: 
 As much as I ever did 
 Rather less than I used to 
 Definitely less than I used to 
 Hardly at all 
 
Q25. I get sudden feelings of panic: 
 Very often indeed 
 Quite often 
 Not very often 
 Not at all 
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Q26. I can enjoy a good book or radio or TV program: 
 Often 
 Sometimes 
 Not often 
 Very seldom 
 
Q27. During the past month, how would you rate your sleep quality overall? 
 Very good 
 Fairly good 
 Fairly bad 
 Very bad 
 
Q28. Do you smoke? 
 Yes, LESS than 39 cigarettes per day 
 Yes, MORE than 39 cigarettes per day 
 No 
 
Q29. How often do you drink alcohol? 
 Never 
 Occasionally, moderate amount 
 Occasionally, alot 
 Regularly, moderate amount 
 Regularly, alot 
 Often, beyond the proper amount 
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Q32. Which ethnic/race designation best describes you? More than one choice is 
acceptable. 
 Native American or Alaska Native 
 Hispanic or Latino 
 Asian 
 Black or African American 
 Native Hawaiian or Other Pacific Islander 
 White 





Q33-Q34: Additional questions - Health Control Group only 
 
Q33. Do you regularly take medication? 
 No 
 Yes, please list ________________________________________________ 
 
Q34. Have you ever been told by a doctor that you have any of the following: 
 
 Osteoporosis 
 Colorectal cancer 




 Kidney stones (nephrolithiasis) 
 Primary sclerosing cholangitis 
 Rheumatoid arthritis 
 Ankylosing spondylitis 
 Sacroiliitis 
 Inflammatory arthritis 
 Osteoarthritis 
 Unspecified joint pain (arthralgia) 
 Uveitis 
 Mouth ulcers (Oral aphthous 
ulcers) 
 Pyoderma Gangrenosum 
 Erythema Nodosum 
 Anal fissure or fistula 
 Intestinal abscess 
 
 Heart Disease 
 Vascular disease 
 Respiratory disease 
 Diabetes 
 Kidney disease 




 Anxiety disorder or panic attacks 
 Depression 
 Neck injury (including whiplash) 
 Multiple chemical sensitivities 
 Irritable bowel syndrome 
 Migraine or tension headaches 
 Temporomandibular Joint Disorder  
 Fibromyalgia 
 Chronic Fatigue Syndrome 
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Q35-Q47: Additional questions - IBD Groups only 
 
Q35. Have you experienced abdominal pain that lasted longer than 1 week during the 
past year?  (Please do not report pain from feverish illness, menstruation, or from 




(Q36: PROMIS Pain Interference 4a – Abdominal pain) 
 
Q36. In the past 7 days… 








How much did abdominal pain interfere with 
your day to day activities?           
How much did abdominal pain interfere with 
work around the home?           
How much did abdominal pain interfere with 
your ability to participate in social activities?           
How much did abdominal pain interfere with 




Q37. In the past 7 days… 
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How intense was your abdominal 








Q38. In the past 7 days… 
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How intense was your 





 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
What is your level of abdominal pain 





Q40. Have you experienced any bodily aches or pains OTHER THAN abdominal pain, 
headaches and/or chest pain, such as pain from muscles, joints, or bones that has 
lasted longer than 1 week in the past year? (Please do not report pain from 
feverish illness, menstruation, surgery within the past year, or acute injury within 
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Q41. Please mark of the REGIONS that you have had pain in the past 12 months that 
lasted longer than 1 week 
 
(Please do not report pain from feverish illness, menstruation, surgery within the past 
year, or acute injury within the past 3 months) 
 








Q42. Please mark ONE region that is your “MAIN" area of pain. 
 
(Please do not report pain from feverish illness, menstruation, surgery within the past 






Q43. How long have you had pain in this area?  
 Years ________________________________________________ 
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(Q44: PROMIS Pain Interference 4a – Musculoskeletal pain) 
 
Q44. In the past 7 days… 








How much did your MAIN pain interfere 
with your day to day activities?           
How much did your MAIN pain interfere 
with work around the home?           
How much did your MAIN pain interfere 
with your ability to participate in social 
activities? 
          
How much did your MAIN pain interfere 
with your household chores?           
 
Q45. In the past 7 days… 
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How intense was your MAIN pain at 
its worst?  
 
 
Q46. In the past 7 days… 
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
How intense was your 
average MAIN pain?   
 
Q47. Today... 
 None                             Max 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
What is your level of MAIN pain right 
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Participant ID Dominant Hand Time Date (dd/mm/yyyy) 
    
 
VDT Test site Trial Left Right 




















B  B  
C  C  
D  D  
E    







Side:      L    /    R 
Trial  NRS (0-100) 
1 
Single Stimulus  
Series (10)  
2 
Single Stimulus  
Series (10)  
3 
Single Stimulus  
Series (10)  
PPT Test site Trial kPa 
Low back 
 



























RETEST (Ice bath) 
Tibialis anterior 
 









Side:      L    /    R 
 
Time of removal NRS (0-100) 
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Appendix N – Study 2: Verbal instructions for sensory testing 
Vibration Detection Threshold 
This is a test of your ability to detect vibration. Once I make it vibrate, I will place this 
tuning fork on bones of both of your wrists and the inside of your ankle. I will have you 
tell me when you feel the sensation of vibration, and then say ‘NOW’ when you no longer 
feel the vibration. I will have you close your eyes for the testing, and do this test 3 times 
at each location. 
 
Semmes-Weinstein Monofilament Examination 
This is a test of your ability to detect light touch on your hands and feet. Once again I will 
have you close your eyes, and then I will press this filament to 6 different places on both 
of your hands, and this different filament to 4 places on both of your feet. I will have you 
say ‘YES’ when you feel the filament touching you. 
 
Temporal Summation 
This is a test of repeated stimulus with a similar filament used in the last test. I will first 
apply a single touch, and ask you to give a number between 0-100 for the discomfort of 
the one touch, where ‘0’ is no pain, and ‘100’ is the most intense pain imaginable. 
Then I will apply a series of 10 stimuli in a row with the same filament, and ask you to 
give a number between 0-100 for any discomfort of the series as a whole. 
 
Pressure Pain Threshold 
This is a test of your sensitivity to deeper pain. I will take this pressure meter and press it 
against one area on your low back and one area on your leg below your knee, and will 
gradually increase the pressure. I want you to say ‘NOW’ as soon as the pressure starts to 
be painful. I am not looking to see how much pain you can tolerate, just simply the 
moment when pressure starts becoming painful. I will do this test 3 times on your back, 
and 3 times on your leg. 
 
Cold Pressor Test 
This test includes 2 procedures that I will do one after another. I will measure your 
pressure pain threshold again (the test we just did) after you have your hand in cold water 
for 2 minutes. I will have you place your hand in this ice bath up to your wrist with your 
fingers spread apart until you can no longer tolerate it OR for a maximum of 2 minutes 
(digital timer). You can remove your hand whenever you wish or when the timer goes off. 
I will have you give me warning just before you take your hand out so I can record the 
time. And then I will ask you to give a number between 0-100 for the amount of 
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Appendix O – Study 2: MSK Pain Regions in IBD Patients (Chapter 8) 
 
Table O.1 
Summary of Self-reported Musculoskeletal Pain Regions of the Upper Body in IBD 
Patients (N=22)   
Body region Identified as painful Identified as region of main pain 
Right anterior (n)   
Wrist/hand 8 1 
Forearm 0 0 
Elbow 1 0 
Upper arm 1 0 
Shoulder 8 0 
Left anterior (n) 
  
Wrist/hand 7 1 
Forearm 0 0 
Elbow 1 0 
Upper arm 0 0 
Shoulder 7 0 
Right posterior (n) 
  
Wrist/hand 3 0 
Forearm 0 0 
Elbow 3 0 
Upper arm 0 0 
Shoulder 4 0 
Left posterior (n) 
  
Wrist/hand 2 0 
Forearm 0 0 
Elbow 2 0 
Upper arm 0 0 





Summary of Self-reported Musculoskeletal Pain Regions of the Lower Body in IBD 
Patients (N=22)   
Body region Identified as painful (n) Identified as region of main pain 
(n) 
Right anterior   
Ankle/foot 5 0 
Lower leg 4 1 
Knee 9 2 
Upper leg 3 0 
Hip/groin 7 1 
Left anterior 
  
Ankle/foot 4 0 
Lower leg 5 0 
Knee 6 1 
Upper leg 2 0 
Hip/groin 6 1 
Right posterior   
Ankle/foot 0 0 
Lower leg 0 0 
Knee 0 0 
Upper leg 1 0 
Gluteus/hip 4 2 
Left posterior 
  
Ankle/foot 0 0 
Lower leg 2 0 
Knee 0 0 
Upper leg 3 0 




Summary of Self-reported Axial Musculoskeletal Pain Regions in IBD Patients (N=22)  
Body region Identified as painful Identified as main region of pain  
Post neck (n) 8 4 
Mid back (n) 11 1 
Low back (n) 11 3 
Chest (n) 3 1 
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Appendix P – Study 2: MSK Pain Regions in IBD Patients (Chapter 9) 
 
Table P.1 
Summary of Self-reported Musculoskeletal Pain Regions of the Upper Body in IBD 
Patients (N=51)   
Body region Identified as painful Identified as region of main pain 
Right anterior (n)   
Wrist/hand 10 2 
Forearm 1 0 
Elbow 3 0 
Upper arm 1 0 
Shoulder 10 0 
Left anterior (n)   
Wrist/hand 11 1 
Forearm 1 0 
Elbow 2 0 
Upper arm 0 1 
Shoulder 8 0 
Right posterior (n)   
Wrist/hand 5 0 
Forearm 0 0 
Elbow 4 0 
Upper arm 1 0 
Shoulder 7 1 
Left posterior (n)   
Wrist/hand 3 0 
Forearm 0 0 
Elbow 3 0 
Upper arm 0 0 





Summary of Self-reported Musculoskeletal Pain Regions of the Lower Body in IBD 
Patients (N=51)   
Body region Identified as painful (n) Identified as region of main pain 
(n) 
Right anterior   
Ankle/foot 7 0 
Lower leg 4 1 
Knee 11 4 
Upper leg 3 0 
Hip/groin 10 1 
Left anterior   
Ankle/foot 6 0 
Lower leg 5 0 
Knee 9 0 
Upper leg 3 0 
Hip/groin 8 1 
Right posterior   
Ankle/foot 2 0 
Lower leg 1 0 
Knee 0 0 
Upper leg 3 0 
Gluteus/hip 
5 3 
Left posterior   
Ankle/foot 2 0 
Lower leg 4 0 
Knee 1 0 
Upper leg 2 0 





Summary of Self-reported Axial Musculoskeletal Pain Regions in IBD Patients (N=51)  
Body region Identified as painful Identified as main region of pain  
Post neck (n) 12 4 
Mid back (n) 14 1 
Low back (n) 15 3 
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Spearman Rank-order Correlations of Measures of Central Sensitization in IBD 
Participants  
Feature 
CSI a PPT (LB) PPT (TA) CPM a TS 
Rho P Rho P Rho P Rho P Rho P 
CSI a - - -.218 .063 -.338 .008 -.285 .021 .011 .471 
PPT (LB) -.218 .063 - - .876 <.001 .390 .002 -.456 <.001 
PPT (TA) -.338 .008 .876 <.001 - - .433 .001 -.464 <.001 
CPM a -.285 .021 .390 .002 .433 .001 - - -.184 .098 
TS b .011 .471 -.456 <.001 -.464 <.001 -.184 .098 - - 
Note. Bold font indicates significant correlation (p ≤ .05). Central sensitization inventory (CSI), 
pressure pain threshold (PPT), low back (LB), Tibialis anterior (TA), conditioned pain 
modulation (CPM), temporal summation (TS). 
a Pearson’s coefficient (r). 
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Appendix R – Study 2: Correlations of Absolute Change Scores for 
Temporal Summation to Participant Features (Chapter 9) 
 
Table 8 
Spearman Rank-order Correlations of IBD Characteristics to Absolute Change Scores 







IBD subtype a  0.178 0.105 
IBD duration  -0.127 0.188 
Age at diagnosis b  0.233 0.050 
Disease extent a  -0.150 0.147 
Surgical input a  0.160 0.131 
Stoma a  0.065 0.325 
Stricturing a  0.183 0.100 
Penetrating a  0.052 0.358 
Perianal a  0.067 0.320 
Short Inflammatory Bowel Disease Questionnaire  0.214 0.065 
Abdominal pain a  0.081 0.286 
Note. Inflammatory bowel disease (IBD. 
a Point-biserial coefficient (rpb). 





Spearman Rank-order Correlations of Psychological Characteristics to Absolute Change 




Perceived stress scale a -0.035 0.404 
Positive and negative affect schedule (positive) a 0.072 0.308 
Positive and negative affect schedule (negative)  -0.065 0.324 
Hospital anxiety and depression scale (anxiety) -0.021 0.441 
Hospital anxiety and depression scale (depression) -0.195 0.085 
Pain catastrophizing scale 0.238 0.064 




Spearman Rank-order Correlations of Demographic, Lifestyle, and Comorbidity Features 
to Absolute Change Scores for Temporal Summation in IBD Participants (N = 51) 
Feature 
 TS 
 Rho P 
Age a  0.225 0.056 
Gender b   0.119 0.202 
Smoking  0.197 0.083 
Alcohol   -0.048 0.370 
Cannabis b  0.134 0.174 
Sleep quality  0.123 0.194 
Total comorbidity  -0.066 0.324 
Musculoskeletal pain b  0.075 0.301 
a Pearson’s correlation (r).  
b Point-biserial coefficient (rpb). 
 
 
 
